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 CD137 (4-1BB, TNFRSF9), a member of the tumor necrosis factor (TNF) 
receptor family, is a potent T cell co-stimulatory molecule. CD137 ligand 
(CD137L) is expressed by antigen presenting cells (APC) as a transmembrane 
protein and transmits activating signals into APC. In this study we investigated 
the effects of CD137L signaling in microglia, the resident APC in the central 
nervous system. In vitro, the murine microglia cell lines BV-2 and N9, as well as 
primary murine microglia responded with activation as evidenced by adherence 
and secretion of proinflammatory cytokines, MMP-9, and soluble intercellular 
adhesion molecule (ICAM). CD137L signaling is also important for microglia 
activation in vivo, since CD137L-deficient mice exhibited profoundly less 
microglia activation during experimental autoimmune encephalomyelitis (EAE) 
which is a well-established murine model for neuroinflammation and human 
multiple sclerosis (MS). Also CD137 is expressed in the CNS of mice during 
EAE. Activated microglia have been reported to mediate the destruction of 
axonal myelin sheaths and cause the death of oligodendrocytes, the main 
pathogenic mechanisms in EAE and MS. Corresponding to lower microglia 
activation there were also fewer apoptotic oligodendrocytes in the CNS of 
CD137L-deficient mice. In vitro co-culture confirmed that CD137L-activated 
microglia induces apoptosis in oligodendrocytes, and identified reactive oxygen 
species (ROS) as the mechanism of apoptosis induction. These data 
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demonstrate activating effects of CD137L signaling to microglia, and show for 
the first time that the CD137 receptor/ligand system may be a mediator of 
neuroinflammatory and neurodegenerative disease, by activating microglia 
which in turn kill oligodendrocytes. 
xi 
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CHAPTER 1 INTRODUCTION 
 
1.1 Microglia in general 
 
 Uniformly distributed through the adult CNS in the brain parenchyma, 
microglia are the resident tissue macrophages of the central nervous system 
(CNS) constituting about 5 to 20% of the entire neuroglial population (Lawson 
et al. 1990; Kettenmann et al. 2005). Like macrophages in other tissues, 
microglia are critical immune effectors in the CNS. Experiments in mice have 
shown that the microglial population turns over about once in the lifespan of a 
mouse (Lawson et al., 1992; Kennedy and Abkowitz, 1997; Massengale et al., 
2005; Wirenfeldt et al., 2005).  
 
 Microglia are highly heterogeneous in morphologies and are cells with high 
plasticity (Graeber, 2010). Microglia may exhibit ramified or amoeboid 
morphologies depending on its activation status. Ramified microglia usually 
corresponds with the “resting” state while the amoeboid macrophage-like 
phagocytic phenotype is widely associated with activation. However, microglia 
are reported to be largely amoeboid during CNS development (Dalmau et al. 
2003).  
 
 As the housekeepers or guardians of the CNS, microglia play a mediating 
role in maintaining CNS homeostasis (Kitamura et al. 2009; Wirenfeldt et al. 
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2011). Microglia patrol the healthy CNS microenvironment for perturbations 
and abnormalities. Retaining their somata in a fixed spatial location, they 
extend and retract their finely branched and ramified structures in different 
directions at their immediate surroundings (Nimmerjahn et al. 2005). Such 
"surveying" or "resting" microglia are very sensitive to any imbalances and 
insults in the CNS parenchyma (Davalos et al. 2005; Wirenfeldt et al. 2011).  
 
 Microglia are important players of the innate immunity in the CNS. They 
rapidly change their phenotype in response to any disturbance of nervous 
system homeostasis and are commonly referred to as activated, characterized 
by the expression of cell surface antigens and frequently associated with their 
amoeboid morphology as well as increased phagocytic capability. Microglia 
express toll-like receptors (TLRs), which recognize pathogen-associated 
molecular patterns (PAMPs) on microorganisms and damage-associated 
molecular patterns (DAMPs) displayed on stressed, injured, infected or 
transformed host cells (Ross, 2010; Takeuchi and Akira 2010; Gordon, 2007). 
In essence, microglia can detect microbial and viral pathogens and tissue 
damage through TLRs (Bianchi, 2007; Palm and Medzhitov, 2009). Microglia 
also bear other carbohydrate receptors such as mannose receptor, CD206, or 
oxidized lipoprotein detectors such as scavenger receptors, CD68, to detect 
microbial carbohydrates or altered lipoproteins. Microglia respond in a graded 
manner to changes in the environment (Graeber, 2004). Following pathological 
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insults, microglia gradually become activated, motile and adopt full immune 
effector functions via these receptors.  
 
 Microglia upon activation adopt very diverse effector functions analogous 
to macrophage populations in other organs. Manipulating the effector functions 
of microglia can potentially modify the outcome of microglia activation. 
Microglia activation is commonly induced through the administration of 
lipopolysaccharide (LPS). When the perturbation or injury were slight, 
microglia can immediately be primed to express scavenger receptors such as 
thrombospondin receptor (CD36), mannose receptor (CD206) and lectin 
domain receptor to bind to pathogens for subsequent internalization (Ross, 
2010). However, when injury is pronounced or severe, microglia transform into 
the activated or reactive phenotype. Reactive microglia are characterized by 
morphological transformation, proliferation and a number of features, such as 
the expression of a wide range of myeloid markers, antigenic markers, 
production of cytokines, chemokines, free radicals, nitric oxide and growth 
factors, and enhanced phagocytic capacity (Streit et al., 2002; Ladeby et al., 
2005; Ransohoff et al., 2009). In addition, activated microglia also upregulate 
major histocompatibility complex (MHC) class II antigens, suggesting that 
activated microglia can serve as APC to circulating T cells. This interaction 
triggers the production of a plethora of inflammatory cytokines, reactive 
oxygen species and nitric oxide (Chan et al., 2007). To date, microglia are the 
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only known endogenous CNS cells that are able to present antigens to T cells 
to initiate adaptive immune responses in the neuropathological states. It 
remains a challenge to better define or qualify the term activated microglia to 
reflect the actual distinct states of activation-associated effector functions 
during neuroinflammation.  
 
 Microglia also display functional versatility or plasticity by controlling the 
level of reactivity to the activating stimulus. There is evidence to support the 
functional plasticity of microglia. In a healthy CNS, microglia phagocytose 
dead or apoptotic neurons via triggering receptor expressed on myeloid cells 
(TREM)-2 that are highly expressed on microglia without inducing 
inflammation. Apart from the phagocytic capability, microglia can also promote 
the death of developing neurons (Ransohoff and Perry, 2009; Marin-Teva et al., 
2004; Bessis et al., 2007). Microglia are also involved in synaptic stripping in 
pathological processes (Trapp et al., 2007; Wake et al., 2009) by responding to 
and modulating the functional state of synapses. Given their specialized ability 
to phagocytose apoptotic newborn cells, microglia have also been coined as 
regulators or promoters of adult neurogenesis in the dentate gyrus and 
subventricular zone (SVZ) of the developing brain (Battista et al., 2006; Choi et 




1.2 Origin of microglia 
 
 In the embryonic and developing CNS, Chan et al. (2007) established that 
microglia are derived from the peripheral mesodermal germ layer, prior to the 
formation of the blood-brain barrier. Early microglia are derived from the yolk 
sac progenitors that colonize the CNS around the second trimester (Kaur et al., 
2001; Chan et al., 2007; Ransohoff and Perry, 2009) contributing to almost all 
of the resident microglial population. During monocyte development, 
granulocyte-macrophage progenitors (GMP) sequentially give rise to 
monoblasts, pro-monocytes and finally monocytes, which are released from 
the bone marrow into the bloodstream. Monocytes can also migrate from the 
blood into tissues to become long-lived tissue-specific macrophages from the 
myeloid origin namely as microglia the CNS, histiocytes in the connective 
tissue, Kupffer cells in the liver, osteoclasts in the bone, and other 
macrophages in the gastrointestinal tract, alveoli, spleen and peritoneum 
(Gordon and Taylor, 2005). 
 
 Under normal or physiological conditions, novel bone marrow-derived 
microglia cannot enter the CNS without prior irradiation that disrupts the blood 
brain barrier. Mildner et al. (2007) demonstrated that bone marrow-derived 
cells could only be detected in the brains of chimeric mice after whole body 
irradiation but not in chimeric mice with head shielding. Using green 
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fluorescent protein (GFP) transgenic bone marrow chimeric mice that were 
previously lethally irradiated, parenchymal microglia retain host characteristics 
while peripheral blood cells were reconstituted with GFP-positive bone marrow 
cells. With head shielding during irradiation, bone marrow-derived cells could 
not be detected; without head shielding, bone marrow-derived Ly-6ChiCCR2+ 
monocytes successfully infiltrated the CNS, suggesting that the blood-brain 
barrier perturbation and inflammatory response induced by irradiation are 
necessary for the migration of microglial progenitor cells from the bone marrow 
to the CNS. This lend support to the claim that adult resting microglia under 
normal or physiological condition can be replenished or maintained intrinsically 
without the need for significant turnover from circulating blood progenitors 
(Kennedy and Abkowitz, 1997; Lassmann and Hickey, 1993). A healthy level of 
microglia in the CNS physiology can be maintained by local proliferation of 
either resident microglia or endogenous microglial-like stem cells from the 
CNS (Geissmann et al. 2010).  
 
 Resident microglial population can also be supplemented with bone 
marrow derived cells that migrate into the CNS from the blood to become new 
microglia in various models of acute CNS injury (Priller et al., 2001; Wirenfeldt 
et al., 2005, 2007; Clausen et al., 2008; Lambertsen et al., 2009) as well as 




 In the mature CNS in the neonate and adult, there are two subpopulations 
of microglia, the resident microglia and bone marrow-derived microglia from 
engrafted blood monocytes (Asheuer et al. 2004; Hess et al. 2004; 
Massengale et al. 2005; Simard and Rivest 2004; Vallieres and Sawchenko 
2003), which may have distinct roles in neurodegeneration. For example, in 
autoimmune T-cell-mediated diseases such as EAE, the infiltration of the CNS 
by Ly-6C1 monocytes leads to exacerbated EAE development and clinical 
symptoms, suggesting a pathological role of this cellular subset (King et al., 
2009; Mildner et al., 2009; Prinz and Priller, 2010). This further substantiated 
the notion that brain macrophages can be derived from both resident microglia 
and haematogenous / myeloid macrophages at the sites of CNS injury. 
 
 A more recent study by Ajami et al. (2011) reported that resident microglia 
and macrophages derived from peripheral monocytes accumulated in the CNS 
in multiple sclerosis and in EAE. These cell types are morphologically identical, 
making it difficult to dissect and characterize their roles in the disease. A 
combination of myeloablation and parabiosis was employed to track monocyte 
CNS infiltration in mice with EAE. The extent of monocyte infiltration strongly 
correlated with the stage and severity of EAE, and blockade of such infiltration 





1.3 Microglia activation - A double-edged sword 
 
 Activated microglia are usually detected in injured CNS sites or lesions in 
neurodegenerative diseases. Activated microglia can cause 
inflammation-mediated neurotoxicity through a process known as reactive 
microgliosis (Fig. 1.1) (Streit, Walter and Pennell, 1999; Block, Zecca and 
Hong, 2007). Triggered by misfolded proteins (β-amyloid in AD or α-synuclein 
in PD) or genetic mutations (SOD1 mutation in amyotrophic lateral sclerosis, 
ALS), microglia can become activated. Upon activation, microglia become 
effective producers of pro-inflammatory factors such as tumour-necrosis factor 
(TNF), interleukin (IL)-1β and IL-6 that are also neurotoxic. Frequently, an 
increase in the inflammatory response causes an upregulation or accumulation 
of nitric oxide (NO) and reactive oxygen species (ROS) in microglia, which 
exacerbate neurotoxic effects (McGeer and McGeer, 2006; Kim and Joh, 
2006). Neuronal damage and loss of axonal support can further activate 
microglia by releasing microglial activators like laminin, matrix 
metalloproteinases (MMPs) and neuromelanin, which then feeds into and 
closes up a self-perpetuating cycle of neuronal death. Therefore, activated 
microglia are capable in causing neuronal loss and severe vascular damage 
within the CNS microenvironment in diverse neuropathological conditions 






Figure 1.1. Reactive microgliosis drives progressive neurotoxicity. 
Microglia can become overactivated and cause neurotoxicity through two 
mechanisms. First, microglia can initiate neuron damage by recognizing 
pro-inflammatory stimuli, such as lipopolysaccharide (LPS), becoming 
activated and producing neurotoxic pro-inflammatory factors. Second, 
microglia can become overactivated in response to neuronal damage (reactive 
microgliosis), which is then toxic to neighbouring neurons, resulting in a 
perpetuating cycle of neuron death. Reactive microgliosis could be an 
underlying mechanism of progressive neuron damage across numerous 
neurodegenerative diseases, regardless of the instigating stimuli. Aβ, 
amyloid-β; H2O2, hydrogen peroxide; IL-1β, interleukin 1β; LPS, 
lipopolysaccharide; MMP3, matrix metalloproteinase 3; MPP+, 
1-methyl-4-phenylpyridinium ion; MPTP, 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NO, nitric oxide; NOO-, 
peroxynitrite; O2
-, superoxide; PGE2, prostaglandin E2; TNFα, tumour 
necrosis factor-α (Adapted from Block, Zecca and Hong, 2007). 
 
 Arguably, the deleterious effect of microglial activation may be context 
dependent. In vivo studies have shown that microglia activation may not be 
solely neurotoxic. Microglia can exert neuroprotective functions through the 
secretion of trophic factors such as glial cell line-derived neurotrophic factor 
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(GDNF), brain-derived neurotrophic factor (BDNF), insulin-like growth factor 
(IGF), hepatocyte growth factor (HGF), neurotrophins (NTs) and 
platelet-derived growth factor (PDGF), which are essential to promote repair, 
healing, survival and growth. They are also capable of eliminating cellular 
debris by phagocytosis, contributing to neuroprotection (Rezaie, 2003; Rezaie 
and Male, 2002; Streit, 2002). For example, Neumann et al. (2009) suggested 
that the cell-to-cell contact of exogenous microglia with injured and/or dead 
neurons in the first neuronal layer from the organotypic hippocampal slice 
cultures (also known as capping) triggers the trophic support mechanism by 
promoting the phagocytic removal of dying or dead neurons and the release of 
neurotrophic growth factors to improve the survival of the neurons in the 
deeper layers in the slice. There is also evidence suggesting that 
bone-marrow-derived cells can differentiate into neuronal cells (Mezey et al., 
2003). 
 
 Like macrophages, microglia display remarkable plasticity and can alter 
their physiology in response to environmental cues, giving rise to different 
populations of cells with distinct functions. Hence, activated microglia can 
essentially assume a broad spectrum of activation states (Gordon and 
Martinez 2010; Mosser and Edwards 2008; Martinez, Helming, and Gordon 
2009; Gordon 2003). Studies have attempted to stage a macrophage 
polarization paradigm for activated microglia in the CNS (Fig. 1.2 A) (Martinez 
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et al, 2008). The M1 pro-inflammatory state involves the production of 
pro-inflammatory cytokines and oxidative metabolites via prototypical 
stimulation by interferon-γ, LPS and other TLR activators. M1 macrophages 
produce IFN-γ, TNF-α, IL-1β, IL-18, chemokines and proteases. The M1 
pathway is important for helper T cell type 1 (Th-1) responses, killing of 
intracellular pathogens, promoting strong IL-12-mediated Th1 responses and 
mediating tumor resistance (Kofler and Wiley, 2011).  
 
 Overexpression of granulocyte macrophage colony stimulating factor 
(GM-CSF) and IL-4 followed by LPS in microglia in vitro leads to increased 
production of the anti-inflammatory cytokine IL-10, IL-1 receptor antagonist 
(IL-1ra), and the type II IL-1 decoy receptor (Mantovani et al., 2002; 
Mitrasinovic et al., 2005) leading to the alternative activation or M2 pathway. 
As its name suggests, M2 supports the Th-2-associated effector functions. In 
general, M2 macrophages eliminate harmful debris, promote angiogenesis, 
matrix remodelling and coordinate wound healing. For example, M2-polarized 
macrophages play a role in the resolution of inflammation through high 
endocytic clearance capacities and trophic factor synthesis, accompanied by 
reduced pro-inflammatory cytokine secretion, and are regarded as reparative 
and anti-inflammatory (Martinez et al, 2008). Conversely in the tumor 
microenvironment, M2 macrophages can be redirected to become 
tumor-associated macrophages (TAM), which can facilitate tumor growth, 
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angiogenesis and metastasis by secreting various growth factors and 
suppressing the anti-tumor immune responses, and are regarded as 
pro-tumoral and detrimental (Bingle et al., 2002; Lin and Pollard, 2004). 
 
 
 The M2 pathway can be further subdivided into different phenotypes given 
the elicited or associated functional differences. M2a macrophages (induced 
by exposure to IL-4 or IL-13) & M2b (induced by stimulation with immune 
complexes in combination with IL-1β or LPS), macrophages exert 
immunoregulatory functions by secreting anti-inflammatory cytokines such as 
IL-10 and MMPs and drive Th2 responses. M2c macrophages (generated by 
stimulation with IL-10, TGF-β or glucocorticoids), on the other hand, play a 
predominant role in the suppression of immune responses and tissue 
remodeling. An intricate balance between the two polarization pathways may 
determine the protective or deleterious role of microglial activation during CNS 
injury and diseases (Li et al. 2007; Hanisch and Kettenmann, 2007; Schwartz 
et al. 2006).  
 
 In addition, new categories of macrophage populations were proposed 
based on three different homeostatic activities namely host defense, wound 
healing and immune regulation (Fig. 1.2 B) (Mosser and Edwards, 2008). 
These three basic macrophage populations can blend into various degree or 
“shades” of activation. This classification better illustrates how macrophages 
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can evolve to exhibit characteristics that are shared by more than one 
macrophage population, which the linear polarization classification of M1 / M2 
fails to address adequately. As such, the concept of “regulatory macrophages” 
emerges from this new classification. Regulatory macrophages, which produce 
high levels of IL-10 and down regulate IL-12 production, are regarded as 
anti-inflammatory, and can arise from innate or adaptive immune responses 
(Gerber and Mosser, 2001). The ratio of IL-10 to IL-12 can be used to define 
regulatory macrophages. Clear functional and biochemical differences 
between regulatory and wound-healing macrophages exist. Regulatory 
macrophages, unlike wound-healing macrophages, do not contribute to the 
production of the extracellular matrix, and they frequently express high levels 
of costimulatory molecules (CD80 and cD86) and can be APC to T cells 






Figure 1.2. Classification of macrophage populations. (A) A 
monochromatic depiction of the nomenclature showing the linear scale of the 
two macrophage designations, M1 and M2. (B) The three populations of 
macrophages that are classified based on the three different homeostatic 
activities – classically activated macrophages, would-healing macrophages, 
and regulatory macrophages (Adapted from Mosser and Edwards, 2008). 
 
 Microglia activation may result in a broad spectrum of indications and 
implications. Therefore, the polarization and differentiation of macrophages 
and microglia may explain the differing functional properties of activated 
microglia (Sica et al., 2008; David and Kroner, 2011). M1-like microglia activity 
in the CNS is usually associated with the progression and pathogenesis of 
neurodegenerative disorders by contributing to neuroinflammation and 
neurodegeneration through the production of pro-inflammatory mediators and 
neurotoxic oxidative metabolites. Being neuroprotective, M2-type microglia 
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upon activation lead to enhanced secretion of trophic factors and phagocytosis 
of cellular debris or harmful plaques. A better definition of microglia activation 
through research encompassing macrophage polarization may be useful to 
predict or decipher the behavior of activated microglia under certain 
neuropathological conditions, whether a pro- or anti-inflammatory signature 
will be preferentially adopted. New knowledge and better understanding of the 
role(s) of activated microglia in neurodegenerative diseases will allow the 
formulation of effective therapeutic approaches in future. 
 
1.4 Microglia in neurodegenerative diseases 
 
 The loss of distinct neuronal cells in defined CNS regions is a general 
characterization of neurodegenerative diseases (Prinz and Mildner, 2011). 
Frequently, activated microglia are reported to be highly associated and 
implicated in many neurodegenerative disorders such as Alzheimer’s disease 
(McGeer and McGeer, 1995, 1996; Barger and Harmon, 1997; Benvenisten, 
Nguyen and O’Keefe, 2001; Robert and Griffin, 2005), Parkinson’s disease 
(Henrik et al., 2003), multiple sclerosis (Jack et al., 2005) and HIV1-associated 
dementia (Rock et al., 2004). As activated microglia play a significant role in 
the pathogenesis and progression of the diseases they are associated with, it 
is almost impossible to effectively describe neuroinflammatory disorders 




 1.4.1 Multiple sclerosis 
 
 MS is a severe autoimmune disease of the CNS, characterized by 
demyelination or the loss of axonal myelin sheaths involving neuronal 
inflammation and degeneration as well as neurological and behavioral 
abnormalities (Compston and Coles, 2002; Noseworthy et al., 2000). The 
immune system of MS patients recognizes CNS myelin as foreign antigen and 
raises an immune response against it. The pathological hallmark of MS is 
inflammatory focal demyelination accompanied with axonal loss and limited 
remyelination leading to chronic multifocal sclerotic plaques or lesions.  
 
 Microglia may play the exclusive role in phagocytosing myelin after axonal 
injury in the CNS microenvironment (Nielsen et al., 2009). During EAE, the 
primed autoreactive CD4+ T and CD8+ T cells secrete proinflammatory 
cytokines like IFN- and TNF-α that subsequently activate microglia in the CNS. 
Anti-myelin Th-1 cells infiltrate the brain by crossing the blood brain barrier, 
and their reactivation via antigen-presenting cells (APCs) such as activated 
microglia results in inflammatory demyelination.  
 
 A major problem with MS is that its pathogenesis is poorly understood. 
Considerable amount of MS research is being conducted using experimental 
autoimmune encephalomyelitis (EAE), a murine model of neuroinflammation 
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that mimics some aspects of MS (Wekerle, 2008; Baker et al., 2011). 
Upregulation of MHC antigens on microglia is one of the first molecular 
changes described in MS and EAE (Sanders and Keyser, 2007). This indicates 
that microglia can act as APC to mediate an inflammatory Th-1 response, 
which contributes to neurodegeneration.  
 
 To evaluate whether the CD40-CD40L (CD40-CD154) interaction was 
pathogenic in EAE, a CD40L neutralizing antibody was introduced to SJL mice 
that were given proteolipid protein with adjuvant to induce EAE but EAE did not 
develop with the prophylatic treatment of the neutralizing antibody (Gerritse et 
al, 1996). It was later shown that genetic deficiency in CD40L (Grewal et al., 
1996) or antibody-mediated inhibition of CD40L (Howard et al., 1999) resulted 
in attenuation of Th-1 differentiation and effector functions such as reduced 
numbers of encephalitogenic effector T cells. Becher et al. (2001) showed that 
CD40 expression by parenchymal microglia was responsible for recruitment or 
retention of encephalitogenic T cells producing the Th-1 cytokine, IFN-γ. 
Further, treatment of microglia with a combination of granulocyte 
macrophage-colony stimulating factor and CD40L was demonstrated to 
promote differentiation and expression of the pan-DC marker, CD11c. These 
CD11c+, CD11b+ "DC-like" microglia found in EAE brain lesions in T-cell 
containing inflammatory foci not only morphologically resemble DCs, which 
secrete the Th-1-promoting cytokine IL-12 p70 but also stimulated allogeneic T 
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cell proliferation (Fischer and Reichmann, 2001). Although their origin was 
unclear, it was demonstrated that "CNS DCs" or "DC-like" microglia are 
responsible for activation of naïve T cells in response to endogenous myelin 
epitopes (also known as "epitope spreading") initiated in the CNS, not in the 
peripheral lymphoid organs (McMahon et al., 2005). Therefore, CD40-CD40L 
interaction on microglia drives the adaptive function of these cells by producing 
a "DC-like" activated microglia phenotype that promotes encephalitogenic 
Th-1 cell differentiation and effector functions during EAE or MS. 
 
 The surge in IFN-γ from auto reactive CD4+ T cells decreases neuronal 
survival by activating microglia that damage CNS cells through the release of 
cytotoxic factors such as glutamate, nitric oxide, reactive metabolites and 
pro-inflammatory cytokines (Butovsky et al., 2005). Pro-inflammatory mediator 
production is capable of driving persistent neuroinflammation and neurotoxicity 
during reactive microgliosis (Streit, Walter and Pennell, 1999; Block, Zecca 
and Hong, 2007). In MS, this positive feedback loop potentiates 
neuroinflammation and CNS damage. In addition, activated microglia can 
produce IL-12, IL-18, IL-23 and IL-27, which then drive the differentiation of 
na ve Th cells into Th-1 cells.  urther, activated microglia can also function as 
APCs to prime the na ve Th cells into mature CD4+ T cells.  
 
 In the absence of microglia-derived TNF, inflammatory demyelination is 
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suppressed (Klinkert et al., 1997). Without TNF, extensive microglial glutamate 
release, which causes neurotoxicity, fails to occur (Takeuchi et al., 2006).  
 
 Microglia also exert oxidative stress. Nitric oxide synthesized by inducible 
nitric oxide synthase (iNOS) at high concentrations is involved in CNS 
demyelination. Combined with ROS, NO forms the highly neurotoxic molecule, 
peroxynitrite. Microglial distribution in chronic active MS lesions is correlated 
with iNOS expression, which leads to NO production and subsequent ROS 
generation (Hill et al., 2004). 
 
 Chemokine and chemokine receptors play instrumental roles in the 
migration of lymphocytes into the CNS. Chemokine receptors CCR1, CCR2, 
CCR3, CCR5, and CCR8 are found on microglia present in active MS lesions 
and CCR8 expression is directly correlated with ongoing active demyelination. 
In addition, CCR1 knockout mice exhibited an attenuated form of EAE, 
whereas CCR2 knockout mice showed a partial or complete resistance to EAE. 
Delayed onset of clinical symptoms and attenuated EAE progression were 
observed in CCR8 knockout mice (Aloisi, 2001).  
 
 Apoptotic oligodendrocytes triggered by the tumor necrosis-related 
apoptosis-inducing ligand (TRAIL) or the Fas and FasL (CD95L) pathways 
further exacerbates the demyelinating status in MS. Immunohistochemical 
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analysis revealed increased Fas expression on oligodendrocytes on MS 
lesions while the microglia and lymphocytes in the lesions showed intense 
staining for  asL (D’Souza et al., 1996). In chronic and acute MS lesions as 
well as in EAE brains, there is an increased production of TRAIL by activated 
microglia and infiltrating immune cells (Canella et al., 2007). 
 
 Other than neurodegenerative and neurotoxic effects, activated microglia 
can also produce neuroprotective functions via the production of 
anti-inflammatory mediators. Via the cyclooxygenase (COX) pathway, 
prostanoids (prostaglandins and thromboxanes) are synthesized. cPGs PGA2 
and d15 PGJ2, products of PGD2 metabolism, are effective in counteracting or 
inhibiting NO production in murine microglia that are stimulated with either LPS 
or IFN-γ and TNF (Storer et al., 2005). These two cPGs can inhibit the 
production of TNF, IL-1β, IL-6 and macrophage chemotactic protein (MCP)-1 
(or CCL2). PGJ2 suppresses the microglial secretion of IL-12 and inhibits Th-1 
differentiation (Natarajan and Bright, 2002). Therefore, microglia can also 
function as a negative regulator of its own perpetual neurotoxic stimulation, 
and the behavior and effects of microglia largely depend on external stimuli.  
 
 TNF may also stimulate oligodendrogenesis, leading to remyelination and 
amelioration of MS lesions. Adequate TNF signaling through tumour necrosis 
factor receptor superfamily member 1B (TNFR2) can induce proper 
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remyelination in the cuprizone-induced demyelination model (Arnett et al. 
2001). This may be due to direct or indirect stimulatory effects of TNF on the 
proliferation of oligodendrocyte progenitor, which can reconstitute myelin. With 
IL-4 stimulation, greater oligodendrogenesis is promoted with significant 
reduction in neurological deficits (Butovsky et al., 2006). Oligodendrogenesis 
can also be promoted with submaximal concentrations of IGF-I, which 
prevents the acute effect of glutamate-mediated toxicity on oligodendrocytes in 
vitro and inhibits apoptosis of mature oligodendrocytes during primary 
demyelination (Mason et al., 2000; Ness and Wood, 2002).  
 
 Coexpression of Fas / FasL and Bax on brain and infiltrating T cells in the 
CNS is closely associated with apoptotic cell death during EAE. The detection 
of FasL-induced autoreactive T cell apoptosis during EAE is an example of the 
dampening or neutralization of neuroinflammation via increased death of 
inflammatory immune cells (Kohji et al., 2000).  
 
 1.4.2 Alzheimer’s disease 
 
 Extracellular accumulation of amyloid-β (Aβ) protein, a proteolytically 
processed part of the amyloid precursor protein (APP), is a hallmark of 
Alzheimer’s disease (AD). Aβ can potentially form fibrillar structures that can 
aggregate into senile plaques. Accumulation of activated microglia are 
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observed at brain regions with amyloid deposits (Itagaki et al., 1989; 
Perlmutter et al., 1990). In addition, fibrillar Aβ1-42 is responsible in activating 
microglia through TLR2 in AD (Jana et al., 2008). It has been hypothesized 
that the subsequent production of potential neurotoxic molecules by activated 
microglia such as proinflammatory cytokines and reactive oxygen species can 
exacerbate the neurodegenerative pathologies observed in AD (Akiyama et al., 
2000).  
 
 TLRs functionally interact with other cell surface receptors, including CD36, 
α6β1 integrin, CD47 and scavenger receptor A, that bind to fAβ to initiate the 
activation of intracellular signaling pathways (Bamberger et al., 2003; 
Reed-Geaghan et al., 2009). This receptor complex elucidates the mechanistic 
capability of fAβ to elicit the production and secretion of proinflammatory 
(Th1-type) cytokines (Mantovani et al., 2004). 
 
 Activated microglia being professional macrophages clear Aβ plaques by 
phagocytosis. Any microglial metabolic process that compromises this function 
is therefore neurodegenerative. For example, at later stages in AD, genes 
involved in Aβ clearance are down-regulated, contributing to Aβ accumulation 
(Hickman et al., 2008).  
 
 A new hypothesis for AD pathogenesis points to microglial senescence. 
23 
 
During senescence, microglia lose their normal homeostatic and 
neuroprotective functions and become dystrophic or dysfunctional. Dystrophic 
microglia are characterized by abnormally structured cytoplasmic processes 
associated with tau pathology. The functional impairment of microglia such as 
decreased phagocytosis leading to a decreased rate of amyloid clearance is 
tightly associated with either increased neurotoxicity or the formation of 
neurofibrillary tangles (Hickman, Allison, and El Khoury, 2008; Richartz et al., 
2005; Streit et al., 2008). The compromised effectiveness and efficiency in Aβ 
clearance permits the acceleration of plaques development. Moreover, 
activation may shorten the microglia lifespan by increasing microglial cell 
death with the concomitant release of neurotoxic substances, promoting 
neurodegeneration in AD (Streit et al., 2004). 
 
 The TG β receptor is also implicated in AD pathogenesis. Town et al. 
(2008) expressed a dominant negative form of the TG β receptor using a 
CD11c promoter in myeloid lineage cells. The plaque pathology was 
significantly reduced, which corresponded with behavior improvement in aged 
APP-expressing Tg2576 mice when TG β signaling was suppressed. It was 
proposed that inhibition of TGF-b- Smad2/3 innate immune signaling in 
bone-marrow-derived cells improved AD-like pathology. 
 
 Chemokine receptors are expressed by microglia. The chemokine receptor 
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CX3C-chemokine receptor 1 (CX3CR1), or fractalkine receptor, expressed on 
microglia, plays a part in the recruitment of microglia to injured CNS that 
accounts for neuronal loss. In transgenic mouse models of AD, CX3CR1 
deficiency resulted in reduced β-amyloid deposition (Lee et al., 2010), as 
CX3CL1 – CX3CR1 signaling may have inhibiting effect on phagocytic function 
of microglia. 
 
 When exogenous microglia are injected into the lateral ventricle in rats 
previously injected with Aβ into the hippocampus, the injected cells migrated 
and accumulated around Aβ deposits. They exhibit phagocytic activity and led 
to a substantial decrease in the level of Aβ (Takata et al., 2007). In an AD 
model, numerous bone marrow derived microglia (BMDM) are found to be 
closely associated with amyloid plaques in the CNS of APP/PS1 mice. BMDM 
infiltrated the CNS to eliminate the amyloid deposits by phagocytosis and 
restrict the formation of Aβ plaques, which then slow down the progression of 
the disease (Simard et al., 2006; Kakimura et al., 2002).  
 
 El-Khoury et al. (2007) reported the loss of CCR2 or CD192 in the 
APP-expressing mice was associated with the impairment of chemotaxis and 
migration of blood monocytes into the CNS, suggesting that CCR2 plays an 
important role in CNS microglial accumulation and effective phagocytic 
clearance of Aβ plaques. CCR2-deficient APP-transgenic mice also displayed 
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defective recruitment of CCR2-expressing microglial precursor to the CNS. 
The ligand for CCR2, CC-chemokine ligand 2 (CCL2, also known as MCP1) 
has been reported to be localized with the brain endothelial cells and mature 
amyloid plaques in the AD brains (Ishizuka et al., 1997). Stimulation of 
microglia and astrocytes with Aβ also enhances the release of in the CCL2 into 
the extracellular brain microenvironment (Smits et al., 2002). CCL2-expressing 
endothelial cells and amyloid deposits then recruit plaque- associated 
microglia and astrocytes to the region through CCR2 signaling.  
 
 CD14, TLR2 and TLR4 also play critical roles in the phagocytic uptake of 
fAβ by microglia (Reed-Geaghan et al., 2009). Microglia from CD14-deficient 
mice phagocytosed less fibrillar Aβ42 than that from the wild-type mice. 
APPswe / PSEN1dE9 mice with inactive TLR4 displayed an increase in Aβ 
load in the brain cortex and hippocampus when compared with mice in which 
the TLR4 gene is intact. The accumulated Aβ burden is due to impaired 
microglial-mediated Aβ clearance, which depends on TLR4 function (Tahara et 
al., 2006). However, when APPswe / PSEN1dE9 mice were crossbred with 
TLR2
−/− 
mice, the resulting transgenic TLR2
−/−
 mice showed delayed Aβ 
deposition through 6 months of age (Richard et al., 2008). As TLR2 is also 
required for phagocytosis of amyloid deposits, the result seems contradictory. 
However, the age of the mice in the TLR4 and TLR2 experiments did not tally. 
The mice in the TLR4 experiment were at least 14 months old whereas the 
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TLR2−/− mice are more than twice younger, which provided a new insight for 
the opposing effects observed in AD pathogeneses due to microglia of different 
age. The endogenous microglia can contribute to the effective clearance of 
amyloid plaques in status nascendi but once the plaques are established at 
later disease stages, the activated adult microglia could already be exhausted 
or depleted. 
 
 M1 activated microglia can also contribute to neuroprotection in AD 
instead of neurotoxicity. Overexpression of IL-6 in the murine brains of APP 
transgenic TgCRND8 and TG2576 mice lead to the up-regulation of glial 
phagocytic markers in vivo and enhanced microglia-mediated phagocytosis of 
Aβ aggregates in vitro, resulting in extensive gliosis and marked reduction in 
Aβ depositions (Chakrabarty et al., 2010). 
 
 1.4.3 HIV-1 associated dementia 
 
 Microglia express CD4 receptors and chemokine receptors such as CCR3 
and CCR5 that enables the human immunodeficiency virus (HIV) to bind to 
and infect microglia (He et al. 1997). Hence, microglia become a prime target 
of HIV in the CNS. Monocytes infected with HIV in the peripheral blood can 
also act as carriers for HIV to enter through the blood brain barrier into the 
CNS parenchyma to infect microglia (Williams and Blakemore, 1990). 
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Eventually, HIV infection of the brain can result in dementia (Navia et al., 1986; 
Garden, 2002). 
 
 Microglial HIV infection and viral replication lead to a surge in neurotoxic 
pro-inflammatory cytokines (Ryan et al., 2002). The simian immunodeficiency 
virus (SIV) model of HIV infection also results in enhanced microglial activation 
(Sopper et al., 1996). Through interaction with viral proteins like transactivator 
of transcription (Tat) and gp120 (Kong et al., 1996; Sheng et al., 2000; 
D’aversa et al., 2004; Garden et al., 2004), and soluble factors released from 
infected cells (Lipton et al., 1995), microglia become activated during HIV 
pathogenesis. 
 
 Neuronal autophagy plays a crucial neuroprotective role in HIV infection 
(Alirezaei et al., 2008). Virus-infected microglia mediate neurotoxicity in HIV-1 
via the disruption of neuronal autophagy. In the SIV model, infected microglia 
inhibit neuronal autophagy and contribute to decreased neuronal survival. TNF 
and glutamate are two major mediators of HIV-induced neurotoxicity and both 
yield similar effects on decreasing autophagy in neurons. p62 mRNA was 
increased in the SIV encephalitic brains and as well as in brains from 
individuals with HIV dementia, and abnormal neuronal p62 dot structures 




 1.4.4 Amyotrophic lateral sclerosis 
 
 Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive 
neurodegenerative disorder that specifically affects the upper and lower motor 
neurons, leading to atrophy of skeletal muscle, spasticity, paralysis, and 
eventually mortality within four to six years. Twenty percent of familial ALS 
cases are caused by a mutation in the ubiquitously expressed gene, 
superoxide dismutase (SOD)1 encoding the ROS-scavenging metalloenzyme, 
copper zinc SOD. SOD mutant mice develop more activated microglia (Beers 
et al. 2006). PU.1 SOD1G93A pups reconstituted with wild-type BM had 
prolonged survival outcome and decreased motor neuron loss, indicating a 
pathological role of SOD1G93A microglial cells (Beers et al., 2006). mSOD1 
protein can activate microglia and trigger ROS production that subsequently 
induce motor neuron injury and cell death through a CD14/TLR pathway (Zhao 
et al., 2009). In addition, there was increased expression of inducible nitric 
oxide synthase, the catalytic subunit of the phagocyte NADPH oxidase (NOX2), 
IL-10, IL-6, TNF-a and CCL2, which are characteristic of the Th-1 inflammatory 
response. Compared to the wild-type mice, the lack of the fractalkine receptor 
(CX3CR1) in CX3CR1-/- mice exacerbates neuronal loss in amyotrophic lateral 
sclerosis as well as Parkinson’s disease, suggesting that CX3CR1-CX3CL1 




 1.4.5 Parkinson’s disease 
 
 Second to AD, Parkinson’s disease (PD) is one of the most common 
age-related neurodegenerative disorders. Degeneration of dopaminergic 
neurons (DN) of the substantia nigra, presence of intra-neural eosinophilic 
inclusions called Lewy bodies and marked accumulation of the misfolded and 
aggregated -synuclein protein are the pathological hallmarks of PD. The 
cause of PD remains elusive but a neurotoxin, 
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), has been described to be 
involved in the degeneration of DN (Langston and Ballard, 1983; Langston et 
al., 1983), leading to the development of a MPTP-induced, PD-like disease 
animal model. Enhanced neurotoxic effects of MPTP were also observed in 
CX3CR1-/- mice. 
 
 Microglia can become activated by the MPTP-dependent production and 
release of misfolded -synuclein by DN (Dauer and Przedborski, 2003; Su et 
al., 2007; Zhang et al., 2005). The accumulation of these activated microglia is 
evident; surrounding the DN, they also expressed the classically activated M1 
macrophage phenotype (McGeer et al., 1988; Hunot et al., 1999). Moreover, 
they released free radicals and pro-inflammatory cytokines, which initiated a 
self-propagating cycle of DN neuronal injury and death. Elevation of misfolded 
and aggregated -synuclein led to further oxidative stress and intensified the 
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release of DN neuronal -synuclein, which exacerbated DN 
neurodegeneration. Further, increased lipid peroxidation as well as carbonyl- 
and nitrotyrosine-modified proteins were also observed in CNS nigral tissue.  
 
 Injured neurons polarize the M2 microglia, Th2 and Treg cells via the 
release of chemokines. For example, M2 microglia released IGF-1 and other 
neurotrophic factors, which protected the DN. In addition, adoptive transfer of 
T cells in MPTP-induced PD was found to be neuroprotective. Th-2 and Treg 
maintained a neuroprotective M2 microglial phenotype through the release of 
IL-4, IL-10 and TGF-β. Treg suppress microglial synthesis and release of ROS 
that can be induced by misfolded -synuclein. Th-2 and Treg cells might also 
protect neurons directly by cell-contact-dependent mechanisms or by 
releasing BDNF and other neurotrophic factors.  
 
 1.4.6 Therapeutic indications 
 
 The knowledge of bone marrow-derived cells being able to repopulate or 
maintain the resident microglia in the CNS creates new therapeutic 
opportunities. For example, bone marrow-derived blood monocytes may be 
introduced into the CNS as a source of microglia in the AD model since 
activated bone marrow-derived macrophages are primarily responsible for 
phagocytosis of cellular debris and antibody clearance. In addition, they may 
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potentially replace defective or senescent resident microglia in AD. Delivery of 
functional genes coding for normal proteins or ROS scavenging enzymes such 
as SOD to the CNS may generate neuroprotective and beneficial effects. 
 
 Glatiramer acetate (GA) administration to demyelinated mice drives the 
release of neurotrophic factors in the spinal cord, which corresponded to the 
enhancement of remyelination in MS. A T-cell based vaccination with GA can 
result in decreased plaque formation and induction of neurogenesis in APP 
mice (Butovsky et al. 2006). The injection of GA-primed or activated T cells 
also attenuates the MPTP-induced SN cell loss in PD models by increasing 
secretion of the anti-inflammatory cytokines IL-4 and IL- 10, as well as TGF-β, 
and decreasing pro-inflammatory cytokines by activated microglia. An 
alternative neuroprotective effect of GA is the modulation of the differentiation 
and survival of Th17 cells via signal transducer and activator of transcription 
(STAT)3 activation and RORγt by cytokines (Nurieva et al., 2007 Wei et al., 
2007; Zhou et al., 2007). GA also known as Copolymer 1, Cop-1, or Copaxone 
is currently an approved drug by Food and Drug Administration (FDA) for the 
treatment of relapsing MS.  
 
1.5 CD137 and biological activities 
 
Characterized by cysteine-rich repeats in the extracellular domain 
(Mallet et al., 1991), CD137 (TNFRSF9 / 4-1BB / ILA), a member of the Tumor 
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Necrosis Factor (TNF) Receptor Superfamily (TNFRSF9), is originally coined 
as a potent or inducible T cell costimulatory molecule, which promotes survival, 
maintains cellular division and facilitates differentiation to effector and memory 
cells (Kwon et al., 1989; Schwarz et al., 1993; Hurtado et al., 1997; Kim et al., 
1998; Takahashi et al., 1999). Quintessentially, CD137L signaling induces 
murine and human hematopoietic progenitor cell proliferation, and 
differentiation to macrophages (Jiang, Chen and Schwarz, 2008; Jiang et al., 
2008) as well as human monocytes into inflammatory dendritic cells (Kwajah 
and Schwarz, 2010). Delivering potent costimulatory signals upon activation, 
CD137 is also involved in the regulation of multiple and diverse types of 
immune responses (Watts, 2005; Tamada and Chen, 2006; Lee and Croft, 
2009; Thum, Shao and Schwarz, 2009; Wang et al., 2009; Fernández Do 
Porto et al., 2012). 
 
CD137 stimulation promotes apoptosis in both neutrophils and 
eosinophils even in the presence of GM-CSF and / or IL-5 survival factors 
(Heinisch et al., 2000). However in mouse, the ligation of CD137 on 
neutrophils by anti-CD137 antibody was reported to induce intracellular Ca
2+
 
influx, and to enhance the reactive oxygen species generation and phagocytic 
activities, which was essential for host defense against intracellular pathogens 
like Listeria monocytogenes (Lee et al., 2005). CD137 is inducible on mast 
cells upon the stimulation through the high-affinity receptor for IgE (FcγRI). 
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Nishimoto et al. (2005) further discovered that agonistic anti-CD137 antibodies 
can enhance FcγRI-induced cytokine production and secretion from mast cells. 
Therefore, CD137 stimulation seems to be important in regulating granulocyte 
function during the initiation as well as the resolution of an inflammatory 
response at least as a positive signaling pathway for mast cells. 
 
 The CD137 signal to T cells is able to substitute the CD28 costimulatory 
signal. High expression levels of CD137 can be detected on activated T cells 
and cross linking of CD137 delivers potent costimulatory signals to T cells. M. 
tuberculosis antigen stimulation was reported to specifically up-regulate 
CD137 on T cells and the inhibition of the CD137 pathway enhanced the levels 
of IFN-γ and TNF produced by monocytes and NK against M. tuberculosis 
(Fernández Do Porto et al., 2012). CD137 blockage also significantly 
decreased the percentage of IFN-γ and TNF producing lymphocytes targeting 
the pathogen and the specific degranulation of CD8+ T cells accompanied with 
increased T cells apoptosis.  
  
 Upon stimulation with TNF, LPS, and IL-1β, CD137 expression was 
upregulated on lymphatic endothelial cells (LECs) from undetectable baseline 
levels (Teijeira et al., 2012). Cross-linking of CD137 on activated LECs with an 
agonistic mAb resulted in NF-κB nuclear translocation, the up-regulation of 
VCAM and the production of the chemokine CCL21. Enhanced 
34 
 
CCR7-dependent monocyte-derived dendritic cells transmigration was 
observed with CD137-activated LEC monolayers cross-linked with the 
agonistic mAb or the natural ligand (CD137L). Employing explanted human 
skin tissue, it was also demonstrated that inflamed skin contains abundant 
CD137+ lymphatic vessels and that ex vivo incubation of explanted human 
dermis with TNF enhanced CD137 expression in lymphatic capillaries. Further, 
CD137 agonistic antibody induced CCL21 expression and DC accumulation at 
close proximity to the lymphatic vessels, demonstrating that the inflammatory 
function of lymphatic vessels could be regulated by CD137. 
 
 The co-stimulatory effect of CD137 on T cell proliferation and activation 
makes it a suitable target in tumor immunotherapy for which anti-CD137 
antibodies are being developed. Agonistic monoclonal antibodies (mAbs) 
against CD137 greatly enhance T cell-mediated immune responses against 
different types of tumors and viruses. Agonistic anti-CD137 antibodies were 
demonstrated to improve the efficacy of vaccines against influenza and 
poxvirus (Halstead et al., 2002; Vidric et al., 2004). In addition, the inclusion of 
a CD137 ligand-expressing vector in a vaccine, or engineered expression of 
CD137 ligand on monocytes enhanced their ability to elicit anti-HIV and 
anti-influenza specific CD8+ T cell responses in human and mouse models 
respectively (Bukczynski et al., 2004 and 2005; Harrison, Bertram and 
Ramshaw, 2006; Wang et al., 2009). Albeit the induction of CD137 expression 
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on immune cells enhances the protective immune responses against invasive 
infectious viral pathogens including HIV, whether CD137L will be 
therapeutically effective in chronic and latent infections remains to be 
determined, as previous studies were performed ex vivo and in the absence of 
a high viral load. 
 
 CD137 agonists are attributed as effective immune stimulators, leading to 
elimination of mastocytoma, sarcoma, colon carcinoma and melanoma in mice 
(Croft, 2003; Sica and Chen, 2000; Watts, 2005). Above that, the 
administration of recombinant CD137L or anti-CD137 antibodies effectively 
caused the regression of established tumors in murine in vivo models (Melero 
et al., 1997; Sica and Chen, 2000; Wilcox et al., 2002a; Croft, 2003; Watts, 
2005; Kim et al., 2009; Li et al., 2007). In addition, activated NK cells 
expressing CD137 are required for the anti-tumor effects of CD137 agonists. 
Moreover, CD137 agonists are also reported to ameliorate autoimmune 
responses and produce therapeutic effects in different animal models of 
autoimmune diseases (Foell et al., 2003; Mittler, 2004; Myers et al., 2005; Kim 
et al., 2011; Sun et al., 2002). Furthermore, humanized anti-CD137 antibodies 
had undergone preclinical testing (Hong et al., 2000; Son et al., 2004) as well 
as Phase I / II clinical trial for cancer immunotherapy (Sznol et al., 2008). 
Activation of CD137 leads to enhanced memory T cell survival and 
proliferation, increased NK and T cell cytotoxicity, enhanced CD4/CD8 cell 
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costimulation, enhanced DC antigen presentation and augmentation of 
cytokine production. The wide tolerable dosage range and potent clinical 
activity justified the further evaluation of the humanized antibody treatment 
both as a single agent and in combination with other treatment modalities 
(Demarest, Hariharan and Dong, 2011). 
 
 1.5.1 Expression of CD137 
 
 CD137 expression on primary immune cells is activation-dependent and 
transient (Schwarz et al., 1995). CD137 is primarily expressed on the surface 
of activated CD4+ and CD8+ T cells, (DeBenedette et al., 1997; Schwarz et al., 
1995, 1996; Melero et al., 1998), monocytes (Kienzle et al., 2000), follicular 
dendritic cells (DCs) in the germinal centres (Pauly et al., 2002; Wilcox et al., 
2002b), natural killer (NK) cells (Baessler et al., 2010) and neutrophils 
(Heinisch et al., 2000; Simon, 2001; Lee et al., 2005). In man, CD137 
expression on eosinophils could be observed in patients suffering from 
IgE-mediated allergic responses, but not in normal subjects or those patients 
suffering from non-IgE-mediated eosinophilic disorders (Heinisch et al., 2001). 
Besides immune cells, proinflammatory factors activate primary articular 
chondrocytes to express CD137 (von Kempis, Schwarz and Lotz, 1997). 
CD137 is also highly expressed on certain cancer cells (Melero et al., 1997; 
Lisignoli et al., 1998; Ringel et al., 2001), tumor vessel walls (Broll et al., 2001), 
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hypoxic endothelial cells, atherosclerotic lesions, inflamed vascular endothelial 
cells (Drenkard et al., 2007) and lymphatic blood vessels (Teijeira et al., 2012). 
 
 1.5.2 Genetic and protein structures of CD137 
 
 CD137 can either exist as a type I transmembrane glycoprotein on 
immune cells (Schwarz et al., 1993), or as a soluble protein due to mRNA 
splicing that is found to be enhanced in the sera of individuals with rheumatoid 
arthritis (RA) (Setareh et al., 1995; Michel et al., 1998).  
 
 The murine CD137 gene is mapped on chromosome 4 (Kwon et al., 1989). 
The human CD137 gene is mapped on chromosome band 1p36, where the 
genes of four other members of the TNFRSF, TNFRII, CD30, OX40 and 
TRAMP/Apo3, are also found (Schwarz et al., 1993). Both human and murine 
CD137 are made up of eight exons. Exon VII encodes for transmembrane 
domain (Fig. 1.3 A and B). A smaller isoform lacking this exon generated by 
differential splicing generates soluble CD137 (sCD137) (Setareh et al., 1995; 
Michel et al., 1998). The expression of soluble CD137 lags behind that of 
membrane bound CD137 by approximately 24 hours and it has been proposed 
that as activation of lymphocytes through membrane-bound CD137 delivers a 
potent stimulatory signal then soluble CD137 may provide a negative control 




 The type I transmembrane glycoprotein, CD137, consists of a signal 
peptide, an extracellular domain, a transmembrane domain, and a cytoplasmic 
domain, which is necessary for signal transduction into the cell. Within the 
extracellular region, there are four cysteine-rich domains or regions (CRD), 
which are distinctive of TNFR superfamily members. The five regions within 
the cytoplasmic domain are well conserved between mouse and man, 
indicating that they might be instrumental for CD137 function. Murine and 
human CD137 polypeptides (Fig. 1.3 C and D) share 60% similarity and have 
similar topological structures. The structural characteristics of human CD137 






Figure 1.3. Schematic diagrams of murine and human CD137 mRNA and 
protein structures. (A) murine CD137 mRNA, accession number: 
NM_011612; (B) human CD137 mRNA, accession number: NM_001561; (C) 
murine CD137 protein, accession number: P20334; and (D) human CD137 
protein, accession number: Q07011. STS, sequence-tagged site; CDS, coding 
sequence. The genetic sequences and primary structures of CD137 are 




Table 1. Structural features of human CD137 protein.  
 
Position (amino acid) Structure feature 
1-23  Signal peptide 
24-255  Mature peptide 
19-106  TNFR domain  
24-186  Extracellular domain 
187-213  Transmembrane region 
214-255  Cytoplasmic domain for interaction with LRR-1  
24-45 Repeated region 
47-86 Repeated region 
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LRR-1 indicates leucine-rich repeat protein. Adapted from the Entrez Protein 
database. 
 
 1.5.3 Diseases associated with CD137  
 
 CD137 is detected as a neoantigen on several types of tumor cells 
including Reed-Sternberg cells in Hodgkin’s lymphoma (Anderson et al., 2012; 
Ho et al., 2012), chronic lymphocytic leukaemia (CLL), osteosarcoma (Lisignoli 
et al., 1998), pancreatic cancer (Ringel et al., 2001) and rhabdomyosarcoma 
(Broll et al., 2001). CD137 in both membrane-bound form and soluble form is 
also reported to be involved in or associated with some autoimmune diseases, 
such as herpetic stromal keratitis (HSK) (Seo et al., 2003), rheumatoid arthritis 
87-118 Repeated region 
119-159  Repeated region 
29-36, 43-47, 79-81 Protein binding site 
19, 29, 33, 35, 44, 47, 57 Parallel homodimerization interface 
53, 63, 72, 94, 102  Antiparallel homodimerization interface  
56-57, 62,64 50’s loop TN  binding region 
94, 102-106 90’s loop TN  binding region 
138, 149 Glycosylation site 
56  Variant (A  T) 
115 Variant (K  N) 
176 Variant (A  D) 
250 Variant (E  G) 
28, 37 Disulfide link 
31, 45 Disulfide link 
48, 62 Disulfide link 
65, 78  Disulfide link 
68, 86 Disulfide link 
88, 94 Disulfide link 
99, 106 Disulfide link 
102, 117 Disulfide link 
121, 133 Disulfide link 
139, 158  Disulfide link 
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(RA) (Seo et al., 2004), multiple sclerosis (MS) (Sharief, 2002; Jung et al., 
2004), systemic lupus erythematosus (SLE) and Behcet’s disease (Shao et al., 
2008; Jung et al., 2004).      
 
1.6 CD137 ligand 
 
The natural ligand for CD137, CD137 ligand (CD137L) is a type II 
membrane glycoprotein (Goodwin et al., 1993) expressed on the surface of 
APC including monocytes, macrophages, B cells and dendritic cells. It is also 
expressed on activated T cells (Laderach et al., 2003; Polte et al., 2007; Salih 
et al., 2000).  
 
Apart from co-stimulation of T cells by activating CD137 receptor 
(Langstein et al., 1998), CD137L propagates activating signals back into the 
APCs, which induces proliferation, prolongs survival and enhances the 
secretion of pro-inflammatory cytokines (Langstein et al, 1998; Langstein and 
Schwarz, 1999). This reciprocal signaling ability between both the receptor 
and its corresponding ligand is known as bidirectional signal transduction, 
which typically exists for members of the TNF and TNFR families (Eissner et 
al., 2004). Reverse or CD137L signaling commonly refers to signal 





CD137L signaling has diverse roles in the activities of a variety of cell 
types including APC of myeloid origin such as monocytes, dendritic cells (DC) 
and macrophages (Shao and Schwarz, 2011). CD137L is expressed 
constitutively on monocytes. CD137L signaling prolonged monocyte survival 
via M-CSF induction and enhanced proliferation and endomitosis of human 
peripheral monocytes (Langstein, Michel and Schwarz, 1999). CD137 could 
function as an amplifier of developing immune responses by activating and 
increasing the number of monocytes, which are the precursors of 
macrophages and inflammatory DCs in vivo (Zhu et al., 2001). CD137L 
cross-linking induced the expression of markers of the mature DCs, including 
CD11c, CD86 and MHC-II (Kim et al., 2002). Moreover, CD137L signaling 
promoted cellular adherence and mediated the release of pro-inflammatory 
cytokines such as IL-6 and IL-12 (Laderach et al., 2003). Furthermore, 
CD137L signaling resulted in the differentiation of peripheral human 
monocytes to inflammatory DCs (Kwajah and Schwarz, 2010). CD137L 
signaling in DCs promotes DC activation and maturation, signified by the 
enhanced antigen presentation, which is required to propagate or to elicit 
stronger immune responses. 
 
 1.6.1 Expression of CD137L 
 
 CD137 ligand (CD137L / TNFSF9 / 4-1BBL), the natural ligand for CD137, 
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is a type II transmembrane protein of the TNF superfamily (Goodwin et al., 
1993; Alderson et al., 1994). CD137L is expressed mainly on APC including B 
cells, DC and monocytes/ macrophages. Human and murine transformed B 
cells constitutively express CD137L while activation may be required for 
primary B cells (Pollok et al., 1994; Zhou et al., 1995; DeBenedette et al., 1997; 
Palma et al., 2004). CD137L is also expressed constitutively on peripheral 
monocytes and monocyte/macrophage cell lines (Pollok et al., 1994; Futagawa 
et al., 2002; Ju et al., 2003; Laderach et al., 2003). On DC, CD137L is 
expressed at low levels on both murine and human cells. However, CD137L 
expression can be upregulated by proinflammatory stimuli, including IL-1, 
CD40 ligand, LPS and double stranded RNA (Futagawa et al., 2002; Laderach 
et al., 2003; Kim et al., 2002; Lee, Chang and Lin, 2003). 
 
 1.6.2 Genetic and protein structures of CD137L 
 
 The CD137L gene (Fig. 1.4 A and B) is located on chromosome 17 in the 
mouse (Goodwin et al., 1993) and on chromosome 19p13.3 in man (Alderson 
et al., 1994). The CD137L polypeptide (Fig. 1.4 C and D) possesses a TNF 
domain, which is structurally analogous to that of TNF and lymphotoxin (LT)-α. 
CD137L proteins form homotrimeric or oligomeric aggregates on cell surfaces 
like other members of the tumor necrosis factor (TNF) superfamily (Rabu et al., 




 The human CD137L has approximately 36% homology to the murine 
protein from sequence analysis. This degree of similarity is modest compared 
to the about 70 to 80% of homology between the human and murine ligands, 
which are also TNF family members (Alderson et al., 1994). There is little or no 
homology of human CD137L to other human TNF family members (Smith, 
Farrah and Goodwin, 1994). Besides CD137, a murine CD137-Fc fusion 
protein could bind to various extracellular matrix proteins, including fibronectin, 
vitronectin, laminin and collagen VI (Chalupny et al., 1992) indicating that an 







Figure 1.4. Schematic diagrams of murine and human CD137L mRNA and 
protein structures. (A) murine CD137L mRNA, accession number: 
NM_009404; (B) human CD137L mRNA, and accession number: NM_003811; 
(C) murine CD137L protein, accession number: NP_033430; (D) human 
CD137L protein, accession number: NP_003802. STS, sequence-tagged site; 
CDS, coding sequence. The genetic sequences and primary structures of 




1.7 Bidirectional signaling of the CD137 receptor / ligand system 
 
 
 CD137L is able to transduce signals into the cells it is expressed on via a 
process called bidirectional signal transduction (Fig. 1.5) (Schwarz, 2005). 
Reverse signaling or CD137L signaling is a signal transduction occurring 
through CD137L. During APC and T cell interactions, the signals through 
CD137L are costimulatory for and activate APCs. In other words, CD137L 
expressed on APC transmits activating signals into APC. In concert with 
CD137, which can also deliver costimulatory signals to T cells, CD137L 
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signaling triggering activation in APC therefore set the stage for a potent 




Figure 1.5. Schematic diagram of bidirectional signal transduction of the 
CD137 receptor / ligand system (Adapted from Schwarz, 2005). 
 
 
 1.7.1 Biological functions of CD137L signaling 
 
 
 The biological effects and functions of CD137L signaling in mammalian 
cells are summarized in Table 2. Published CD137L signaling effects on 
microglia were included in the table for the most up-to-date chart. 
 
 1.7.2 CD137L signaling in bone marrow-derived cells 
 
 The expression of CD137L and CD137 in the bone marrow (Saito et al., 
2004; Jiang, Chen and Schwarz, 2008; Jiang et al., 2008; Lee et al., 2008) 
proposed that CD137L signaling could occur in bone marrow progenitor cells 
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other than in differentiated myeloid cells. The proliferation of murine bone 
marrow cells treated with M-CSF is enhanced in the presence of immobilized 
recombinant CD137 (Saito et al., 2004). CD137L signaling also inhibits RANK 
ligand-induced differentiation of bone marrow cells towards osteoclasts (Saito 
et al., 2004; Shin et al., 2006a, 2006b), suggesting that CD137L signaling 
directs the differentiation program of bone marrow cells away from bone 
formation but rather into the myeloid lineage. Nevertheless, total bone marrow 
cells, being a mixture of various cell populations, including differentiated APC, 
cannot effectively provide a clean system to study the effects of CD137L 
signaling in haematopoietic stem/progenitor cells (HSPC). In this aspect, Jiang, 
Chen and Schwarz (2008) reported that CD137 drives murine progenitor (Lin−, 
CD117+) cell proliferation and differentiation to monocytes and macrophages. 
The team further demonstrated that CD137 recombinant protein induced 
proliferation of CD34+ cells or early hematopoietic progenitor cells from human 
umbilical cord blood whereas CD137L agonists were shown to induce 
differentiation of the human progenitors to colony forming units - 
granulocyte/macrophage (CFU-GM) or granulocyte-macrophage progenitors, 
which further differentiate into monocytes and macrophages but not to 





1.7.3 CD137L signaling in B cells 
 
 CD137L is constitutively expressed on murine and human transformed B 
cells while activation may be required for primary B cells (Pauly et al., 2002; 
Pollok et al., 1994). CD137L signaling induces proliferation and 
immunoglobulin synthesis of preactivated B cells (Pauly et al., 2002; Pollok et 
al., 1994). In contrary to the in vitro data, constitutive expression of CD137L on 
APC in transgenic mice leads to a gradual reduction of peripheral B cells after 
three months (Zhu et al., 2001), suggesting that initial or early CD137L 
signaling is activating for B cells but extended CD137L signaling may become 
exhaustive and detrimental to B cells possibly via activation-induced cell 
attrition. Further, the cross-linking of CD137 on monocytes causes the 
induction of B cell apoptosis (Kienzle et al., 2000).  
 
 CD137 expression on follicular DCs in germinal centers support 
CD137L-mediated B cell activation. The expression of CD137 on follicular DCs 
provide costimulatory and survival signals to B cells in the germinal centers, 
which have rearranged their immunoglobulin genes for high affinity binding to 
the antigens (Pauly et al., 2002; Lindstedt, Johansson-Lindbom and 
Borrebaeck,  2003), supporting the contribution of CD137 and CD137L 




 1.7.4 Signaling through CD137L in T cells 
 
 CD137L signaling also occurs in T cells. As opposed to APC, CD137L 
signaling inhibits proliferation and induces apoptosis of human T cells 
(Schwarz et al., 1996; Michel et al., 1999; Ju et al., 2003). Nevertheless, Polte 
et al. (2007) reported that CD137L signaling in murine T cells induces IFN-γ 
release, contributing to immune deviation and the inhibition of the 
Th-2-mediated allergic lung inflammation. 
 
 Except for T cells, CD137L signaling into APCs and their progenitors leads 
to activation, maturation and even proliferation, fueling the initiation and 
amplification of immune responses. Taking the costimulatory signal through 
CD137 into T cells into consideration, the existence of the bidirectional 
signaling of CD137 and CD137L in T cells may be essential for the preparation 
and the development of a more orchestrated and regulated immune response. 
 
 1.7.5 CD137L signaling in DC 
 
 DC are professional APC that initiate an adaptive immune response. 
CD137L is expressed at low levels on murine and human DC, which are 
derived from monocytes or hematopoietic progenitor cells in vitro (Laderach et 
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al., 2003; Kim, Li and Broxmeyer, 2002; Futagawa et al., 2002). CD137L 
signaling in DC enhances their antigen-presenting capability for the initiation of 
immune response and adaptive immunity. However, clarity is needed to 
address whether CD137L alone is sufficient to induce DC differentiation 
directly from hematopoietic progenitors. In addition, it used to be controversial 
whether CD137L signaling alone is sufficient to induce DC activation or 
additional stimulation by CD40 ligand is required. Making a step towards 
answering the scientific question raised, our laboratory reported that the sole 
signal provided by CD137 was sufficient to induce CD137L signaling in 
peripheral blood monocytes and to drive their activation and differentiation into 
mature inflammatory DC with greater T cell costimulatory capacity than 
classical DC (Kwajah and Schwarz, 2010). 
  
 Crosslinking of CD137L on DC induces the upregulation of CD11c, CD80, 
CD86, MHC class II, and CCR7, enhances cellular adherence and triggers the 
release of IL-6, IL-12, and TNF-α (Kim, Li and Broxmeyer, 2002; Futagawa et 
al., 2002; Laderach et al., 2003; Lippert et al., 2008). CD137L-activated DC 
are capable of inducing the proliferation of autologous T cells in 
antigen-specific manner, promoting the release of IL-12p70 and IFN-γ as well 
as supporting T cell differentiation into potent Th1 effectors (Lippert et al., 
2008). These results indicate that CD137L signaling drives the maturation, 
activation and migration of immature DC, which supports the simultaneous 
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potent costimulation of T cells and DC when they interact, When fully engaged, 
the CD137 receptor / ligand system facilitates and supports potent immune 
responses and proinflammatory activities to develop. 
 
 In addition, Wilcox et al. (2002b) reported that freshly isolated mouse 
splenic DCs and bone marrow-derived DC express transmembrane and a 
soluble form of CD137. Triggering CD137 enhances the secretion of IL-6 and 
IL-12 from DC and strengthens the ability of the DC to co-stimulate T cell 
proliferation in vitro. Hence, DC expressing both CD137L and CD137 on their 
surface can be activating via both proteins. However, it remains unclear 
whether both signaling can occur simultaneously and whether a positive 
feedback loop exists in DC activation.  
 
 1.7.6 CD137L signaling in monocytes 
 
 CD137L signaling via the cross-linking of the CD137L on peripheral 
monocytes induces a specific signaling milieu involving protein tyrosine 
kinases (PTK), p38 mitogen activated protein kinase (MAPK), extracellular 
signal-regulated kinase (ERK)-1/2, phosphoinositide-3-kinase (PI3K) and 
protein kinase A (PKA) (Sollner et al., 2007). Signaling through CD137 leads to 
activation of monocytes with enhanced adherence, morphological changes, 
and induced expression of proinflammatory cytokines (TNF, IL-6, IL-8 and 
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IL-12) and activation markers (ICAM-1). Concurrently, it inhibits the expression 
of anti-inflammatory cytokines (IL-10) and differentiation markers (FcγRIII) in 
monocytes (Langstein et al., 1998 and 2000; Laderach et al., 2003). CD137L 
signaling significantly prolongs the survival of monocytes through the induction 
of M-CSF (Langstein and Schwarz, 1999) as well as induces a profound 
proliferation and endomitosis of human peripheral monocytes (Langstein, 
Michel and Schwarz, 1999). Interestingly, the power of CD137 ligand in 
stimulating monocyte proliferation is profoundly higher than that induced by 
other monocyte growth factors such as M-CSF or GM-CSF (Langstein and 
Schwarz 1999a; Ju et al., 2003). Recently, the activating effects of CD137L on 
monocytes have been confirmed in vivo. Transgenic mice overexpressing 
CD137L on APC develop a threefold increase in the number of macrophages 
(Zhu et al., 2001). Conversely, CD137-deficient mice have an accumulation in 
the number of myeloid progenitor cells in the peripheral blood, bone marrow, 
and spleen (Kwon et al., 2002), which may be due to the inability of the 
progenitors to further mature into monocytes, macrophages and even dendritic 
cells as CD137L signaling cannot occur. 
 
 CD137L signaling confers potent signals for the migration of peripheral 
monocytes (Drenkard et al., 2007). Monocytes would encounter CD137 in the 
microenvironment of inflamed tissues where activated immune cells or 
endothelial cells are abundant (Schwarz et al., 1995; Broll et al., 2001; 
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Drenkard et al., 2007). In this context, it is therefore not surprising for CD137L 
signaling to induce proliferation, activation, and migration of monocytes in 
order to further amplify and regulate the ongoing immune response. 
 
Generally, past studies had demonstrated that signaling of CD137L on 
APC mainly functions as an activator and amplifier for ongoing immune 
responses. The studies conducted hitherto mainly focused on developing and 
mature myeloid cells in the blood. No study has been conducted to explore and 
to evaluate the functional effects of CD137 on microglia of the CNS.  
 
Microglia are immune cells of myeloid origin in the CNS, which are 
normally quiescent or in surveillance at rest. Their activation was reported to 
be closely associated with major CNS disorders like Alzheimer’s disease 
(McGeer and McGeer 1995 and 1996; Barger and Harmon 1997; Benvenisten, 
Nguyen and O’Keefe, 2001; Robert and Griffin, 2005), Parkinson’s disease 
(Wilms et al., 2003), multiple sclerosis (Jack et al., 2005) and HIV1-associated 
dementia (Rock et al., 2004). Frequently, microglia are demonstrated to play a 
role in the pathogenesis and progression of the diseases that they are 
associated with. For example, phagocytosis by activated microglia is a 
hallmark of the MS lesion. Interestingly, all of the inflammatory compounds that 





Considering the substantial activating effects of CD137L on the APC of 
myeloid lineage, the hypothesis that cross-linking of CD137L with CD137 may 
influence the activities of microglia, which hence reinforce the immune 
responses in the CNS upon pathological insults, holds a great promise in the 
field of Neuroimmunology.  
 
This project starts with a novel aim to investigate the effects of CD137 
and CD137L activities on murine microglia. The effects of CD137 signaling 
were first studied using BV-2 and N9 microglia cell lines, as well as primary 
microglia. At near confluence, these cells were then harvested and employed 
in an in vitro CD137L signaling culture with either CD137-Fc recombinant 
protein or CD137 expressing T cells. The biological effects and functional 
hallmarks of CD137L signaling were then determined. Supplementing the in 
vitro data, the existence and validity of the CD137 and CD137L co-stimulatory 
pathway in both murine and human pathologies were examined, which will all 




Table 2. Biological functions of CD137L signaling in mammalian cells. 






Induction of TNF, IL-6, IL-8, IL-12, ICAM, and 




Langstein et al., 1998, 2000; 
Laderach et al., 2003 
 Human Induction of M-CSF and prolongation of 
survival 
In vitro Langstein and Schwarz, 1999 
 Human Induced proliferation and endomitosis In vitro Langstein, Michel and Schwarz, 
1999; Ju et al., 2003 
 Human Enhanced migration and extravasation. In vivo Drenkard et al., 2007 
 Human Induction of inflammatory dendritic cells In vitro Kwajah and Schwarz, 2010 
 Mouse Amplification of cell numbers CD137L-trg mice 
 
Zhu et al., 2001 
Macrophages Mouse Downstream of TLR, sustained TNF 
production 
 
CD137L-trg mice Kang et al., 2007 
Dendritic cells (DC) Human Maturation, induction of CD11c, CD86, 
CD137L, MHC-II, IL-12, and cellular 
adherence  
In vitro Laderach et al., 2003; 
Kim et al., 2002 
 Mouse Induction of IL-6, IL-12, CD80 and CD86 In vitro Futagawa et al., 2002 
 Human Maturation by induction of TNF-γ, migration 
by induction of CCR7, enhanced T cell 
proliferation and release of IL-12 p70 and 
IFN-γ 
 
In vitro  
Lippert et al., 2008 
B cells Human Costimulation of proliferation and Ig secretion In vitro Pauly et al., 2002 
 Mouse Costimuation of proliferation In vitro Pollok et al., 1994 
 Mouse Elimination of peripheral B cells  
(3 months later) 




Bone marrow cells Mouse Enhanced proliferation In vitro Saito et al., 2004 
 Mouse Inhibition of osteoclast differentiation In vitro Saito et al., 2004; Shin et al., 
2006a 
 Mouse Enhanced osteoclastogenesis due to 
reduced IL-10 secretion 
 




Mouse Induced proliferation and differentiation to 
macrophages 
In vitro Jiang, Chen and Schwarz, 2008 
 Human Induced proliferation and differentiation to 
monocytes and macrophages 
 
 Jiang et al., 2008 
Microglia Mouse Induction of adherence, phagocytosis, TNF, 
MCP-1, IL-6, IL-1β, IL-12 p40, sICAM, 
MMP-9 production 






In vitro  
Yeo et al., 2012 
T cells Human Inhibition of proliferation and induction of 
apoptosis 
In vitro Schwarz et al., 1996; Ju et al., 
2003 
 
IL: interleukin, ICAM: intercellular adhesion molecule, FCγR: Fc receptor for IgG, M-CSF: macrophage-colony stimulating factor, 
CD137L-trg: CD137 ligand-transgenic, MHC: major histocompatibility complex, CD137-/-: CD137-deficient.
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1.8 Scope and objectives of the project 
 
 Reverse signaling by CD137L activates peripheral monocytes evidenced 
by stronger adhesion, secretion of proinflammatory cytokines (Langstein, 1998 
and 2000) increased survival (Langstein, 1999), proliferation (Langstein, 1999) 
and enhanced migration (Drenkard, 2007). In addition, CD137L signaling 
induces differentiation of monocytes to DC and DC maturation (Lippert, 
2008;Ju, 2009; Kwajah, 2010). Moreover, hematopoietic progenitor cells are 
stimulated by CD137L signaling, which respond with proliferation and myeloid 
differentiation (Jiang, 2008a and b). These data convincingly identify CD137L 
as a potent growth factor for myeloid cells. Nevertheless, the knowledge of 
CD137 and CD137L biology involving microglia has not been reported by 
others in the literature to date. Since APC from the blood express CD137L and 
become activated by CD137L signals, we hypothesize that microglia, the 
resident APC of myeloid origin in the CNS (Davoust, 2008; Prinz, 2011), may 




 To investigate CD137 and CD137 ligand (CD137L) expression and 
activities in murine microglia. 
 
Major goals and milestones: 
 
1. To investigate the effects of CD137L signaling elicited by CD137-Fc 
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recombinant protein on murine microglia in vitro using: 
 
a.  Murine microglia cell lines (BV-2 and N9 cell lines) 
b.  Primary microglia 
 
2. To investigate the effects of CD137L signaling elicited by activated T cells 
on murine microglia in vitro using: 
 
a.  Murine microglia cell lines (BV-2 and N9 cell lines) 
b.  Primary microglia 
 
3. To study the effects of CD137L-activated microglia on CNS cells such as 
oligodendrocytes in Experimental Autoimmune Encephalomyelitis (EAE) as 
a model system. 
 
4. To identify the mechanism mediating CD137-induced microglia activation. 
 
5. To determine in vivo CD137 and CD137L expressions in healthy and 
disease brain tissues using immunohistochemistry (IHC) and 
immunofluorescence (IF). 
 
a. To perform IHC stainings of CD137 and CD137L on WT murine  
  brains. 
b. To perform IHC stainings of CD137 on CD137-/- and CD137L-/-  




c. To perform CD137 and CD137L stainings on the EAE brains. 
 
d.  To perform CD137 and CD137L stainings on healthy and    
  multiple sclerotic human brain tissues. 
 
 
6. To examine a role of the CD137 and CD137L system in the human 
neuroinflammation using healthy and MS brains. 
 
7. To perform IHC and IF stainings for relevant brain cell and disease 
markers. 
  
 The project aims to expand our knowledge and to promote our 
understanding of CD137 and CD137L biology, as well as CD137L signaling in 
relation to microglia. In addition, the human arm of the project, which studies 
CD137 and CD137L system in healthy and MS brain tissues in conjunction 
with the murine work will help to strengthen the murine data and to identify the 
clinical significance and relevance of the CD137 and CD137L system in 
neurodegeneration. The ability to identify the main CNS players that 
exclusively expresses an immune molecule upon activation, which then 
renders them being capable in driving and exacerbating the severity of 
neuroinflammation presents as an attractive approach or strategy for potential 
treatments to be proposed and tested. Upon successful completion of the 
project, new specific protein or cellular targets for the treatment of 
neurodegenerative diseases may be elucidated for further characterization. 
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CHAPTER 2  MATERIALS AND METHODS 
 
2.1 Culture of murine microglia cell lines for CD137L signaling 
 
 Murine microglia cell line, BV-2, was purchased from Banca Biologica e 
Cell Factory – IST Genova. BV-2 cells were first recovered and expanded in 
T75 Nunclon flasks using recommended growth medium, RPMI 1640 
containing 10% fetal bovine serum (FBS). Subsequently, BV-2 cells were 
frozen at ~2 x 106 cells/ml per cryogenic vial. Each frozen vial of BV-2 cells 
was recovered in a T75 flask. Fresh growth medium was changed every three 
to four days before 80% confluence was reached a week later. BV-2 cells 
employed for CD137L signaling were tested to be mycoplasma free. 
 
 The N9 cell line was a gift from Dr. Wong Siew Heng from the Department 
of Microbiology, Immunology Program. Roswell Park Memorial Institute (RPMI) 
1640 cell growth medium containing 10% FBS was employed for the 
expansion of the murine N9 cell line. Subsequently, N9 cells were frozen at ~2 
x 106 cells/ml per cryogenic vial. Each frozen vial of N9 cells was recovered in 
a T75 flask. Fresh growth medium was changed on every two or at most three 
days before 70% confluence was reached in close to a week’s time. N9 cells 
employed for CD137L signaling were tested to be free from mycoplasma 
contamination. 
 
 Cells grown to confluence were harvested using non-enzymatic 
dissociation medium (Sigma) after 15 min incubation at 37°C prior to seeding 
61 
 
for CD137L signaling studies. Cells were removed into respective 50 ml Falcon 
tubes, topped up with 5 volumes of growth media and centrifuged at 1,200 rpm 
for 10 min. Supernatants were removed and cell pellets were dislodged and 
resuspended in respective growth media. Manual cell counting using trypan 
blue was employed to determine the number of viable cells harvested. Cells 
were resuspended in appropriate volumes of growth medium to achieve the 
desired concentrations. 
 
2.2 Culture of murine oligodendrocyte cell line, OLN93 
 
 Murine oligodendrocyte cell line, OLN93, was a generous provision by 
Professor Charanjit from the Department of Anatomy, NUS. OLN93 cells were 
cultured in Dulbecco's Modified Eagle Medium (DMEM) high glucose medium 
(Sigma) containing 10% FBS (Biowest) at 37°C in 5% CO2. Growth medium 
was changed every two to three days before cells reached confluence. At 
confluence, OLN93 cells were harvested using non-enzymatic dissociation 
medium (Sigma). Cells were then transferred into 50 ml Falcon tube, topped 
up with 5 volumes of growth media and centrifuged at 1,200 rpm for 10 min. 
Supernatants were removed and cell pellets were dislodged and resuspended 
in desired growth media. Manual cell counting using trypan blue was employed 
to determine the number of viable cells harvested. Subsequently, cells were 
resuspended in appropriate volumes of growth medium to achieve the desired 
concentration prior to seeding. Cells were employed either alone or in 




2.3 Primary microglia culture 
 
 Six to eight weeks old female C57BL/6 mice were deeply anaesthetized 
with pentobarbitone (90 mg/kg). Transcardial perfusion was performed using 
0.09% NaCl with ice cold heparin. Brain and spinal cord tissues were extracted 
and processed using the MACS Neural Tissue Dissociation kit and the 
GentleMACS Tissue Dissociator (Miltenyi). Manual cell count was performed 
using trypan blue staining, and the cells were resuspended in DMEM high 
glucose containing 10% fetal bovine serum (FBS), 1 x penicillin streptomycin 
(Life Technologies), 50µg/ml gentamycin sulphate (Biological Industries, Israel), 
50µM beta-2-mercapethanol (Sigma) and 10 ng/ml M-CSF (Peprotech). A 
seeding density of 1.5 x 106 cells per ml was employed and cells were 
incubated for up to 4 days at 37°C in 5% CO2. Growth medium with 10 ng/ml 
M-CSF was supplied every 3 to 4 days for up to 4 weeks.  
 
2.4 Preparation of CD137L signaling tissue culture plates 
 
One day prior to cell seeding, sterile 24-well flat-bottomed Nuclon tissue 
culture plates were subjected to PBS (10x ultra pure grade stock from 1st base, 
Singapore), human Fc fragment (Millipore, Temecula California) and human 
CD137-Fc treatment1. This was performed in triplicates for each of the above 
conditions. For dosage dependent assays, Fc fragment and CD137-Fc protein 
were diluted from stock concentrations to 10 µg/ml, and appropriate amounts 
of respective proteins were used to coat the wells at 1.25, 2.5, 5 and 10 µg/ml. 
                                                         
1
 Similarly, PBS, Fc and CD137-Fc treated wells were prepared one day prior to cell seeding 
but using a 96-well flat-bottom Costar tissue culture plate instead for the proliferation assay. 
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The final volume in each well was brought up to 1.5 ml with PBS. The tissue 
culture plates were sealed with parafilm and incubated at 4°C overnight prior to 
usage. Following the overnight incubation of the tissue culture plates in PBS, 
Fc and CD137-Fc, well contents were removed and the wells were rinsed with 
equal volume of PBS before use. Figure 2.2 shows a schematic on 
immobilized CD137-Fc and the interaction with CD137L-expressing cells such 




Figure 2.1. A schematic depiction of recombinant CD137-Fc protein 
immobilized on a tissue culture well and its interaction with 
CD137L-expressing cells. Recombinant CD137-Fc protein was constructed 
from the extracellular domain of CD137 and the Fc domain of an IgG molecule. 
The CD137L signaling culture with CD137L-expressing cells of interest was 
incubated at 37°C in 5% CO2 for up to one week. Subsequently, the various 
effects of CD137L signaling were investigated. 
 
 
2.5 Induction of CD137L signaling 
 
 Tissue culture plates were coated with PBS, 10 µg/ml of human Fc 
fragment (Millipore, Temecula California) or 10 μg/ml human CD137-Fc (R&D 




 For microglia and OLN93 co-cultures, either BV-2, N9 cells or primary 
microglia were co-cultured with OLN93 cells through time on PBS, Fc and 
CD137-Fc coated plates. Murine microglia cells were labeled with 2 µM CSFE 
(Invitrogen) prior to co-culture. 10,000 U/ml of catalase were added to 
designated wells. 
 
2.6 CFSE labeling 
 
 Microglia cells at a concentration of 106 cells/ml were labeled with 2 µM 
Carboxyfluorescein diacetate, succinimidyl ester (CFSE), using the 
CellTraceTM CFSE Cell Proliferation Kit (Invitrogen, CA) according to the 
manufacturer’s protocol. Labeled cells were cultured in plate precoated with 
PBS, 10 μg/ml  c or CD137-Fc. Microglia and oligodendrocytes cocultures 
were harvested after Day 2 and analyzed by flow cytometry.  
 
2.7 Cell count 
 
 2.7.1 Manual cell counting by trypan blue 
 
 Cells were harvested after incubation with 10 mM EDTA/ non-enzymatic 
cell dissociation medium (Sigma) for 10 min. The side of the flasks were 
tapped. Equal volume of PBS was then added. Sterile cell scrapper was used 
to facilitate complete detachment of cells from the surface of the flasks. Cell 
suspension was centrifuged and resuspended in respective culture media. The 
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numbers of viable cells were assessed using 0.4% Trypan blue (Sigma) and 
counted with a haemocytometer (Neubauer). Considering the dilution factor, 
the actual number of cells harvested were computed. 
 
 2.7.2 Cell counting beads by flow cytometry 
 
 Cell samples were stained with 7-AAD for 5 min followed by Annexin V for 
another 5 min. 50 μl of Sphero AccuCount Blank Particles (ACBP-100-10, 
Spherotech, IL, USA) was added to the suspension and mixed well. Samples 
were analyzed by flow cytometry (Cyan, DAKO Cytomation). 7-AAD and 
Annexin V negative cells were gated as the live cells, and double positive cells 
were regarded as dead/ apoptotic cells. The population of beads and target 
cells were gated separately on the forward/side scatter plot based on different 
sizes. The concentration of cells (cells/ml) in each sample was calculated by 
the following formula, and the cell number was calculated as cell concentration 




2.8 Isolation of pan T cells from mouse splenocytes 
  
 Splenocytes from 6 - 8 week-old female mouse spleen were extracted, red 
blood cell (RBC) lysed and filtered prior to T cell isolation using MACS mouse 
Pan T Cell isolation kit (Miltenyi). Freshly isolated splenocytes were labeled 
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with a cocktail of biotin-conjugated antibodies against CD45R (B220), CD49b 
(DX5), CD11b (Mac-1), and Ter-119 expressed on non-T cells (B cells, NK cells, 
dendritic cells, macrophages, granulocytes, and erythroid cells), followed by 
anti-biotin microbeads. The cell suspension was introduced into an LS column 
to follow through a strong magnetic field and the free unbound T cells were 
collected as the eluate. The purity of T cells were > 90% as determined by flow 
cytometry using a PE-conjugated anti-CD3 antibody (eBioscience). 
 
2.9 Surface markers expression 
 
BV-2, N9 and OLN93 cells were stained for both CD137 and CD137L. In 
addition, BV-2 and N9 cells were double stained for CD11b and CD45, and for 
both CD11b and CD137L. Primary microglia were stained for CD137L, CD11b 
and CD45. CD80, CD86, CD40 and MHC class II stainings were also 
performed on activated microglia after coculture with stimulated T cells. 
Respective isotype antibodies were included as baseline controls to determine 
the percentage of expression of the surface markers of interest on different 
cells. Cell surface marker measurements were performed using flow cytometry 
on the Cyan flow cytometer. 
 
2.10 Antibodies and flow cytometry  
 
 Phycoerythrin (PE)-conjugated and unconjugated anti-mouse CD137 
antibody (clone 17B5) and anti-mouse CD137 ligand antibody (clone TKS-1) 
were obtained from eBioscience (San Diego, CA, USA). PE or Fluorescein 
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isothiocyanate (FITC) labeled rat anti-mouse CD11b, CD45, and respective 
isotype controls (rat IgG2a, rat IgG2b, Armenian Hamster IgG) were 
purchased from eBioscience. Non-specific staining was controlled by 
isotype-matched antibodies. A full list of antibodies employed for the project 
are listed in Table 3 below. 
 
Table 3. List of antibodies employed 
Antibody Clone Vendor 
Rat anti-mouse CD137L (PE, biotin) TKS-1 eBioscience 
Rat IgG 2a, κ (PE, biotin) RTK2758 eBioscience 
Hamster anti-mouse CD137 (PE) 17B5 eBioscience 
Armenian hamster IgG (PE, FITC, APC, biotin) eBio299Arm eBioscience 
Hamster anti-mouse CD3e (PE, FITC, APC) 145-2C11 eBioscience 
Rat anti-mouse CD11b (PE, APC) M1/70 eBioscience 
Rat anti-mouse MHC-II (I-A/I-E) (efluor 450) M5/114.15.2 eBioscience 
Rat anti-mouse CD40 (PE) 1C10 eBioscience 
Rat anti-mouse CD80 (PE) 16-10A1 eBioscience 
Rat anti-mouse CD86 (B7-2) (PE) PO3.1 eBioscience 
Rat IgG 2a, κ (PE) eBR2a eBioscience 
Rat IgG 2b, κ (PE) eB149/10H5 eBioscience 
Rat anti-mouse CD86 (PE, biotin) PO3 BD Pharmingen 
Rat (SD) IgG2b, κ (PE, biotin) A95-1 BD Pharmingen 
Hamster anti-mouse CD80 (B7-1) 16-10A1 BD Pharmingen 
Hamster IgG2, κ (PE) B81-3 BD Pharmingen 
Rat anti-mouse CD3 (LEAF) 17A2 BioLegend 
Rat anti-mouse CD3 17A2 BioLegend 
Hamster anti-mouse CD28 (LEAF) 37.51 BioLegend 
Rat anti-mouse GM-CSF (LEAF) MP1-22E9 BioLegend 
Rat anti-mouse CD137L (LEAF) TKS-1 BioLegend 
Rat IgG2b, κ (LEAF) RTK4530 BioLegend 
Rat IgG2b, κ RTK4530 BioLegend 
Syrian hamster IgG (LEAF) SHG-1 BioLegend 
Rat IgG2a, κ (LEAF) RTK2758 BioLegend 
Rat anti-mouse GM-CSF MP1-22E9 BD Pharmingen 
Rat IgG2a, κ R35-95 BD Pharmingen 
   
   
Rabbit anti-mouse Iba-1 Polyclonal Wako 
Chemicals 
Normal Rabbit IgG  - Santa Cruz 
Normal Rabbit IgG-B, biotin  - Santa Cruz 
Donkey anti-rabbit IgG (minimal x-reactivity) 
(DyLight™ 649, Cy5) 
Poly 4064 Biolegend 
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Goat anti-rabbit IgG (H+L), highly cross- 
adsorbed (AF647, Cy5) 
- Invitrogen 
Mouse anti-rat IgG (FITC) - ebioscience 
   
   
Mouse anti-human CD137L (FITC) 5F4 BioLegend 
Mouse anti-human CD137 (biotin) 4B4-1 BD Pharmingen 
Mouse anti-human CD137 (biotin) BBK-2 NeoMarkers 
Mouse IgG1 (unconjugated, PE) MOPC-21  Sigma 
Goat anti-mouse CD137 (biotin)  Polyclonal R&D Systems 
Goat IgG (biotin) Polyclonal R&D Systems 
Donkey anti-goat IgG (H&L), cross- 
adsorbed (Cy3) 
Polyclonal Abcam 
Sheep anti-human Nogo-A Polyclonal R&D systems 
Donkey anti-sheep IgG (H+L) (AF555, Cy3) - Invitrogen 
Normal sheep IgG - Santa Cruz 
   
   
Streptavidin (HRP) - Sigma 
Streptavidin (Cy3) - ebioscience 
   
 
 
2.11 Apoptosis assay 
 
 For assessment of apoptosis cells were stained with 7-AAD (BD 
Pharmingen) and Annexin V Alexa Fluor 647 (BioLegend) according to the 
manufacturer's protocol. The percentage of apoptotic cells was determined by 
flow cytometry. Flow cytometry was performed either on a FACSCalibur (BD 
Biosciences, San Jose, CA) with CellQuest data acquisition and analysis 
software, or on a Cyan flow cytometer (Dako, Denmark) with Summit software.  
 
2.12 Oxidative burst assay 
 
 After 24 h of incubation at 37°C in 5% CO2, cells in the PBS, Fc and 
CD137-Fc wells of the 24-well CD137L signaling plate were subjected to either 
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with and without PMA (0.4 μg/ml) treatment for 1.5 h at 37°C followed by 
addition of 100 ng/ml of dihydrorhodamine, DHR123, (Invitrogen) for 25 min 
incubation at 37°C. Then cells were washed to remove excess DHR123. ROS 
production as a result of oxidative burst was quantified using the FITC channel 
on a Cyan flow cytometer. 
 
2.13 Proliferation assay 
 
Determined by manual cell counting, 5 x 105 cells/ml of N9 cells were 
seeded into each well of a 96-well microtitre plate with eight repeats for three 
conditions namely PBS, Fc and CD137-Fc. Cells were incubated at 37°C in 
5% CO2 overnight. Cells were treated with 20 µL (1 µCi) of 
3H-thymidine the 
next day and incubated for 18 to 24 h. Cells were then frozen prior to the 
determination of 3H levels. 
 
2.14 Phagocytosis assay  
 
The phagocytic ability assessment was performed with 1.0 µm 
yellow-green fluorescent latex beads (FluoSpheres®, Molecular Probes). 50 
beads/ cell of fluorescent latex beads were added to each well and samples 
were incubated at 37°C in 5% CO2 for 1 h. Subsequently, phagocytosis was 
stopped by the addition of ice-cold PBS and cells were washed and treated 
with trypsin to dislodge any surface adherent latex beads. Cells were then 
resuspended in 400 µl PBS and harvested. Flow cytometry was performed to 




2.15 Enzyme-linked immunosorbent assay (ELISA)  
      
Cell culture supernatants at desired time intervals were collected and 
frozen down at -20°C prior to ELISA determination. Depending on the ELISA 
kits (R&D Systems or Peprotech), assays were performed in accordance to the 
manufacturers’ protocols. Briefly, 96-well microtitre plates were coated with 50 
µL of the primary antibodies of interest per well at room temperature overnight 
and then blocked with 150 µL of blocking buffer per well prior to the addition 50 
µL of samples and standards in each respective well. Following the incubation 
of samples and standards, 50 µL of capture biotinylated antibodies were added 
per well. Next, 50 µL of streptavidin-conjugated horse radish peroxidase (HRP) 
was added into each well for 20 to 30 min. For detection, 50 µL of TMB 
substrate were added to each well. 15 to 20 min later, after samples turned 
blue, 50 µL of 2 N H2SO4 was added into each well and the absorbance 
reading was read at 450 nm with a reference wavelength of 595 nm using 
Tecan spectrophotometer. Standard curves were derived using the absorbance 
readings plotted against the serially diluted concentrations of the standards or 
cytokines of interest, and results were expressed as cytokine concentration 
(pg/ml) over the length of treatment, with values compared amongst PBS, Fc 
and CD137-Fc samples. 
 
 ELISA assays for TNF, sICAM-1 and Total MMP-9 (R&D Systems), and 
MCP-1, IL-1β, IL-6 and IL-12 p40 (Peprotech) were performed according to the 
manufacturers’ protocols. All measurements of samples were done in 
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triplicates and standards, in duplicates. 
 
2.16 Intracellular cytokine staining 
 
 Prior to intracellular staining procedure, the inhibitor of protein transport, 
Brefeldin A (stock concentration, 10 mg/ml),  was added at 2000x dilution 
(working concentration, 5 µg/ml) to the single T cell culture and T cell-microglia 
co-culture and incubated at 37°C in 5% CO2 for up to 15 h. Intracellular staining 
for GM-CSF was performed according to the manufacturer's protocol (BD 
Biosciences) and measured using flow cytometry. 
 
2.17 EAE induction2 
 
All institutional guidelines for animal care and use were strictly adhered 
throughout the experiments. C57BL/6 mice were obtained from the Centre for 
Animal Resources (CARE) of the National University of Singapore, and 
CD137L-/- mice were a gift from Amgen and bred in-house under pathogen-free 
conditions. Mice were injected subcutaneously with 100 µg MOG35-55 
(Sigma-Aldrich) and 1 mg heat-killed Mycobacterium tuberculosis H37RA 
(Difco) emulsified in complete  reund’s adjuvant. Pertussis toxin (200 ng in 
PBS; List Biological Laboratories) was injected intraperitoneally on days 0 and 
2 after immunization. EAE clinical symptoms were scored daily as follows: 0, 
no clinical signs; 1, loss of tail tonicity; 2, impaired righting reflex; 3, partial hind 
limb paralysis; 4, total hind limb paralysis. 
                                                         
2
 This procedure was performed by Drs. Julia M. Martínez Gómez and J. Ludovic Croxford. 




2.18 Stereotactical sectioning of formalin-fixed mouse brains 
 
 Extracted CNS were formalin-fixed for up to 96 h. Lying on the dorsal 
surface facing downwards or inwards, the murine brain was accommodated 
into the mouse brain blocker (Model PA 002, David Kopf Instruments) that 
consists of a rectangular block of clear acrylic, which has 13 regularly-spaced 
intervals. Thickness Depth = 5.5 mm, length = 12.5 mm, width = 10.9 mm. The 
brain was then subjected to stereotactical sectioning using a sharp microtome 
blade. Four standardized sections ranging from intervals 1 to 5 (substantial 
nigra), 5 to 7 (hippocampus), 7 to 11 (striatum) and 11 to 13 (cerebellum and 
medulla) were generated from each brain. Intervals 1 to 5 and 5 to 7 feature 
the hippocampus and substantial nigra while intervals 7 to 11 and 11 to 13 




 2.19.1 Immunohistochemical (IHC) stainings 
 
 Animal facilities in the Animal Holding Unit (AHU) of the National University 
of Singapore (NUS) were utilized for the accommodation of the commercially 
purchased C57BL/6 mice in conjunction with the in-house bred CD137-/- and 
CD137L-/- mice before they were employed in the experiments. The mice were 
aged between six to eight weeks old, and were handled according to the 




 Transcardial perfusion was performed prior to sacrificing the mice. CNS 
tissues from naive and EAE-induced mice were extracted and fixed with 10% 
neutral buffered formalin for 3 days. The tissues were sectioned and placed in 
cassette holders. Tissues-containing cassettes were processed under standard 
IHC tissue processing procedure for 18 h, paraffin-embedded using the 
embedding machine, and sectioned at 5 µM thickness using a microtome 
(Leica Microsystems). After deparaffinization in Histo-Clear, and hydration in a 
graded series of alcohol, the slides were pretreated with citrate buffer (Dako) in 
a pressure cooker at 109°C for 20 min for antigen retrieval. Unspecific staining 
was blocked by 2% serum for 30 min. Endogenous peroxidases were 
inactivated by 3% hydrogen peroxide for 15 min. Anti-CD137 (goat polyclonal, 
R&D Systems) and anti-Iba-1 (rabbit polyclonal, Wako Chemicals) in PBS were 
used as primary antibodies and hybridized overnight. The secondary 
Strepavidin-HRP (Sigma) was added for 1 h, followed by DAB+ substrate 
(Dako). The entire procedure was carried out at room temperature, and after 
each step the samples were washed three times using PBS with 0.05% Tween 
20. The tissue sections were counterstained with hematoxylin for not exceeding 
2 min and excess counterstain was washed off with distilled water. Finally, the 
stained slides were dehydrated in a graded series of alcohol followed by 
Histo-Clear and mounted.  
 
 2.19.2 TUNEL and immunofluorescence (IF) stainings 
 
 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
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FITC Assay (Genscript) was performed according to manufacturer's 
instructions. Murine oligodendrocytes (OLN93), activated murine microglia and 
cell nuclei were visualized with Cy3-conjugated anti-Nogo-A (sheep polyclonal, 
R&D Systems), Cy5-conjugated anti-Iba-1 (rabbit polyclonal, Wako Chemicals) 
and DAPI counterstain, respectively. Infiltrating activated murine T cells were 
visualized with FITC-conjugated anti-CD3 and Cy3-conjugated donkey 
anti-goat CD137 on biotin conjugated goat anti-CD137 and DAPI. 
 
 Healthy and multiple sclerotic human brain tissue sections were purchased 
from amsbio LLC, CA, USA. Human oligodendrocytes were detected using 
Cy3-conjugated anti-Nogo-A (sheep polyclonal, R&D Systems) while activated 
human microglia were visualized using FITC-conjugated anti-CD137L (5F4) 
and Cy5-conjugated anti-iba-1 (rabbit polyclonal, Wako Chemicals). Human 
CNS cells, activated microglia and cell nuclei were stained for TUNEL, 
biotinylated anti-CD137 (4B4-1) and Cy3-conjugated streptavidin, 
Cy5-conjugated anti-Iba-1 and DAPI respectively. Anti-fading mounting agent 
(Invitrogen) was added onto the IF-stained tissue samples prior to mounting 
with cover slips. 
 
2.20 Microscopy and photography  
 
 Morphological changes of cells were documented by using a Zeiss 
Axiovert 40 inverted microscope (Zeiss, Göttingen, Germany) and Canon 
Powers hot G6 digital camera. Immunofluorescence was documented using 




2.21 Statistical analysis 
 
 Data are presented as means ± standard deviation for different 
independent experiments. Two-tailed student's t-test was employed to 
determine significant differences between control and treated groups. p value < 
0.05 is regarded as statistically significant. 
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CHAPTER 3 RESULTS 
 
 
 CD137L signaling was reported by our lab to induce differentiation of 
peripheral blood monocytes towards inflammatory dendritic cells (Kwajah and 
Schwarz, 2010). As myeloid cells isolated from the blood were able to become 
activated and matured under the influence of CD137, it is proposed that 
microglia, the CNS immune cells of myeloid origin, may also respond to CD137. 
A two-tier strategy was designed to study and clarify the effects of CD137L 
signaling in microglia. Firstly, the effects of CD137 on microglia cell lines, CNS 
cells and CNS-derived primary microglia would be investigated by incubating 
these cells with an immobilized recombinant CD137-Fc protein in vitro. The 
effects of CD137 on microglia morphological changes, release of 
proinflammatory cytokines, reactive oxygen species (ROS) production, 
proliferation and phagocytic ability were determined. The second arm of our 
approach aimed to demonstrate a functional role of CD137/ CD137L system in 
vivo. The result chapter would present both in vitro and in vivo data to support 
the hypothesis. 
 
3.1 CD137 is a functional activator of murine microglia in vitro 
 
 
 3.1.1 Murine microglia express CD137L and iba-1 
 
 
 Our preliminary data lend support to the hypothesis that CD137L signaling 
drives murine microglia activation. CD137L but not CD137 is expressed on the 
microglia cell lines BV-2 (Figure 3.1 A) and N9 cells (Figure 3.1 B). Similar to 
the microglia cell lines, primary microglia express CD137L and the myeloid 
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nature of primary microglia was confirmed by staining for CD11b and CD45 
(Figure 3.1 C). A CD11b high and CD45 low signature is characteristic of 
resident microglia but not of peripheral monocytes that express high CD45 but 
low CD11b.  
 
 The expression of CD137L on murine microglia qualifies murine microglia 
as an appropriate tool to study the effects of CD137, and CD137L signaling on 
these cells. As previous findings in the lab have demonstrated that murine 
monocytes can become activated by CD137 through CD137L signaling (Tang 





Figure 3.1. Expression of surface markers on murine microglia. 
Expressions of CD137L and CD137 on the murine microglia cell lines (A) BV-2 
and (B) N9 cells, and expressions of CD137L, CD11b and CD45 on (C) 
primary murine microglia were determined by flow cytometry. Open histogram: 
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Isotype controls. Grey histogram: Anti-CD137L monoclonal antibody (clone 
TKS-1) and anti-CD137 monoclonal antibody (clone 17B5). Primary microglia 
was also stained for CD11b and CD45. Numbers in panels indicate the 
percentages of surface marker positive cells. 
 
 
 3.1.2 CD137 induces morphological changes in murine microglia  
 
 
 When cultured with complete media, the untreated BV-2 and N9 microglia 
were semi-adherent and round while untreated primary microglia were 
attached but more well-spread and pleiomorphic. Figure 3.2 A shows the 
morphology of BV-2 and N9 microglia grown in tissue culture flasks prior to any 
treatment. M-CSF-induced primary murine microglia expanded and developed 
colonies or foci through time in tissue culture flasks prior to any treatment 






Figure 3.2. Morphology of murine microglia culture in vitro. (A) BV-2 and 
N9 microglia were expanded and developed on tissue culture flasks for 3 to 4 
days. Microglia morphology were documented by photography at near 
confluence during in vitro culture (20x magnification). (B) Developing murine 
microglia colony in 10% FBS-containing DMEM medium after Day 26 of culture. 
Photographs of murine microglia were documented at 10x and 20x 




 CD137L signaling activates microglia in vitro. CD137L signaling in 
microglia cells was induced with a recombinant CD137 protein that consists of 
the extracellular domain of CD137, fused to the constant domain of human 
IgG1 (Fc). This CD137-Fc fusion protein was immobilized on tissue culture 
plates to allow it to crosslink CD137L and thereby induce CD137L signaling in 
the microglia cells. Uncoated wells (PBS) and wells coated with Fc protein 
were used as negative controls.  
 
 The activation of microglia by CD137L signaling was presented as 
increased adherence, cell spreading and other morphological changes. The 
attachment of primary microglia on tissue culture plates was already visible 
after 1 h of seeding in the presence of CD137-Fc but not under the PBS and Fc 
control conditions (Figure 3.3 A). Morphological changes of BV-2, N9 and 
primary microglia were evident as early as one day after initiating CD137L 








Figure 3.3. CD137L signaling induces morphological changes in murine 
microglia in vitro. Microglia cells were grown on plates that had been coated 
with PBS or 10 µg/ml of Fc control protein or 10 µg/ml of CD137-Fc protein. (A) 
Attachment and morphological changes of primary microglia were documented 
by photography (40x magnification) 1 h after plating. Scale bar: 20 µm. (B) 
Attachment and morphological changes of BV-2 and N9 cells and primary 
microglia were documented by photography (63x) 24 h later. Cells exposed to 
immobilized CD137-Fc protein developed long spiky projections* and became 






3.1.3 CD137 induces murine microglia to secrete proinflammatory   
  cytokines and mediators 
 
 CD137L signaling in BV-2 cells led to a significant increase in tumor 
necrosis factor (TNF) when compared to the PBS and Fc controls and the 
increased concentrations of TNF secreted through time were dependent on 
and proportional to the dosage of CD137-Fc employed (Figure 3.4). As the 
statistically significant peak in TNF secretion was the greatest at 10 µg/ml 
CD137-Fc when compared to the PBS and Fc controls, the optimum 





Figure 3.4. CD137-Fc induced an increase in TNF secretion by BV-2 
microglia dose dependently. BV-2 cells at 105 cells/ml seeding density were 
introduced  into respective PBS-treated, Fc-treated and CD137-Fc-treated 
wells and incubated for up to 5 days before the cell supernatants were 
harvested for ELISA determination of TNF. Statistical data were analyzed and 
presented as mean ± standard deviations of triplicate measurements. This 
data was representative of two independent experiments. Grey bars = Day 1, 
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White bars = Day 3, Black bars = Day 5. * P < 0.05 as compared to the 
respective controls.  
 
 
 CD137L engagement induced the secretion of proinflammatory cytokines 
including TNF, IL-1β, IL-6, IL-12 and MCP-1 by two murine microglia cell lines 
as well as in primary microglia (Figure 3.5 A - C). Also, matrix 
metalloproteinase (MMP)-9 and soluble ICAM were released by murine 
microglia in response to CD137L signaling. CD137 did not induce murine 








Figure 3.5. CD137L-activated murine microglia secrete proinflammatory 
cytokines and mediators. Murine microglia were grown on tissue culture 
wells that had been coated with PBS (grey bars) or 10 µg/ml of Fc control 
protein (white bars) or 10 µg/ml of CD137-Fc protein (black bars) through time. 
The concentrations of cytokines and mediators in supernatants of (A) BV-2, (B) 
N9 and (C) primary microglia were determined by ELISA at indicated time 
points. Depicted are means ± standard deviations of triplicate measurements. 
These experiments are repeated three times with comparable results. * p < 
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0.05; ** p < 0.01, as compared to the respective controls. 
 
 
 3.1.4 CD137 fails to induce BV-2 microglia to secrete anti-inflammatory  
      cytokine 
 
 CD137 was previously reported to inhibit the expression of 
anti-inflammatory cytokine, IL-10, by human peripheral monocytes. IL-10 
levels were found to be the similar or comparable between treated and control 
samples for murine microglia (Figure 3.6). Not only that CD137-Fc failed to 
enhance IL-10 secretion by CD137L-activated BV-2 cells through time, neither 
was IL-10 abrogated with CD137-Fc treatment. Hence, IL-10 concentrations 





Figure 3.6. CD137L-activated BV-2 microglia do not secrete 
anti-inflammatory cytokine. BV-2 microglia were grown on tissue culture 
wells that had been coated with PBS (grey bars) or 10 µg/ml of Fc control 
protein (white bars) or 10 µg/ml of CD137-Fc protein (black bars) through time. 
The concentrations of IL-10 in supernatants were determined by ELISA at 
indicated time points. Depicted are means ± standard deviations of triplicate 




 3.1.5 CD137 enhances the phagocytic capability of murine microglia  
 
 A critical functional assessment of macrophage or microglia activation is 
phagocytosis. Like monocytes or macrophages upon activation, the phagocytic 
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Figure 3.7. Enhanced phagocytic capacity of CD137L-activated murine 
microglia. The phagocytic capacity of (A) N9 and (B) primary microglia were 
determined by adding FITC-labeled latex beads for 1 h before analysis by flow 
cytometry. Control: Autofluorescence of the cells. Numbers above the 
histograms state the percentages of positive cells and mean fluorescence 
intensities (MFI) for FITC staining. These experiments were repeated three 
times with similar results. 
 
 
 3.1.6. CD137 induces greater ROS production by BV-2 microglia 
 
 As pro-inflammatory cytokines and ROS production are closely associated, 
we speculated that CD137 may also have an effect on murine microglia in 
terms of enhancement in ROS production. CD137 was discovered to drive ROS 
production by BV-2 microglia (Figure 3.8), characterized by DHR123 
incorporation. DHR123 is an uncharged and non fluorescent ROS indicator. It 
passively diffuses across membranes where it is oxidized to cationic 
rhodamine 123 that localizes in the mitochondria, releasing a green 
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fluorescence for detection and quantification using flow cytometry. 
 
 
Figure 3.8. CD137L-activated BV-2 microglia generate greater amount of 
ROS. BV-2 cells were cultured on uncoated plates (PBS) or plates coated with 
Fc or CD137-Fc protein for 24 h, and were then preactivated with 0.4 µg of 
PMA for 1 h, stained with DHR123 before production of ROS was quantified by 
flow cytometry. White histogram: No DHR123. The number in the panel 
indicates the percentage of positive cells. 
 
 
 3.1.7. CD137 causes a decrease in N9 microglia proliferation 
 
 The proliferative potential of cells usually reveals the health and activation 
state of cells, and N9 microglia's ability to proliferate was measured using 
3H-thymidine incorporation assay. However, unlike the effects observed in 
monocytes, CD137 induced a decline the proliferation rate of N9 microglia 
(Figure 3.9). It is likely that activated N9 microglia are committed to other 
functional cellular activities than proliferation especially since they are not 
progenitor cells. As other cellular programs were preactivated instead, cells 
could have also undergone activation-induced cell death, which led to a 






Figure 3.9. Reduced proliferation rate of N9 microglia upon CD137 
treatment. N9 microglia were seeded at a density of 105 cells/ml and were 
cultured in complete medium in 96-well tissue culture plate with wells that were 
PBS-treated, coated with 10 µg/ml Fc or CD137-Fc protein respectively for 24 
h followed by 0.5 μCi of 3H-thymidine labeling over 18 to 24 h at 37°C 
incubation. The rate of 3H-thymidine incorporation was plotted as a function 
against the different treatments and the proliferation profiles were determined 
on day 2. Depicted are means ± standard deviations of triplicate 
measurements. ** p < 0.01, as compared to the respective controls. The 
results are representative of two independent experiments. 
 
 
3.2 CD137L-activated murine microglia kills oligodendrocytes 
 
 
 Microglia has been shown to play a pivotal role in EAE and MS (Dheen, 
Kaur and Ling, 2007; Gay, 2007). The major pathogenic event in MS is the 
killing of oligodendrocytes by activated immune cells including microglia, 
leading to the loss of axonal myelin sheaths and the subsequent death of the 
affected neurons (Li et al., 2008). Subsequent in vitro studies aimed to 
determine the fate of murine oligodendrocytes when co-cultured with 
CD137L-activated murine microglia. 
  
 To check on the suitability of the oligodendrocyte cell line, OLN93 cells, as 
target cells for co-culture with murine microglia, the expressions of CD137 and 
CD137L of the former were tested using flow cytometry. In contrast to murine 
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microglia, neither CD137 nor CD137L was expressed by the oligodendrocyte 
cell line OLN93 (Figure 3.10 A) and could also not be detected on primary 
oligodendrocytes (not shown). In addition, treatment of OLN93 cells alone with 
recombinant CD137-Fc protein had no significant effect on the cell numbers 
(Figure 3.10 B). Further, treatment of either N9 cells alone or OLN93 cells 
alone with recombinant CD137-Fc protein had no effect on the rate of 
apoptosis (Figure 3.10 C). These experiments laid the foundation for OLN93 








Figure 3.10. CD137 does not induce apoptosis of OLN93 cells alone or N9 
microglia alone. (A) Expressions of CD137 and CD137L on the 
oligodendrocyte cell line OLN93 was determined by flow cytometry. Open 
histogram: Isotype controls. Grey histogram: Anti-CD137 monoclonal antibody 
(clone 17B5); anti-CD137L monoclonal antibody (clone TKS-1). White bar = 
PBS; white bar = Fc and black bar = CD137-Fc (B) OLN93 cells alone or N9 
cells alone were cultured at a seeding density of 1.5 x 105 cells/ml at 37°C for 
24 h on plates that had been coated with nothing (PBS) or 10 μg/ml of  c 
control protein or 10 μg/ml of CD137-Fc protein. 50 μl or 50,000 counting 
beads were added into a fixed final volume of OLN93 cells harvested from 
PBS, Fc and CD137-Fc wells after 7-AAD and Annexin V stainings. The 
number of OLN93 cells and beads were acquired by flow cytometry. Average 
cell count was calculated as cell concentration times the initial volume for 
triplicates of each condition. Depicted are means ± standard deviations of 
triplicate measurements. (C) The rates of apoptosis of N9 and OLN93 cells 
were determined 24 h after initiation of CD137L signaling by 7-AAD and 
Annexin V stainings. Numbers in quadrants indicate the percentages of cells. 
Results are representative of two independent experiments. 
 
 
 Blast-like cells suggest the preparation of cells to undergo proliferation. 
Many blast-like cells were observed in the PBS and Fc control conditions but 
not in the CD137-treated condition during murine microglia and 
oligodendrocyte co-culture (Figure 3.11). Moreover, there appeared to be a 
healthier or more balanced co-existence of N9 and OLN93 cells in the control 
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conditions. However, there were fewer or no attached OLN93 cells in the 
CD137-Fc coated wells compared to the control wells. As CD137L-activated N9 
cells interacted with OLN93 cells, the number of attached blast-like OLN93 cells 
with dendritic protrusions diminished, leaving many empty pockets or regions 
on the surface of the culture wells that were devoid of cells. It was suspected 
that more CD137L-activated N9 cells interacted with the OLN93 cells by 




Figure 3.11. Morphological observations of N9 microglia and OLN93 
co-culture. N9 cells were incubated with OLN93 cells at 105 cells/ml (1:1 
seeding ratio) at 37°C for 24 hours under PBS or 10 µg/ml of Fc or 10 µg/ml of 
CD137-Fc conditions. Observations were made under a light microscope and 
documented by photography at 20x magnification. Scale bar: 50 μm.  
 
  
 To further evaluate the above speculation that the blast-like cells were 
OLN93 cells but not murine microglia, an effort was made to distinguish the 
cellular identities within the co-culture system. N9 cells were CFSE-labeled 
prior to incubation with unlabeled OLN93 cells in vitro. Corresponding light and 
fluorescence microscopy images revealed that the CSFE-stained N9 cells were 
small and round looking. OLN93 cells that were blast-like in the control 
conditions did not stain for CFSE, and were absent in CD137-Fc co-culture 
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(Figure 3.12 A). Interestingly, large empty areas devoid of cells were observed 
in the CD137-Fc coculture as compared to the control conditions. Conversely, 
OLN93 cells were then CFSE-labeled prior to incubation with unlabeled N9 
cells in a separate experiment. Combining light and fluorescence microscopy 
images, it was ascertained that the blast-like cells in the PBS and Fc-treated 
control conditions were indeed OLN93 cells, which stained for CFSE, and these 
cells were not detected in the CD137-Fc condition (Figure 3.12 B). Hence, 
CD137L-activated murine microglia may have prohibited proliferation or 
induced death of the OLN93 cells, which would have been attached as 







Figure 3.12. Light and fluorescent photographs of N9 microglia and 
OLN93 co-culture. (A) CFSE-labeled N9 cells were co-cultured with unlabeled 
OLN93 cells at 105 cells/ml seeding density (at 1:1 seeding ratio) on PBS or 10 
µg/ml of Fc or 10 µg/ml of CD137-Fc coated plates. Observations and 
photographs were taken 24 h later at 20x magnification. Scale bar: 50μm. (B) 
N9 cells were incubated with CFSE-labeled OLN93 cells at 37°C for 24 hours at 
similar cell seeding density and ratio under the respective conditions. 




 To elucidate the type of cell death that OLN93 cells had undergone, the 
apoptosis assay exploiting the combined use of Annexin V and 7-AAD was 
employed to determine the nature of OLN93 cell death. In addition, inclusion of 
FACS counting beads aimed to determine the cell numbers of OLN93 cells 
under PBS, Fc and CD137-Fc conditions. When CD137L-activated murine 
microglia were incubated with oligodendrocytes, the former induced 
oligodendrocyte cell death via apoptosis as witnessed by the increase in 
Annexin V and 7-AAD stainings on the CFSE-negative OLN93 cell population 
(Figure 3.13 A), and there was no difference in the apoptosis profile of murine 
microglia. In addition, the survival outcome results were supported with 
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absolute quantification of viable OLN93 cells, showing that there was indeed 
fewer number of viable OLN93 cells in the coculture (Figure 3.13 B). The 
decrease in the live OLN93 cell number was accompanied by an induction of 
apoptotic cell death of the oligodendrocytes. Therefore, co-culture with 
CD137L-activated murine microglia promoted oligodendrocyte cell death via 









Figure 3.13. CD137L-activated murine microglia induce apoptosis of 
OLN93 cells. (A) CFSE-labeled N9 cells or CFSE-labeled primary microglia 
were co-cultured with OLN93 cells, respectively, at 105 cells/ml seeding density 
(at 1:1 seeding ratio) on plates that had been coated with nothing (PBS) or 10 
µg/ml of Fc control protein or 10 µg/ml of CD137-Fc protein. The rates of 
OLN93 cell apoptosis in co-cultures with N9 cells or with primary microglia 
were determined at 24 h or 48 h, respectively, after initiation of CD137L 
signaling by 7-AAD and Annexin V stainings. Numbers in quadrants indicate 
percentages of OLN93 cells. (B) 50 μl or 50,000 counting beads were added 
into a fixed volume of cells harvested from PBS, Fc and CD137-Fc wells after 
7-AAD and Annexin V stainings. The number of unstained OLN93 cells and 
corresponding number of beads were acquired by flow cytometry. The average 
cell count was calculated as cell concentration times the initial volume for 
triplicates of each condition. Depicted are means ± standard deviations of 
triplicate measurements. * p < 0.05, as compared to the respective controls. 
These results are representative of three independent experiments. White bar 
= PBS; white bar = Fc and black bar = CD137-Fc 
 
 
3.3 Mechanism of oligodendrocytes apoptosis  
 
 The nature of apoptosis of OLN93 cells could either be death receptor- or 
ROS-mediated. Previously, CD137L-activated monocytes were shown to 
induce apoptosis in T cells when they are in co-culture, and this cell death was 
mediated by ROS (Kwajah et al., 2011). Moreover, since CD137L engagement 
on BV-2 microglia induced ROS production, the possibility of oligodendrocytes 
apoptosis being ROS-mediated or -dependent could not be eliminated. To 
clarify the above hypothesis, the coculture system was treated with the ROS or 
hydrogen peroxide (H2O2) scavenger, catalase. If apoptosis were to be 
ROS-dependent, the addition of catalase would be able to rescue 
oligodendrocytes from apoptosis . Indeed, when the BV-2 and OLN93 cells 
were co-cultured on CD137-Fc coated plates, the apoptosis of the latter was 
found to be less profound in the presence of catalase compared to that in the 
coculture conditions without catalase treatment in the FACS dot plot (Figure 
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3.14 A). The percentage of 7-AAD+ OLN93 cells indicating late apoptotic and/or 
dead OLN93 cells for various conditions are quantitatively represented in a bar 
chart. The profound elevation in the percentage of dead OLN93 cells detected 
without catalase addition was significantly reduced or rescued to control level 
with the incorporation of catalase in the CD137-Fc co-cultures (Figure 3.14 B), 
suggesting and signifying that ROS derivatives such as H2O2 and/ or OH
- 






Figure 3.14. Apoptosis of OLN93 cells in the presence of CD137-activated 
BV-2 microglia is reversed upon catalase treatment. (A) BV-2 cells were 
co-cultured with OLN93 cells at a 1:1 ratio with or without 10,000 U/ml catalase. 
The rate of apoptosis of cultures was determined after 24 h by 7-AAD and 
Annexin V staining. Numbers in quadrants indicate percentages of cells. (B) 
The percentages of 7-AAD+ OLN93 cells with and without catalase treatment 
of B are presented as means ± standard deviation of triplicate measurements. 
* p<0.05; ** p<0.01, as compared to the respective controls. These 
experiments were repeated up to three times with similar results. White bar = 
PBS; white bar = Fc and black bar = CD137-Fc 
 
 To ascertain whether oligodendrocyte killing is mediated by microglia 
through CD137L signaling, OLN93 cells were cultured with primary murine 
microglia derived from WT and genetically-modified CD137L-deficient mice. 
Interestingly, the apoptotic profile of OLN93 cells was substantially reduced 
when primary microglia derived from CD137L-deficient CNS were present 
whereas apoptosis was still profound in the situation where WT primary 
microglia were present in the co-culture (Figure 3.15). The results confirmed 







Figure 3.15. CD137-activated microglia from WT but not CD137L-deficient 
mice induces oligodendrocyte death. Primary murine microglia and OLN93 
cells were cultured at a 1:1 ratio (105 cells/ml of seeding density each) on 
24-well tissue culture plate. Co-cultures were introduced into wells that were 
PBS or 10 μg/ml of  c control protein or 10 μg/ml of CD137-Fc protein treated. 
The rates of OLN93 cell apoptosis in co-cultures with primary microglia from 
WT or CD137L-/- mice was determined 48 h after initiation of CD137L signaling 
by 7-AAD and Annexin V staining. Numbers in quadrants indicate percentages 
of cells. These experiments were repeated two to three times with similar 
results. 
 
3.4 Microglia activation requires CD137L 
 
 Since the apoptotic effect on OLN93 cells could only be exerted by WT but 
not CD137L-deficient microglia, we raised the question on whether CD137L is 
absolutely required for murine microglia activation. It was decided that activated 
T cells be employed for coculture with murine microglia since activated 
leukocytes infiltrating an inflamed CNS are a potential source of CD137. To 
simulate the activated leukocytes in vivo, murine T cells were subjected to 
anti-CD3 and anti-CD28 stimulation in vitro. Preactivated T cells from WT but 
not CD137-deficient background were found to express CD137 (Figure 3.16 A) 
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and secrete IFN-γ (Figure 3.16 B). Murine microglia had no further stimulating 




Figure 3.16. Anti-CD3 and anti-CD28 activate WT T cells only. (A) WT and 
CD137-deficient T cells were cultured at seeding density of 5 x 106 cells/ml in 
either PBS-treated (untreated control) or 5 µg/ml of anti-CD3 and 5 µg/ml of 
anti-CD28 treated tissue culture wells in a 12-well plate at 37°C for 2 days. The 
expressions of CD137 were determined by flow cytometry. Open histogram: 
Isotype control. Grey histogram: Anti-CD137 monoclonal antibody (clone 
17B5). Numbers in panels indicate the percentages of CD137+ cells.  
 
  
 CD137 has been shown to induce activation of murine microglia via 
CD137L signaling. It was hypothesized that CD137-expressing T cells could 
potentially activate murine microglia. A co-culture system involving the two cell 
populations was established to investigate the activating effect(s) that 
CD137-expressing T cells might have on the murine microglia. As the most 
fundamental readout, it was observed that BV-2 and N9 cell lines developed 








Figure 3.17. Preactivated T cells induce morphological changes of 
murine microglia. WT T cells were cultured at seeding density of 5 x 106 
cells/ml in either PBS-treated (untreated control) or 5 µg/ml of anti-CD3 and 5 
µg/ml of anti-CD28 treated tissue culture wells in a 12-well plate at 37°C for 2 
days. N9 or BV-2 microglia were cultured at 105 cells/ml each with 2 x 105 
cells/ml of preactivated CD137-expressing T cells determined by flow 
cytometry. Shown are representative images of attachment and morphological 
changes of N9 cells and BV-2 microglia documented by photography 24 h later. 
Cells exposed to CD137-expressing T cells developed long spiky projections* 
(also shown within insert) and became amoeboid cells^ with shortened 
protrusions#. The results are representative of 2 separate experiments. 40x 
magnification. Scale bar: 20 µm. stim. T cells = preactivated T cells. 
 
 
 The productions of MCP-1 and s-ICAM by murine microglia were 
upregulated via CD137L-signaling (Figure 3.5). Therefore since they can be 
induced in CD137L-activated microglia, MCP-1 and s-ICAM are being 
measured to determine whether CD137-CD137L interactions are important for 
microglia activation. Similar to recombinant CD137 protein treatment, 
CD137L-activated microglia by preactivated T cells secreted enhanced levels 
of sICAM (Figure 3.18) and MCP-1 (Figure 3.19). Postulating that the secretion 
of proinflammatory cytokines by activated microglia might depend on 
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CD137L-signaling, the effect to an antagonistic anti-CD137L antibody, TKS-1, 
was investigated in the T cell-microglia co-culture. In the co-culture system 
comprising of WT murine microglia and preactivated T cells, the elevated level 
of MCP-1 was attenuated to baseline in the presence of TKS-1 (Figure 3.19). 
Moreover, preactivated T cells failed to induce secretion of MCP-1 in the 
presence of microglia derived from CD137L-deficient CNS (Figure 3.19), 
further demonstrating that murine microglia activation or enhanced MCP-1 





Figure 3.18. Preactivated T cells induce sICAM secretion as a 
inflammatory marker for murine microglia activation. BV-2 or N9 microglia 
were cultured with T cells at a seeding density of 105 cells/ml at 1:1 ratio for up 
to 5 days. Supernatants were collected for sICAM determination by ELISA. 
Depicted are means ± standard deviations of triplicate measurements. The 
results are representative of 2 independent experiments. unstim. T cells = 





Figure 3.19. In vitro MCP-1 production in murine microglia and 
preactivated T cells coculture is CD137L-dependent. Primary microglia 
derived from WT or CD137L-deficient CNS were seeded at 3 x 105 cells/ml with 
105 cells/ml of T cells at 3:1 ratio with isotype control antibody or with anti-TKS-1 
(2.5 µg/ml) for 3 days. Supernatants were then collected for MCP-1 (CCL-2) 
determination by ELISA. Depicted are means ± standard deviations of triplicate 
measurements. These results are representative of three independent 
experiments. unstim. T cells = unactivated T cells; stim. T cells = preactivated 
T cells; WT µglia = wild-type microglia; LKO µglia = CD137L-deficient microglia. 
* p<0.05, ** p<0.001. 
 
 
 Murine GM-CSF whose expression is driven by the orphan nuclear 
receptor, RORγt, was reported by Codarri et al. (2011) to be an essential 
growth factor critical for the development of EAE. As GM-CSF is produced by T 
cells, it is being measured to determine whether CD137-CD137L interactions 
are important for T cell activation. GM-CSF was found to be enhanced in the 
supernatants from the co-culture system of murine microglia and 
CD137-expressing T cells using ELISA (Figure 3.20 A). In the co-culture 
consisting of BV-2 and preactivated T cells, the elevated level of GM-CSF in 
the supernatant was reduced to baseline in the presence of TKS-1 (Figure 
3.20 A), suggesting that enhanced GM-CSF secretion by preactivated T cells 
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also depended on CD137L. Using intracellular stainings on the co-culture of 
murine microglia and preactivated T cells, it was confirmed that the latter was 
the main producer of GM-CSF in vitro (Figure 3.20 B). This means that 
microglia does not necessarily need to become activated to elevate 






Figure 3.20. Enhanced secretion of GM-CSF by preactivated T cells 
requires CD137L in vitro. (A) BV-2 or N9 microglia were labelled with 1 µM of 
CFSE prior to incubation with primary T cells at 1:1 seeding ratio (105 cells/ml 
seeding density). Intracellular staining was performed on the Brefeldin 
A-treated cells. Numbers on the dot plots indicate the percentages of stained 
cells. (B) BV-2 microglia (105 cells/ml) were co-cultured with primary T cells (2 x 
105 cells/ml) at 1:2 ratio with isotype control antibody or with anti-TKS-1 (2.5 
µg/ml) for up to 5 days. Supernatants were collected at Day 5 for ELISA 
determination of GM-CSF. Depicted are means ± standard deviations of 
triplicate measurements. These results are representative of 2 independent 
experiments. unstim. T cells = unactivated T cells; stim. T cells = preactivated 
T cells. ** p<0.001. 
 
 
 As activated resident microglia were reported to differentiate into 
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functionally mature and effective APC in the encephalitic CNS (Fischer and 
Reichmann, 2001), efforts were directed at studying whether the maturation of 
primary microglia into APC required CD137L or could be influenced by 
CD137L-deficient microglia. To specifically examine if microglia maturation 
depends on CD137L signaling, preactivated T cells were co-cultured with 
primary microglia derived from either WT or CD137L-deficient CNS. 
Preactivated T cells drove the in vitro maturation of only WT primary microglia. 
Positive shift in percentages of staining and MFIs for WT primary microglia 
signified that cell surface markers like CD80, CD86, MHC II and CD40 were 
upregulated on WT primary microglia compared to primary microglia derived 
from CD137L-deficient CNS in the presence of CD137-expressing T cells 
(Figure 3.21). This further affirmed that murine microglia activation and 




Figure 3.21. CD137L is essential for activation and maturation of 
microglia in vitro. Primary microglia derived from WT or CD137L-deficient 




cells/ml of T cells at 3:1 ratio for 5 
days. Cells were harvested and stained for anti-CD80, anti-CD86, anti-CD40 
and anti-MHC II along with anti-CD11b. Opened histograms: Isotype IgGs 
104 
 
stainings; Opened histograms with vertical grids: Respective activation markers 
on CD137L-/- microglia;  Grey histograms: Respective activation markers on 
WT microglia. This experiment was repeated twice with comparable results. 
 
 
3.5 In vivo expression analysis in murine CNS 
 
 The above in vitro experiments employing immune and CNS cells 
specifically indicated that CD137L is not only able to activate microglia but is 
also essential, suggesting that CD137-CD137L system might play an active 
role especially during pathogenesis in the CNS. Hence, after having 
demonstrated in vitro that CD137L signaling activates microglia, we aimed to 
confirm these data in vivo.  
 During EAE progression, the detection of infiltrating activated or 
auto-reactive T cells into the CNS corresponded to the severity of the disease. 
Hence, it was important to determine whether T cells or more importantly 
activated ones could be found in the CNS of EAE mice. Using IHC staining, the 
cervical spinal cords from EAE WT and EAE CD137L-/- mice were stained for 
anti-CD137 alongside with a positive A20-CD137 tumor control. Circular cells 
that stained for CD137 were detected in the EAE WT cervical spinal cord but 
not in the case of EAE CD137L-/- mice (Figure 3.22 A). This suggested that 
activated T cells expressing CD137 had likely infiltrated into the CNS of EAE 
WT mice. However, the absence of a T cell marker rendered the above claim 
incomplete. Therefore, immunofluorescence stainings was subsequently 
performed with anti-CD3, anti-CD137, anti-Iba-1 antibodies and DAPI on 
cervical spinal cords of EAE WT or EAE CD137L-/- mice. CD137 was employed 
as a marker for T cell activation, CD3 as a marker for T cells and Iba-1 as an 
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activated microglia marker and DAPI as a nuclear counter-stain. CD3 and 
CD137 double-positive cells were detected at close proximity with Iba-1 
positive cells in EAE WT spinal cords but not in the CD137L-/- model subjected 
to similar EAE induction regime (Figure 3.22 B), further indicating that 
activated leukocytes had infiltrated into the CNS of EAE animals only when 
CD137L was intact to allow the neuroinflammatory effects of CD137L-signaling. 
Importantly, activated T cells that entered the EAE spinal cord presented as a 








Figure 3.22. Activated T cells infiltrated into EAE WT spinal cord. (A) 
Cervical spinal cord tissue sections of WT and CD137L-/- mice with EAE were 
immunohistochemically stained with an isotype control antibody or for CD137 
(brown). An A20-CD137 tumor tissue section was included as a positive 
control for CD137 staining. Tissue sections from the cervical spinal cords of 
WT (B) and CD137L-/- (C) mice with EAE were stained for activated microglia 
using a Cy5-labeled anti-Iba-1 antibody (magenta). Activated T cells were 
stained yellow resulting from an overlay of red and green detected by 
Cy3-labeled anti-CD137 (polyclonal, Sigma) (red) and FITC-labeled anti-CD3 
(clone: 17A2) (green). Nuclei were visualized by DAPI (blue). Magnification: 
40x. Overview of coronal sections of cervical spinal cords with ventral horn 
region marked by white open circle (B i and C i). Single stainings for Cy5, Cy3, 
FITC and DAPI were depicted in Bii and C ii. 
 
 Since CD137L was detected on murine microglia via flow cytometry, the 
possibility remained that resident cells within the CNS might also express the 
putative binding partner, CD137, to invoke EAE pathogenesis more efficiently 
and effectively in the CNS microenvironment in response to the EAE 
pathogenic insult or trigger, other than just relying on activated infiltrating T cells 
to stimulate microglia. To clarify the hypothesis, efforts were channelled at 
investigating the in vivo expression or prevalence of CD137 in the murine CNS 




 IHC staining for anti-CD137 was performed on WT, CD137-/- and CD137L-/- 
brains of mice without any treatment (Figure 3.23). Given its relevance and 
implications in EAE, the cerebellum was identified at the brain region for 
investigations. A20-CD137 tumor tissue was employed as a positive control for 
anti-CD137 staining. The cerebellum of the WT brain was found to have some 
basal level of expression of CD137 as indicated by a weak anti-CD137 staining 
on the cell bodies of the Purkinje neurons identified by their unique morphology 
and cellular localization along the cerebellum. CD137 staining was not uniform 
as few but not all the Purkinje neurons had stained for anti-CD137 in WT 
cerebellum. Interestingly, enhanced CD137 expression was found on the cell 
bodies of nearly every Purkinje neuron lining the periphery of the gray matter, 
indicating that CD137 could be upregulated in response to the absence of 
CD137L signal in the CD137L-/- cerebellum. The inability to detect CD137 in the 
CD137-/- brains further proved the specificity and validity of the staining directed 
against CD137. Unlike the isotype antibody, anti-CD137 stained the 





Figure 3.23. CD137 is upregulated in CD137L-/- cerebellum in vivo. 
Immunohistochemical stainings for anti-CD137 (brown) and for isotype 
antibody were performed on formalin-fixed paraffin-embedded murine WT, 
CD137L-/- and CD137-/- cerebellar sections. An A20-CD137 tumor tissue 
section was included as a positive control for CD137 staining. 40x 
magnification. Scale bar: 20 µm. 
 
 Furthermore we employed EAE, a murine model of neuroinflammation and 
human MS, to provide a better understanding on the distribution of CD137 in 
the CNS during pathogenesis. Anti-CD137 immunohistochemical staining was 
performed on EAE and naive WT brains (Figure 3.24). Enhanced CD137 
expression was detected in EAE WT brain, including the cerebellum. More 
specifically, intensified CD137 stainings were only detected on cells in the 
hypothalamic region and on the Purkinje neurons in close association to the 
periphery of the gray matter of the cerebellum. In addition, A20 cells were 
stained with anti-CD137 but not with the isotype IgG. A20-CD137 tumor tissue 





Figure 3.24. EAE WT brains expressed CD137. Immunohistochemical 
stainings for CD137 (brown) and with isotype IgG were performed on 
formalin-fixed paraffin-embedded EAE WT brain sections. An A20-CD137 
tumor tissue section was included as a positive control for CD137 staining. The 
red open rectangular boxes on the figures (5x magnification) represent the 
exact locations at the brain of the respectively expanded insets (40 
magnification, scale bar: 20 µm).  
 
 Since the manifestations of EAE pathogenesis were largely reported in the 
affected spinal cords, the need to link and augment the IHC findings in the brain 
with spinal cord data would be crucial and useful. For better confidence and 
completion, anti-CD137 stainings were thus performed on the EAE WT along 
with naive WT spinal cords (Figure 3.25). Particularly, enhanced anti-CD137 
stainings were detected on the CNS cells in the gray matter of the EAE WT 
spinal cords. Although the identity of the CNS cells in the spinal cord that 
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stained for CD137 remained obscure, spatial location of these cells in the gray 
matter region of the spinal cord indicated that these CD137-expressing cells 
are likely to be neurons, suggesting that neurons might also express CD137 
during EAE pathogenesis. This notion could be further veridied with 
co-localization analysis using a neuronal marker. A20-CD137 positive control 
stained for CD137 but not with the isotype IgG. CNS cells from the EAE cervical 
spinal cord developed enhanced CD137 expression compared to the naive WT 
cervical spinal cord.  
 
 
Figure 3.25. EAE WT cervical spinal cord expresses CD137. CNS cells in 
formalin-fixed paraffin-embedded EAE WT and naive WT cervical spinal cords 
were immunohistochemically stained with an isotype control antibody or for 
CD137 (brown). An A20-CD137 tumor tissue section was included as a 
positive control for CD137 staining. The red open rectangular boxes on the 
figures (10x magnification) represent the exact locations at the spinal cords of 
the respectively expanded insets (40 magnification, scale bar: 20 µm).   
 
 As CD137 expression was enhanced in naive CD137L-/- cerebellum, it was 
speculated that the same might also be observed in the EAE CD137L-/- 
cerebellum. To verify this hypothesis, anti-CD137 stainings were performed in 
parallel on WT and CD137-/- cerebella (Figure 3.26). In the EAE WT cerebellum, 
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enhanced CD137 expression was detected on the Purkinje neurons. Also, in 
the EAE CD137L-/- cerebellum, the expression of CD137 was intensified on the 
Purkinje neurons suggesting that a feedback response by upregulating CD137 
might become activated in the absence of CD137L. Therefore, as CD137L was 
devoid in the CD137L-/- cerebellum, a compensatory upregulation of CD137 in 
the EAE CD137L-/- mice to invoke CD137L signaling for EAE development was 




Figure 3.26. CD137 expression is intensified in EAE-induced CD137L-/- 
cerebellum. EAE-induced WT and CD137L-/- cerebellar sections were 
immunohistochemically stained for CD137 (brown) and with an isotype 
antibody. An A20-CD137 tumor tissue section was included as a positive 
control for CD137 staining. 40x magnification. Scale bar: 20 µm. 
   
 The Iba-1 antigen is expressed by activated but not by resting microglia. 
The brain cortices and dorsal column of the spinal cords of WT mice with EAE 
exhibited strong Iba-1 expression whereas little or no Iba-1 expression could 
be detected in corresponding tissues of CD137L-/- mice with EAE (Figure 3.27 
A). In the EAE-induced CD137L-/- mice, the number of Iba-1+ cells, staining 
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intensity, standard area and perimeter were significantly reduced (Figure 3.27 
B), suggesting lower microglia activation and further indicating that limited 
redundancy exists to replace the CD137L signal. Hence, it is conceivable that 
the absence of CD137L in the CNS of CD137L-/- mice could only influence the 
development of EAE if also CD137 would be present. Indeed, 
immunohistochemical stainings for CD137 confirmed that its expression in the 






Figure 3.27. CD137L signaling activates microglia in vivo. (A) CD137L is 
required for activation of microglia in vivo. Cortex and spinal cord tissue 
sections of WT and CD137L-/- mice with EAE were immunohistochemically 
stained with an isotype control antibody or for Iba-1 (brown). Shown in the 
inset is a close-up of a single Iba-1-positive microglia cell in the cortex of a WT 
mouse with EAE. (B) Quantifications of Iba-1+ microglia, staining intensity, 
area and perimeter in the spinal cords and cortices of WT (black bar) and 
CD137L-/- (white bar) mice with EAE. Evaluated were three fields from two 
serial sections each using the Metamorph NX Software. Depicted are 
means ± standard deviations. Above are representative results of two 




 At present, an abundance of activated microglia, the major immune 
responders of neuroinflammation and its effects could also be detected in EAE 
WT but not EAE CD137L-/- CNS (Figures 3.24 and 3.25). However, whether the 
existence of activated microglia would correspond to the detriment of the 
oligodendrocytes in the EAE-induced WT CNS remained to be elucidated. To 
establish an in vivo link with the in vitro data, the next strategy was designed to 
investigate the frequency of apoptotic oligodendrocytes in the CNS of WT and 
CD137L-/- mice with EAE by immunofluorescence staining for 
apoptosis-specific DNA fragmentation and Nogo-A, an oligodendrocyte marker. 
The absence of CD137L, which was associated with much lower microglia 
activation also resulted in a lower number of oligodendrocytes undergoing 
apoptosis in the dorsal column of the spinal cord as well as the white matter of 
the cerebellum (Figure 3.28 A). Nine times more apoptotic oligodendrocytes 
could be detected in the cerebella of WT mice compared to CD137L-/- mice 
during EAE (Figure 3.28 B). Reduced microglia activation was associated with 
decreased oligodendrocyte death during the development of EAE in the 
CD137L-/- mice, while the reverse scenario was detected during EAE 
pathogenesis in the WT mice. These data corresponded with previous in vitro 
findings that CD137L-activated microglia resulted in the decreased viability of 
murine oligodendrocytes (Figure 3.13) in which the apoptosis of OLN93 cells 






Figure 3.28. CD137L-activated microglia induce oligodendrocytes 
apoptosis in vivo. (A) The presence of CD137L is required for 
oligodendrocyte apoptosis in EAE. Tissue sections from the dorsal column of 
the spinal cord and the white matter of the cerebellum of WT and CD137L-/- 
mice with EAE were stained for oligodendrocytes using a Cy3-labeled 
anti-Nogo-A antibody (red). Apoptosis was detected by TUNEL staining (green). 
Nuclei were visualized by DAPI (blue). The yellow staining results from an 
overlay of red and green and indicates apoptotic oligodendrocytes. 
Magnification: 40x. (B) Quantifications of apoptotic oligodendrocytes in the 
cerebellum of WT (black bar) and CD137L-/- mice (white bar) with EAE. 
Evaluated were three fields from two sections each using the Metamorph NX 
Software. Depicted are means ± standard deviations. ** P < 0.001. 
 
3.6 Staining analyses in healthy and MS human brains 
 
 A greater extent of microglia activation corresponded with an enhanced 
oligodendrocyte apoptosis during EAE. Moreover, CD137 is expressed on 
murine CNS cells or particularly by the Purkinje cells in vivo during EAE. These 
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scientific evidences in the murine system triggered and strengthened the need 
to investigate whether the CD137-CD137L system also exists and contributes 
to human disease progression. Therefore, to investigate whether a similar 
scenario could be detected in the human situation, healthy human and MS 
brain tissues were sourced for subsequent studies that aimed to establish and 
provide clinical relevance and significance.   
 
 Given the wide implications of the human temporal lobe (Honer et al., 1987; 
Pozzilli et al., 1991) and cerebellum (Rustin et al. 1995; Waxman, 2005) in MS, 
the two brain regions were selected for further investigations. Firstly, an 
antibody against Nogo-A, an oligodendrocyte marker, was employed to stain 
healthy and MS cerebellar tissues especially since oligodendrocytes, the main 
producers of the myelin sheaths, are frequently reported to suffer 
incapacitation and death during MS. A decrease in Nogo-A staining was 
detected in the MS but not in the healthy cerebellum (Figure 3.29 A). The 
qualitative results were confirmed with quantification of the number and 
staining intensity of the oligodendrocytes in the respective tissues (Figure 3.29 
B). 





Figure 3.29. Reduced healthy oligodendrocytes in MS brain sections. (A) 
Representative images of healthy and MS cerebellar sections stained with a 
Cy3-labeled anti-Nogo-A antibody (red). Nuclei were visualized by DAPI (blue). 
Magnification: 40x. (B) Quantifications of total oligodendrocytes and staining 
intensity in the healthy (white bars) and MS (black bars) cerebellar sections. 
Evaluated were three fields from two sections each using the Metamorph NX 
Software. Depicted are means ± standard deviations. ** P < 0.001. 
 
 
 The reduction in oligodendrocyte numbers during MS could be due to 
either defective production (oligodendrogenesis) or cell death via activated 
microglia. Leveraging on immunofluorescence, respective stainings for 
apoptosis-specific DNA fragmentation and for Nogo-A were concurrently 
performed on healthy and MS brain sections. Similar to the murine findings, 
TUNEL and Nogo-A double-positive cells indicative of dead oligodendrocytes 
were only detected in the MS but not in the healthy brain serial sections (Figure 
3.30 A), suggesting that one possible mode of reduction in healthy 
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oligodendrocytes could be cell death. Moreover, quantitative analyses of the 
increase in the number and the staining intensity of apoptotic oligodendrocytes 
in the MS compared to the healthy temporal lobe (Figure 3.30 B) further 




Figure 3.30. Enhanced apoptotic oligodendrocytes in MS brain. (A) Tissue 
sections from the healthy and MS temporal lobe sections were stained for 
oligodendrocytes using a Cy3-labeled anti-Nogo-A antibody (red). Apoptosis 
was detected by TUNEL staining (green). Nuclei were visualized by DAPI 
(blue). The yellow staining results from an overlay of red and green and 
indicates apoptotic oligodendrocytes. Above is a representation of a set of 
serially-sectioned and stained healthy and MS temporal lobes. Magnification: 
40x. (B) Quantifications of apoptotic oligodendrocytes and staining intensities 
in the healthy (white bars) and MS (black bars) temporal lobes. Evaluated were 
three fields from two sections each using the Metamorph NX Software. 
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Depicted are means ± standard deviations. ** P < 0.001. 
 
  
 To investigate whether activated microglia could be involved in causing the 
death of oligodendrocytes in vivo, the healthy and MS brain tissues were also 
stained with anti-Iba-1 for activated microglia. Corresponding to the increase in 
dead oligodendrocytes, enhanced Iba-1 staining was detected in MS but not in 
the healthy cerebellum (Figure 3.31 A). The quantification of the number and 
staining intensity of activated microglia (Figure 3.31 B) rendered support to the 
qualitative IF staining results (Figure 3.31 A). Hence similar to EAE, activated 
microglia could potentially be associated with the increased death of 




Figure 3.31. Increased human microglia activation in MS brain. (A) The 
increase of apoptotic oligodendrocytes corresponds with the increase of 
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activated microglia in human MS brains. Serial tissue sections from the healthy 
and MS cerebellar sections were stained for activated microglia using a 
Cy5-labeled anti-Iba-1 antibody (red). Nuclei were visualized by DAPI (blue). 
Shown are representative images from a set of serially-sectioned and stained 
healthy and MS cerebella. Magnification: 40x. (B) Quantifications of activated 
microglia and staining intensities in the healthy (white bars) and MS (black 
bars) temporal lobes. Evaluated were three fields from two sections each using 




 Given the ability to detect corresponding increases in activated human 
microglia with increases in apoptotic human oligodendrocytes, it was 
postulated that the CD137-CD137L system might be involved in MS 
progression and pathogenesis. To verify the activation of CD137L-signaling in 
human microglia, healthy and MS temporal lobes were 
immunofluorescence-labeled with anti-CD137L and anti-Iba-1 since murine 
microglia were previously found to express CD137L. Co-immunofluorescence 
staining using anti-CD137L and anti-Iba-1 revealed that CD137L was 
co-expressed on Iba-1+ cells in MS but not in healthy human brain tissues 
(Figure 3.32 A and B). The detection of CD137L and Iba-1 double-positive cells 
indicated that activated microglia expressed CD137L, which provided a novel 
and important link for CD137L with human microglia activation during MS. This 
further supported the finding that the increase in apoptotic human 
oligodendrocytes which corresponded to the increase in activated human 
microglia in the brain, could potentially be associated with microglia activation 









Figure 3.32. Activated human microglia express CD137L in MS brains. 
Tissue sections from the healthy and MS temporal lobe (A) and cerebellar 
sections (B) were stained for activated microglia using Cy5-labeled anti-iba-1 
antibody (red) and FITC-labeled anti-CD137L (clone 5F4) antibody. Nuclei 
were visualized by DAPI (blue). The yellow staining results from an overlay of 
red and green, indicating CD137L-expressing activated microglia. The inserts 
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within the images indicate close-up visualization of activated microglia. Shown 
are representative images from a set of serially-sectioned and stained healthy 
and MS temporal lobes and cerebella at 40x magnification. Experiments were 
repeated twice with similar results. 
 
  
 The above results built confidence and justifications to address or to detect 
the presence and involvement of CD137-expressing human cells in the CNS 
that could cross-link and activate human microglia for the propagation of the 
disease. Immunofluorescence stainings for anti-CD137 was performed on both 
healthy and MS cerebella (Figure 3.33). Human tonsil tissue was included as a 
positive control for anti-CD137 staining. Greater intensity of CD137 staining or 
expression was detected on the Purkinje neurons of MS than of healthy human 
cerebellum. Apart from the Purkinje neurons, the inner gray matter of the 






Figure 3.33. CD137 is detected on Purkinje neurons in the MS cerebellum. 
Tissue sections from the healthy and MS cerebella were stained with a 
Cy3-labeled anti-CD137 (clone: 4B41) antibody (red). Nuclei were visualized 
by DAPI (blue). Human tonsil tissue (left panel) was included as a positive 
control for CD137 staining. Shown are representative images from a set of 




 Indeed, being one of the most common regions for MS attacks and 
relapses, the involvement and implications of Purkinje neurons at the 
cerebellar region is cannot be ruled out. In addition, immunofluorescence 
stainings for CD137 and anti-Iba-1 were performed on healthy and MS brain 
tissues (Figure 3.34). Importantly, immunofluorescence imaging again detected 
CD137+ Purkinje neurons and this time they were found to be in contact with 
activated microglia only during MS but not under healthy conditions, suggesting 





Figure 3.34. Purkinje neurons closely interact with activated microglia in 
the MS cerebellum. Tissue sections from the healthy and MS cerebella were 
stained with a Cy3-labeled anti-CD137 (clone: 4B41) antibody (red) and a 
Cy5-labeled anti-Iba-1 antibody (white). Nuclei were visualized by DAPI (blue). 
Inserts show specifically enlarged regions along the healthy and MS cerebella 
where the Purkinje cells are residing and detected by anti-CD137. Human 
tonsil tissue (left panel) was included as a positive control for CD137 staining. 
Depicted are representative images from a set of serially-sectioned and 
stained healthy and MS cerebella at 40x magnification. 
 
 
 To provide a better understanding on the health status of the cells of interest 
in the CNS, intracellular staining of apoptosis-specific DNA fragments was 
further introduced into the double staining regime (Figure 3.35). Interestingly, 
co-localization for TUNEL signal with CD137 staining was specifically detected 
on human Purkinje neurons along the MS cerebellum but not at the same 
location in the healthy or physiological situation. Once again, 
immunofluorescence imaging successfully detected dead Purkinje neurons in 
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the proximity with activated microglia only during MS but not under healthy 
conditions. Not only the Purkinje neurons, the granular neurons were also 
detected to have undergone apoptosis during MS. Therefore, under human 
neurodegenerative and pathological circumstances such as MS, the effects of 
CD137L-signaling in activated microglia triggered by CD137 might be 
detrimental not only to oligodendrocytes but also to neurons expressing CD137 
such as the Purkinje neurons (found to be confined within the same vicinity and 
in close association with activated microglia), which all contributed to the highly 
deregulated and intensified worsening of the chronic debilitating disease. 
 
 
Figure 3.35. Apoptotic Purkinje neurons closely interact with activated 
microglia within the same area in the MS cerebellum. Tissue sections from 
the healthy and MS cerebella were stained with a Cy3-labeled anti-CD137 
(clone: 4B41) antibody (red) and a Cy5-labeled anti-Iba-1 antibody (white). 
Apoptosis was detected by TUNEL staining (green). Nuclei were visualized by 
DAPI (blue). The yellow staining results from an overlay of red and green and 
indicates apoptotic neurons. The insert within the image indicate a close-up 
visualization of apoptotic neuron and activated microglia. Shown are 
representative images from serially-sectioned and stained healthy and MS 






 Recombinant CD137 protein or anti-CD137L antibodies were 
demonstrated to induce activation, survival and proliferation in peripheral 
monocytes (Langstein et al., 1998; Langstein and Schwarz, 1999; Langstein, 
Michel and Schwarz and 1999; Zhu et al., 2001; Ju et al., 2003). Moreover, 
CD137 triggered the differentiation of monocytes into matured DC (Kim et al. 
2002; Laderach et al. 2003; Lippert et al. 2008; Kwajah and Schwarz, 2010). 
Apart from acting mature monocytes, CD137 induced hematopoietic progenitor 
cells to grow and to differentiate into monocytes and macrophages (Jiang et al., 
2008; Jiang, Chen and Schwarz, 2008). All these data indicated that CD137 
can be a potent growth and differentiation factor for monocytic cells. Our study 
further expanded the list of myeloid responders to CD137 by contributing to a 
new chapter on the previously unreported effects of CD137 and CD137L 
signaling involving microglia.  
 
4.1 What are the effects of CD137L signaling on microglia? 
 
 The key discovery and description of a functional biological process known 
as phagocytosis by Nobel Prize laureate, Elie Metchnikoff, a century ago (1908) 
opened a plethora of research opportunities in innate immunity concerning 
macrophage biology (Gordon, 2007). In innate immunity, resident 
macrophages provide immediate defense against foreign pathogens and 
coordinate leukocyte infiltration (Martinez et al., 2008). Macrophages 
contribute to the balance between antigen availability and clearance through 
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phagocytosis and subsequent degradation of apoptotic cells, microbes and 
possibly neoplastic cells (Gordon, 2003). In adaptive immunity, macrophages 
collaborate with T and B cells, through both cell-to-cell interactions and fluid 
phase-mediated mechanisms, based on the release of cytokines, chemokines, 
enzymes, arachidonic acid metabolites and reactive radicals (Gordon, 2003; 
Martinez et al., 2008). Our results demonstrated the plasticity of 
CD137L-activated microglia, which can potentially participate in and contribute 
to both innate and adaptive immune responses, supported by distinctive 
functional readouts. 
 
 4.1.1 Morphology 
 
 The activating effects of CD137L signals on myeloid cells are well 
documented (Shao and Schwarz, 2011). CD137L signaling induces 
attachment, activation, migration, survival, proliferation and differentiation in 
human monocytes (Langstein, 1998; Langstein et al., 1998; Langstein and 
Schwarz, 1999; Langstein, Michel and Schwarz and 1999; Langstein et al., 
2000, Drenkard et al., 2007; Kwajah and Schwarz, 2010). Since microglia, the 
main resident myeloid cells in the CNS are similar or identical to tissue 
macrophages when activated (Prinz and Mildner, 2011; Davoust et al., 2008) it 
was surmised that the CD137L signal activates microglia, and indeed our 
results confirmed this notion. 
 
 We have investigated the role of CD137 in microglia biology using murine 
cell lines and primary culture. CD137L signaling induced attachment and 
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morphological changes of BV-2, N9 and primary microglia as early signs of 
cellular activation. Interestingly, the murine cell lines developed spiky 
protrusions upon activation while the more pleiomorphic primary microglia had 
their processes shortened and also become amoeboid under CD137 treatment 
(Figure 3.3).  
 
 Amoeboid microglia were found in the developing CNS of rats but they 
disappeared soon after birth (Ling et al., 1979; Dalmau et al., 1997). Amoeboid 
microglia were able to develop long crenulated extensions and transform into 
ramified morphology in the adult CNS (Ling, 1979; Kaur and Ling, 1991). This 
is not difficult to reconcile as a developing CNS may require more extensive 
housekeeping regime and adjustments that require more reactive or amoeboid 
microglia, while the quiescent ones would start to develop during resting or 
surveillance period at a normal or physiological condition.  
 
 Adding on to microglia plasticity, Yokoyama et al. (2004) demonstrated that 
microglia had the potential to transform into neurons, astrocytes or 
oligodendrocytes, which further suggested ramified microglia to be a distinct 
pool of multipotent stem cell reserve in the adult CNS and potential candidates 
in CNS repair. Therefore, the heterogeneous and complex morphological 
changes of murine microglia triggered by CD137-CD137L interactions might 
represent microglia at different stages of activation and development in culture.  
 




 Quiescent ramified microglia could be transformed into activated brain 
macrophages, which are also known as reactive microglia (Kreutzberg, 1996; 
Stence, Waite and Dailey, 2001). An important function of reactive microglia is 
the ability of these immunocompetent cells to undergo transformation into 
phagocytes in an effort to ensure the CNS integrity by removing cell debris 
during CNS disease and injuries as well as during development (Kim and de 
Vellis, 2005). Other than having round cell body, amoeboid microglia also 
possess pseudopodia and thin filopodia-like projections and contain numerous 
lysosomes, which is characteristic of an actively motile phagocytic phenotype. 
The formation of cellular structures such as lamellipodia was also detected 
during the course of CD137L signaling. Interestingly, murine microglia were 
also found to acquire an enhanced ability to phagocytose when treated with 
CD137 (Figure 3.7), signified by an increase in the percentage of 
phagocytosing cells with a higher MFI. 
 
 4.1.3 Cell surface markers 
 
 The CR3 complement receptor, Mac-1 (CD11b/CD18) is widely employed 
for the identification of murine microglia whereas CD45 is a hemopoieitic and 
myeloid cell marker. CNS microglia were reported to adopt a CD11bhigh and 
CD45low signature while peripheral monocytes and macrophages were 
reported to exhibit a CD11bhigh CD45high phenotype (Sedgwick et al., 1991; 
Kingham et al., 1999; Hooper, Taylor and Pocock, 2005). Murine microglia 
expressed high levels of CD137L but not CD137 (Figure 3.1). In addition, 
primary microglia stained highly for CD11b but lowly for CD45, confirming the 
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myeloid nature of these cells. These findings provided a foundational platform 
for the subsequent incubation of these cells with CD137 recombinant protein 
and CD137-expressing cells. Interestingly, CD11b-expressing murine microglia 
were found to express CD137L, indicating that the CD137 and CD137L 
co-stimulatory pathway might have direct and specific effects on murine 
microglia through CD137L signaling.  
 
 It was reported that reactive microglia also expressed other surface 
molecules necessary for antigen presentation including major 
histocompatibility complex (MHC) class II antigen, CD40, B7 and ICAM-1 
(Streit et al., 1989; Benveniste et al., 2001). In addition, activated microglia are 
also capable of secreting zinc-dependent endopeptidases, matrix 
metalloproteinases, which are modifiers of extracellular matrix (Jourquin et al., 
2003). CD137L-activated murine primary microglia from wild-type background 
when cross-linked with CD137 recombinant protein were induced to express 
higher amounts of surface proteins such as MHC II, CD80, CD86 and CD40 
(Figure 3.21), which revealed a greater activation and maturation of murine 
primary microglia with greater antigen presenting capability. The increments in 
these surface molecules are not detectable on primary microglia generated 
from the CD137L-/- CNS, suggesting that CD137L signaling may be critical for 
the activation and maturation of murine microglia.  
 
 4.1.4 Cytokines, soluble factors and ROS 
 
 Similar to macrophages, reactive microglia that are phagocytic also 
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secrete a number of inflammatory mediators such as interleukins (Kim et al., 
2005), monocyte chemotactic protein-1 (MCP-1) (Kim et al., 2005), TNF 
(Combs et al., 2001; Taylor et al., 2005) and interferon-gamma (IFN-γ) (Suzuki 
et al., 2005), that orchestrate the immune response in CNS. Other factors or 
mediators secreted include prostanoids (Minghetti and Levi 1995; Pyo et al., 
1999; Pinteaux et al., 2002), glutamate (Piani and Fontana, 1994; Kingham et 
al., 1999), quinolinic acid (Espey et al., 1997; Guillemin et al., 2004), 
cathepsins (Kingham and Pocock, 2001), tissue plasminogen activator (Flavin, 
Zhao and Ho, 2000) and soluble FAS ligand (Ciesielski-Treska et al., 2001; 
Taylor et al., 2005).  
 
 Albeit there is a species difference since murine monocytes do not 
differentiate into DC as do human monocytes in response to CD137L signaling 
in vitro (Tang et al., 2011), in vivo activation of microglia does produce a 
proinflammatory state. In addition, a proinflammatory state was induced by 
CD137L signaling in the murine microglia cell lines, BV-2 and N9, as well as 
primary microglia. 
 
 TNF, IL-1β, IL-6 and MCP-1 productions were significantly increased by 
CD137L-activated primary microglia. Indeed, apart from induced production of 
proinflammatory cytokines, CD137L-activated primary microglia were also 
found to secrete soluble intercellular adhesion molecule-1 (sICAM-1) and 
matrix metalloproteinase-9 (MMP-9), which are important mediators for cellular 
adhesion and transmigration, respectively (Figure 3.5). Apart from IL-6 that fell 
below the detection limit of the ELISA kit, TNF, IL-1β and MCP-1 levels were all 
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significantly elevated in response to CD137L signaling in N9 microglia. While 
TNF secretion was dose dependently increased, the anti-inflammatory cytokine, 
IL-10, remained low or unaffected during CD137L signaling as compared to 
PBS- and Fc-treated controls. As proinflammatory cytokines are closely 
associated with ROS production, the ROS status of CD137L-activated murine 
microglia was investigated. Confirming the notion, CD137L-activated BV-2 
microglia in the presence of CD137 recombinant protein generated a higher 
percentage of ROS than PBS and Fc treated control cells. The results indicated 
that in vitro CD137L-signaling in murine microglia assigned a proinflammatory 
signature to the immunocompetent cells. 
 
 In general, the CD137L signal seems to induce a proinflammatory state in 
myeloid cells as evidenced by proinflammatory cytokine secretion and ROS 
production in microglia and monocytes. Also, CD137L-DC induce T cells to 
secrete IFN-, IL-13 and IL-17 but to reduce IL-10 (Kwajah and Schwarz, 
2010). 
 
 4.1.5 Proliferation profile 
 
 The anti-proliferative effect of CD137L signaling on murine microglia 
characterized by the decrease in 3H-thymidine incorporation into the cellular 
genome suggested a possibility that activated cells were triggered and 
dedicated to undergo a special cellular program such as in vitro differentiation 
and maturation into more specialized cells in response to CD137 recombinant 
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protein. This was further supported by the phagocytosis assay when activated 
murine microglia increased phagocytic capacity in response to CD137L 
signaling (Figure 3.7). Therefore, CD137 played the role of a differentiating and 
maturation factor rather than a promoter for proliferation. Nonetheless, other 
than a decrease in the rate of proliferation, an increase in activation-dependent 
cell death might also have contributed to the lower number of cells present 
when activated by the recombinant CD137 protein. Retrospectively, given that 
cell lines are usually optimized to favour fast proliferation, any perturbation that 
disrupts the optimal growth condition could also potentially and possibly lead to 
a decrease in proliferation. 
 
4.2 What is the significance of CD137L-activated microglia in the CNS? 
 
 Microglia has been shown to play a pivotal role in EAE and MS (Dheen, 
Kaur and Ling, 2007; Gay, 2007). The major pathogenic event in MS is the 
killing of oligodendrocytes by activated immune cells leading to the loss of 
axonal myelin sheaths and the subsequent death of the demyelinated neurons. 
Activated microglia has been demonstrated to induce programmed cell death 
in oligodendrocytes (Li et al., 2008).  
 
 Further, CD137 and its ligand have been shown to influence the 
development of EAE. Agonistic anti-CD137 antibodies administered during the 
induction phase reduced the incidence and severity of the disease. Potential 
mechanism are an increased activation of T cells and a subsequent higher rate 
of activation induced cell death, as well as a skewing of the T cell response 
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towards regulatory T cells (Sun et al., 2002; Kim, 2011; Martínez Gómez, et al., 
2012).  
 
 4.2.1 Apoptotic murine oligodendrocytes via oxidative burst in   
   CD137L-activated microglia  
 
 As the activation of macrophages and microglia can be mediated by 
numerous pathways and is highly redundant, the fact that the CD137L signal 
seems to be pivotal for microglia activation since considerably fewer activated 
microglia were found in the CNS of CD137L-/- mice compared to WT mice 
during EAE (Figure 3.27 A and B), was rather surprising. Nevertheless, it 
provided a basis for activated microglia to be identified as the potential 
candidate responsible for oligodendrocytes apoptosis as a result of CD137L 
signaling. 
 
 Supported by metamorph software quantification, the lower microglia 
activation in CNS of CD137L-/- mice correlated with the decrease in the 
number of dying oligodendrocytes during EAE (Figure 3.28), implying that the 
activated microglia caused the oligodendrocyte death via CD137L signaling. 
The immunofluorescence staining data could be confirmed by demonstrating in 
vitro that CD137L-activated microglia induces oligodendrocyte apoptosis. 
Indeed, the pathological relevance of the in vivo findings are supported by the 
discovery that both microglia cell lines as well as primary microglia induced the 





  Confirmed by catalase rescue of oligodendrocytes survival (Figure 3.14 A 
and B), the induction of murine oligodendrocyte apoptosis by 
CD137L-activated murine microglia (Figures 3.13 and 3.14) occurs via the 
production of ROS. This parallels induction of T cell apoptosis by 
CD137L-activated monocytes which occurs during the first 24 h of CD137L 
engagement, and which is thought be a mechanism of infection-induced T cell 
attrition (Kwajah et al., 2011). Only longer term CD137L-signaling induces 
differentiation of monocytes to proinflammatory CD137L-DC (Kwajah and 
Schwarz, 2010; Ju et al., 2009). 
 
 There were also more Nogo A stained oligodendrocytes in healthy 
cerebellum and temporal lobe with greater staining intensity as compared to 
respective MS brain tissues (Figure 3.29). Importantly upon further evaluation, 
substantially greater number and staining intensity of TUNEL and Nogo A 
double positive cells or apoptotic oligodendrocytes were detected in MS 
temporal lobe, which were significantly lesser in the healthy temporal lobe 
(Figure 3.30). Comparable with the murine pathological findings in vivo, little or 
no Iba-1 positive cells were detected in the healthy human brain tissues while 
the MS brain tissues had developed a greater microglia activation status in 
terms of absolute number and staining intensity (Figure 3.31), which also 
matched well in response to the increase in apoptotic oligodendrocytes 
detected only in the MS brain sections, suggesting that activated human 
microglia, like activated murine microglia, may lead to poorer survival outcome 
of the oligodendrocytes during MS. Encouragingly, the novel detection of 
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CD137L and Iba-1 double positive cells in MS temporal lobe and cerebellum but 
not under healthy conditions further boosted confidence to the hypothesis that 
human oligodendrocyte cell death could occurs via CD137L signaling in 
activated human microglia. 
 
  Given these data and our findings that in the absence of CD137L there is 
less microglia activation and less oligodendrocyte apoptosis, one could 
speculate that EAE induction in CD137L-/- mice may result in a reduced 
severity. However, the effects of CD137 or CD137L manipulations are very 
difficult to predict. For example, treatment of tumor-bearing mice with agonistic 
anti-CD137 mAb enhances the anti-tumor immune responses leading to tumor 
rejection (Melero et al., 1997). Yet treatment with the very same mAb 
ameliorates collagen-induced arthritis and chronic graft-versus-host disease 
(Foell et al., 2004; Kim et al., 2005). But it exacerbates acute graft-versus-host 
disease (Blazar et al., 2001). The reasons for these unexpected and difficult to 
reconcile effects are not yet fully understood. Therefore, it is important to 
address experimentally what influence the absence of CD137L may have on 
EAE in terms of behavioral aspects as well as clinical scoring. 
  
 4.2.2 Apoptotic neurons and activated microglia in human CNS 
 
 Compared to the healthy human cerebellum, MS cerebellum stained more 
strongly for CD137 (Figure 3.33). Apart from the Purkinje neurons, the granular 
neurons are likely to be stained for CD137. In addition, Iba-1 stained strongly 
for MS cerebellum but not the healthy cerebellum. Iba-1-positive activated 
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microglia are pleotropic - they can appear amoeboid as well as develop 
extensive environmental cue sensing dendrites or cellular projections whereas 
resting microglia are rarely amoeboid. Moreover, Iba-1 positive activated 
microglia in close contact with anti-CD137-stained Purkinje neurons are 
detected in MS cerebellum but not in healthy cerebellum. Furthermore, 
anti-CD137-stained Purkinje neurons in MS cerebellum are also TUNEL 
positive i.e. apoptotic and found to be in association with Iba-1-positive 
microglia in the MS cerebellum, which are absent in the healthy human 
cerebellum. Apart from the Purkinje neurons, the granular neurons in the gray 
matter could also be apoptotic. 
 
 Propelled by the discovery that CD137-expressing cells were detected in 
the CNS during EAE and MS, the presence or upregulation of the 
CD137L-expressing cells was also anticipated. As a result of CD137 activation, 
CD137L expression could be intensified or more cells could be positively 
stained for CD137L in EAE or MS brains compared to those that are 
disease-free. Developing and supporting the notion, the detection of CD137L 
on human activated microglia is promising. Leveraging on the 
biotin-streptavidin affinity, human CD137 was successfully detected with a 
Cy3-conjugated streptavidin, demonstrating for the first time that human 
neurons may express CD137. This provides a critical link for subsequent 
investigations of CD137 and CD137L activities in the CNS especially during 
neuroinflammation. 
 
 Therefore, CD137L-activated human microglia may drive the killing or 
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apoptosis of not only human oligodendrocytes but also human Purkinje 
neurons as well during MS but not healthy state brains. However, the 
mechanism(s) of killing await further confirmation through exploiting the in vitro 
co-culture systems involving the respective human cells. Similar to the murine 
work strategy, it is hoped that the postulation being CD137L-activated human 
microglia, under the influence or stimulation by CD137, may exacerbate 
neurodegeneration by killing human oligodendrocytes in MS could be 
demonstrated in vitro. The effort will bring clarity to the postulation that CD137 
and CD137L signaling could potentially be a novel immune receptor-ligand 
system in EAE and MS pathogeneses. 
 
4.3 Is CD137L essential for microglia activation? 
 
 When co-cultured with CD3 and CD28 activated WT T cells, BV-2, N9 and 
primary microglia secreted significantly higher levels of sICAM-1 than that in T 
cell or murine microglia single culture conditions (Figure 3.18), suggesting that 
not only CD137 recombinant protein but also activated T cells expressing 
CD137 could lead to murine microglia activation even though inhibiting 
CD137L on murine microglia with an antagonistic anti-CD137L antibody 
(TKS-1) to interrupt CD137-CD137L interaction did not affect murine 
microglia’s ability to secret sICAM-1 in the presence of preactivated T cells. 
Preactivated T cells refer to CD3 and CD28 activated T cells and the former 
term will be used throughout the rest of the paper.  
  
 Although CD137L-activated murine microglia did not further enhance IFN-γ 
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secretion by preactivated WT T cells (Figure 3.16), preactivated T cells 
expressing CD137 do activate murine microglia in vitro leading to 
morphological changes (Figure 3.17). Further when co-cultured with 
preactivated WT T cells, murine microglia secreted progressively and 
significantly elevated levels of MCP-1 than in T cell or microglia single culture 
conditions (Figure 3.19). Moreover, WT microglia and preactivated WT T cells 
enhanced secretion of MCP-1 was also attenuated with TKS-1 to a baseline 
level similar or comparable to that from the CD137L-/- background derived 
microglia and preactivated T cells co-culture, suggesting that murine microglia 
activation depends on CD137L, which is required to cross talk with CD137 
expressed on the T cells.  
 
 Further, when co-cultured with BV-2 as well as with N9 microglia, activated 
WT T cells secreted significantly higher levels of GM-CSF than that in single T 
cell culture and the co-cultures with anti-CD137L treatment led to significant 
reduction in GM-CSF production (Figure 3.20). Hence, inhibiting CD137L on 
murine microglia or blockage of CD137-CD137L interaction attenuated T cells 
ability to secret GM-CSF. 
 
 GM-CSF was reported to be critical for the manifestation of EAE or MS 
since both GM-CSF-/- mice and anti-GM-CSF neutralizing antibody prevented 
or protected the animals from the disease with improved outcome than the WT 
untreated animals (Codarri et al., 2011). The increase in GM-CSF with an 
intact or functioning CD137 and CD137L system may be important for the 
recruitment of other immune or scavenger cells including microglia to mediate 
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or even exacerbate neuroinflammation. Similar to the results observed in 
CD137L-/- mice, TKS-1 treatment or blockage of the CD137/ CD137L pathway 
reversed LPS-induced septic shock in WT mice (Vinay et al., 2004). In addition, 
TKS-1-treated cecal ligation and puncture (CLP) mice also had improved 
survival compared to WT mice with CLP procedure (Nguyen et al., 2009). This 
survival advantage was associated with lower production of chemokines and 
proinflammatory cytokines as well as better bacterial clearance due to increase 
numbers of infiltrated peritoneal neutrophils and macrophages in the CLP 
model with TKS-1 treatment than in the control mice. Therefore, like the 
beneficial effects observed in the sepsis experiments, the neutralization of 
CD137L by TKS-1 might play a role in alleviating EAE or MS through 
preventing the T cells from secreting enhanced levels of GM-CSF as well as 
reduction in proinflammatory cytokine (MCP-1) production due to less 
microglia activation, which otherwise could be driven by CD137 and CD137L 
co-stimulation. 
 
 Preactivated WT T cells drove the activation and further maturation of WT 
microglia only but not microglia cultured from CD137L-/- CNS in vitro. After 
coculture with preactivated WT T cells, microglia from the WT but not 
CD137L-/- CNS produced substantial increment in percentage and in MFI of 
differentiation markers namely CD80, CD86, CD40 and MHCII, signifying that 
CD137L is required for activation and adaptive maturation of murine microglia 
in vitro (Figure 3.21). Furthermore, murine microglia from EAE CD137L-/- CNS 
failed to lead to oligodendrocyte apoptosis as opposed to murine microglia 
from EAE WT CNS, demonstrating that the in vitro killing of oligodendrocytes 
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critically depended on CD137L-activated microglia (Figure 3.15). The 
dampening of microglia activation (Figure 3.27 A and B) that corresponded to 
lesser oligodendrocyte apoptosis (Figure 3.28 A and B) in CD137L-/- CNS 
further indicated the non-redundancy and potency of CD137L signals in 
contributing to the deleterious effects in the pro-inflammatory and degenerating 
CNS. 
 
 Our murine studies demonstrated that CD137L is required for microglia 
activation but also for regulating the functional effects that would govern the 
fate of other CNS cells such as oligodendrocytes during neuroinflammation. 
Nevertheless, further experiment such as to determine whether microglia from  
the CD137L-/- CNS also remain unactivated upon LPS treatment is necessary 
to affirm the absolute requirement of CD137L for microglia activation.  
 
4.4 Cross talk and cellular sources of CD137 and CD137L in the CNS 
 
 Importantly, the in vitro CD137L functional data need to be fortified with 
either direct or indirect in vivo evidence(s) of CD137-CD137L activities, i.e. 
whether these interactions via CD137 and CD137L expressing cells are 
actually occurring in the CNS.  
 
 Investigations conducted to evaluate the involvement of CD137 under 
neuroinflammatory or pathological conditions such as EAE, a prototype for 
T-cell-mediated autoimmune disease, shed light on the cellular source(s) of 
CD137 in the inflamed CNS. CD137 was originally found on activated T cells, 
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and activated T cell can quickly upregulate CD137 expression (Kwon et al., 
1989; Schwarz et al., 1993). CD137 expression on T cells is also strictly 
activation dependent (Schwarz et al., 1995). Given the consideration, it was 
hypothesized that the CD137-expressing cells detected in the EAE cervical 
spinal cords are likely to be activated T cells that have infiltrated into the CNS 
through the disrupted blood brain barrier during EAE pathogenesis. These 
activated T cells expressing CD137 would in turn crosslink and activate 
CD137L-expressing cells such as microglia in the brain to exacerbate 
neuroinflammation and degeneration.  
 
 The identification of the CNS cells expressing CD137 is greatly facilitated 
with coronal brain sections prepared by a more standardized sectioning at 
defined steoreotactical coordinates using a mouse brain blocker, which is a 
device to hold the murine brain at a specific orientation for sectioning at a 
particular topography, along with professional advice from a neuroanatomist 
and pathologist. Moreover, employing double immunofluorescent labeling with 
an apoptosis indicator not only promoted the discovery of the CD137 and 
CD137L expressing cells in the CNS but also helped in determining the 
survival status of the cells in query under the disease microenvironment. 
Furthermore, the application of the technique on MS and healthy human brain 
samples contributed in determining the association the murine findings with the 
human disease. 
 
 Apart from CNS cells in the gray matter of the EAE WT cervical spinal cord 
that stained for CD137, cells along the spinal cord periphery also stained for 
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CD137 using IHC. The two populations of CD137-expressing cells revealed 
were likely to be different considering their difference in cellular localization and 
sizes. 
 
 The prevention of EAE in CD137L-/- mice can have several reasons such 
as impaired T cell priming and/or migration to the CNS (Martinez Gomez et al., 
2012). To verify the postulation that the CD137-expressing cells that were 
smaller in size were infiltrating activated T cells, immunofluorescence stainings 
were performed. Supported by the double-immunofluorescence staining, CD3 
and CD137 double positive cells were detected in close association with the 
Iba-1 positive or activated microglia in the EAE WT but not EAE CD137L-/- 
cervical spinal cord (Figure 3.22 B), indicating that the smaller-sized cells that 
immunohistochemically stained for CD137 previously were indeed activated T 
cells (Figure 3.22 A). This further supported the in vitro results of 
CD137L-induced murine microglia activation by preactivated WT T cells that 
could potentially involve CD137 and CD137L interaction in CNS disorders as 
discussed in Chapter 4.3.  
 
 Following the stereotactical sectioning of murine EAE and naive WT brains, 
CD137 expression was detected on cells of the cerebellum, hypothalamus and 
cervical spinal cord of the EAE WT mice (Figures 3.24 and 3.25). Comparing to 
the naive WT or EAE CD137L-/- cerebellum, CD137 was topographically 
detected to be enhanced on the large inhibitory neurons, Purkinje cells, only in 
EAE WT cerebellum suggesting that CD137 could become upregulated on 
neuronal cells during the course of neuroinflammation. Since the gray matter of 
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the CNS is primarily comprised of neuronal cell bodies and dense dendrite 
networks, the CD137-expressing cells that were larger in size in the gray matter 
of the EAE WT spinal cord morphologically resembled and were likely to be 
neurons as well. Further of human relevance, enhanced CD137 expression 
was also detected on the Purkinje neurons (Figure 3.33) and in close contact 
with activated microglia (Figure 3.34) only in MS but not in healthy cerebellum. 
Hence, the specific detection of CD137 expression on the Purkinje neurons 
lining the cerebellum opened door to the possibility of CD137-CD137L 
interaction being a novel neuron-glia signaling association that warrants further 
investigations. 
  
 Human CD137 antigen is reported to be expressed on activated B cells, 
Reed Sternberg cells and peripheral blood monocytes but is absent from 
resting T cells (Kienzle and von Kempis, 2000; Ho et al., 2012). In non 
lymphoid cells, expression has been reported in blood vessel walls, on the 
endothelial layer and on vascular smooth muscle cells. Adding on to the 
existing literature, CD137 on either activated T cells or neurons can be coined 
as a functional activator for murine microglia during EAE or MS. The increase 
in the inflammatory response further induced an accumulation of ROS in 
CD137L-activated murine microglia when crosstalk occurs with CD137, which 
in turn kill oligodendrocytes. 
 
 Not only that CD137L is expressed by murine microglia (Figure 3.1), it is 
also specifically expressed on human microglia in the temporal lobe (Figure 
3.32 A) and the cerebellum (Figure 3.32 B) of the MS brain but not in the 
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corresponding healthy brain regions. This serves as an important anchor to 
augment the murine results with new investigations and findings involving 
CD137L-activated human microglia in MS. Indeed, preliminary pathological 
evidence shows the reduction of oligodendrocytes in the MS but not in the 
healthy brains (Figure 3.29). Further, the occurrence of more dead 
oligodendrocytes which corresponded with an increase in activated microglia in 
the MS but not in the healthy brains revealed the potential and possible 
implications of CD137L signaling in activated human microglia. At this juncture, 
all the comparisons of IF stainings and quantifications between human healthy 
and MS brain tissues suggested that the effect of CD137L-activation on 
microglia and the greater occurrence of dead oligodendrocytes may be valid 
not only in EAE but also in MS. 
 
 IHC and IF stainings provided compelling pathological evidence that cells in 
the EAE WT CNS also expressed CD137 (Figures 3.22 - 3.26). In the EAE WT 
cerebellum, CD137 expression was found to be enhanced on the Purkinje 
neurons compared to the naive WT cerebellum (Figure 3.24). However, CD137 
expression was even further or more greatly enhanced on the Purkinje neurons 
in the EAE CD137L-/- cerebellum suggesting the attempt to trigger or restore 
CD137L signaling in microglia for EAE progression, which could be driven by 
CD137 (Figure 3.26). Since CD137L-activated microglia is required for EAE 
development and its neuroinflammatory effects, CD137 expression was 
upregulated in the EAE CD137L-/- CNS in order to activate the microglia 
through CD137L signaling, which was impaired and therefore futile. Of clinical 
relevance, CD137 expression was also detected on the Purkinje cells in close 
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association with activated microglia only in the MS cerebellum but not in the 
healthy cerebellum (Figure 3.34). Furthermore, CD137-expressing Purkinje 
neurons were apoptotic and again detected to be in close contact with activated 
microglia during MS (Figure 3.35). Therefore, the paired CD137 and CD137L 
signaling pathway could be a novel immune co-receptor-ligand system that 
might be essential for not only murine but also human microglia activation 
potentially via CD137-expressing neurons as well in both murine and human 
CNS during neuroinflammation. As the discovery of activated microglia and the 
enhanced frequency of CD137-expressing cells in human MS parallels our 
findings in murine EAE, this further implies that activation of microglia by 
CD137L may also be pathogenic mechanism contributing to human MS. 
 
4.5 MS therapy 
 
4.5.1 Current MS therapy 
  
 Apart from glatiramer acetate, which is an FDA approved drug for the 
treatment against relapsing MS, several promising and robust drug candidates 
are also in development. Given its ability to reduce brain loss and damage in 
two large Phase III clinical trials, an oral drug, fingolimod (Gilenya®), has 
gained FDA approval in 2010 and is currently marketed by Novartis for 
relapsing MS therapies. Fingolimod is comprised of sphingosine 1-phosphate 
receptor (S1P-R) modulators, which inhibit the migration of T cells out of lymph 
nodes and thereby preventing them from mounting deleterious attacks on the 




 On the other hand, following the successful of the Phase III trial for MS, 
Genzyme, a Sanofi company, has been issued the green light by FDA to 
market the drug known as teriflunomide (Aubajio ®) for the treatment of 
relapsing forms of MS this September, as reported by the Multiple Sclerosis 
Resource Centre hosted through the world wide web. Teriflunomide is an 
immunomodulatory, disease-modifying oral drug with anti-inflammatory 
properties. Through blocking the de novo synthesis of pyrimidines by 
selectively and reversibly inhibiting a critical mitochondrial enzyme, 
teriflunomide offers anti-proliferative and anti-inflammatory properties, which in 
turn inhibit the proliferation and function of activated, but not resting, T and B 
lymphocytes. As the slowly dividing or resting lymphocytes are unaffected by 
the drug, the immune system's response to infection remains uncompromised. 
Another investigational oral drug for relapsing-remitting MS treatment by 
Biogen Idec known as BG-12 (dimethyl fumarate) is following closely along the 
clinical pipeline. 
 
 4.5.2 View on new potential treatment alternative 
 
 As CD137L is required for microglia activation and adaptive maturation, 
which were impaired when CD137L was either inhibited or in the case of 
CD137L-/- mice, further staining evidence from healthy and pathological brain 
tissues supported the notion that impaired CD137L signaling might incapacitate 
microglia activation and render them futile in participating in and sustaining the 
pro-inflammatory response or microenvironment favouring neurodegeneration. 
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Hence, local inhibition of CD137L signaling in microglia using monoclonal 
anti-CD137L could be a promising or viable strategy to modulate EAE or MS 
progression. Disease severity and further CNS atrophy could potentially be 
reduced through dampening neuroinflammation, which would otherwise be 
exacerbated in the presence of CD137L-activated microglia in the inflamed 
CNS. 
 
 However, before even considering CD137L as a target for localized 
treatment in EAE/ MS, it is important to define the exclusivity of its expression or 
abundance in the murine and the human CNS. In addition, given the plasticity of 
CNS cells such as the microglia, greater time and disciplined efforts are 
required to better understand the role of CD137 and CD137L system in not just 
neurodegeneration but also during physiological state. Further works then need 
to be designed for lead target identification and optimization to gain a deeper 
understanding, which is required to discern the therapeutic possibilities and 
implications of targeting the CD137 and CD137L system in human brains in 
subsequent clinical testings. 
 
4.6 Ongoing and future studies 
 
 In view of the heterogeneous morphologies of CD137L-activated microglia 
induced by CD137 interaction, it may be worthwhile investigating small 
GTPases as a first step towards identifying other signaling mechanism(s) or 
molecules that could be involved with CD137-induced microglia activation. 
Small GTPases of the Rho family such as RhoA, Rac1 and Cdc42 (cell division 
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cycle 42) are known regulators of the actin cytoskeleton (Maekawa et al., 
1999). Briefly, the activation of small GTPases leads to the following 
phenomena. 
i. RhoA activation  stress fibres 
ii. Rac1 activation  lamellipodia or membrane ruffles 
iii. Cdc42 activation  filopodia 
 
It is hypothesized that small GTPase(s) in microglia may become 
activated upon treatment with recombinant CD137 protein. Changes in cell 
morphologies require cytoskeletal reorganizations. Without cytoskeletal 
remodeling, the microglia, when activated, would not be able to adhere and 
function as phagocytes (Niedergang and Chavrier, 2005). Hence, to 
understand the process leading to the functional outcome of microglia 
activation, focusing on small GTPase-mediated cytoskeletal rearrangement is 
likely to generate a lead. 
 
 PBS and Fc controls alongside with CD137-Fc would be adequate for a 
start to study small GTPase activation in murine microglia cell lines. To further 
demonstrate that small GTPase involvement is induced by CD137L signaling, 
a CD137L inhibitor (in excess amount compared to the CD137-Fc employed) 
could also be employed. Next, to ensure that the activation of the small 
GTPase is essential for a functional outcome, functional biological readouts 
like cellular attachment, morphological changes, cytokine secretion and 
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phagocytosis in the presence and absence of a particular small GTPase 
inhibitor during CD137L signaling could also be investigated. The above is 
proposed to be performed in essence to support the hypothesis that CD137L 
signaling may activate small GTPases in order to cause microglia to change 
from a quiescent (semi-adherent) to an activated (adhering and 
phagocytic) form. Furthermore, murine microglia derived from CD137L-/- mice 
could also be employed for CD137L signaling to confirm that morphological 
changes, cytokine secretion and phagocytosis are indeed CD137 and CD137L 
system dependent. 
 
 As discussed in Chapter 4.4, enhanced CD137 expression was detected in 
the EAE but not the naive WT CNS. Although the cellular localization, size and 
morphology suggested that the Purkinje neurons at the cerebellum were 
stained for CD137 during EAE, further studies can also be designed to double 
immunolabel the tissue with CD137 and a neuronal marker such as βIII tubulin. 
The detection of CD137 and βIII tubulin co-expression on similar cells at the 
same localization in the EAE WT cerebellum would confirm the identity of the 
Purkinje neurons. In addition, the double immunofluorescence using the two 
markers can also be employed for MS and healthy cerebellum to ascertain 
whether human Purkinje neurons also express elevated levels of CD137. The 
strategy will help to identify a common association in which CD137 is 
implicated during both EAE and MS. 
 
 The detection of other TUNEL-positive cells instead of just apoptotic 
oligodendrocytes in EAE WT CNS supported the speculation that other CNS 
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cells could also be apoptotic during the disease progression. Of high relevance, 
it would also be meaningful to investigate whether apoptotic neurons are 
present in the murine EAE CNS by incorporating an apoptosis marker or 
TUNEL staining with βIII tubulin. In addition, the inclusion of Iba-1 staining 
would provide further clues regarding the involvement of activated microglia in 
murine neuropathology in vivo. Future in vitro experiments involving coculture 
of murine microglia with CD137-transfected murine neuronal or glia cell lines 
can be employed to augment the in vivo evidences. 
 
 Moreover, biochemical assessments can also be employed to determine 
whether a defective negative feedback exists due to the loss or apoptosis of 
Purkinje neurons. The detection of perturbations or an accumulation in 
intracellular calcium as well as neurochemical measurements demonstrating a 
decrease in GABA production by inhibitory neurons that inversely corresponds 
with an increase in glutamate secretion by excitatory neurons may suggest and 
foster the hypothesis that deregulated neuronal signaling and excitoxicity may 
lead to metabolic exhaustion and eventually the death of neurons due to the 
impaired GABAnergic or inhibitory response that can potentially be triggered 
by CD137 and CD137L pathway involving CD137L-activated microglia induced 
killing of CD137-expressing Purkinje neurons. Furthermore, behavioral studies 
such as rotatory chair testing on naive WT and EAE WT and EAE transgenic 
mice could be performed to generate supportive evidences along with clinical 
scoring and survival testing. The inability to neutralize the CNS excitatory 
signals and response due to CD137 and CD137L interaction could potentially 




 It was previously reported that CD137 and CD137L can be expressed in 
the human CNS during MS, and that the expression increases during 
inflammation caused by mycobacterial infection (Curto et al., 2004). Further, 
CD137 and CD137L interactions were found to regulate the innate and 
adaptive immune response of the host against M. tuberculosis (Fernández Do 
Porto et al., 2012). Moving forward, there remains a need to employ human 
monocytes or microglia and human oligodendrocytes to ascertain the clinical 
relevance of microglia activation during MS in vitro. Critical questions to be 
answered are: What are the biological effects of CD137 on human microglia? 
Do CD137L-activated human microglia kill human oligodendrocyte? What is 
the mechanism of human oligodendrocyte apoptosis as a result of human 
microglia activation via CD137?  
 
 Importantly, CD137-expressing apoptotic human Purkinje neurons were 
detected in close proximity to the CD137L-activated human microglia in the 
MS brain tissues. This finding further suggested a possibility that 
CD137L-activated microglia may induce the death of CD137-activated Purkinje 
neurons via CD137-CD137L interaction, resulting in the progressive 
deterioration of the CNS integrity during MS. Recent research articles created 
a platform for the verification of the involvement of the Purkinje neurons under 
a new chapter of the CD137-CD137L signaling story. Authors collectively 
suggested that EAE or MS is potentially a disease of the inhibitory neurons at 
the gray matter whereby the loss of Purkinje neurons attributed cerebellar 
dysfunction and behavioral deficits in MS (MacKenzie-Graham et al., 2009; 
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Giuliani et al., 2011). Earlier, our laboratory also observed CD137 upregulation 
on RS cells in Hodgkin’s lymphoma (Ho et al., 2012). Although the context may 
be different, this suggests that CD137 may truly be important in different 
human diseases. Hence, it may be worthwhile to explore the in vitro or ex vivo 
effects of CD137 and CD137L interactions between microglia and Purkinje 
neurons. Moreover, apart from in vitro functional experiment that may face 
constraints due to the limited availability of human-derived Purkinje neurons 
and microglia, the detection of other apoptotic markers such as cleaved 
caspase-3 with anti-CD137 staining may also help to further foster our claim 
regarding apoptotic Purkinje cells demonstrated by TUNEL and CD137 
stainings in MS brain tissues.  
 
 Inevitably, as a confirmation to the pathological evidence showing a 
corresponding increase in activated human microglia with an increase 
apoptotic human oligodendrocytes, it would thus be critical and useful to further 
investigate the human system ex vivo using human microglia and human 
oligodendrocytes. The HOG cell line is a human immature oligodendroglia cell 
line commonly employed to study oligodendrocyte differentiation and function. 
It is likely that HOG cell line may not be activated by CD137 since OLN93 
oligodendrocytes neither express CD137 nor the corresponding ligand. 
However, this assumption needs to be verified on HOG cells using flow 
cytometry prior to employing them for coculture with human microglia to study 
the activating effects of the latter. The utilization of HOG cells hold with it the 
promise of the human relevance for the previously established EAE findings 
whereby the roles of CD137L-activated human microglia can be further 
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substantiated. Potentially, given if HOG cells do not bear any receptor or ligand, 
HOG cells can also be employed to study oligodendrocyte differentiation. If 
CD137 protein is able to induce HOG differentiation to mature oligodendrocytes, 
it may suggest the existence of an alternative ligand other than CD137L, and 
open new doors into the field of CD137L research.  
 
 Alternatively, the human oligodendrocytic hybrid cell line (MO3.13) 
coculture with either CD137L-activated human monocytes-derived microglia or 
the human microglia cell line, HMC3, could also be performed for in vitro 
apoptosis assessment of human oligodendrocytes under the influence of 
CD137L-activated human microglia using Annexin V and 7-AAD stainings. 
This approach aims to confirm the finding that increased apoptotic human 
oligodendrocytes corresponded with microglia activation in the MS brains. 
Should human oligodendrocyte apoptosis be enhanced in vitro, we could 
further study the mechanism(s) of cell death (e.g. ROS- or death 
receptor-mediated). The rescue of the human oligodendrocytes from apoptosis 
can potentially elucidate or confirm the mechanism of killing of human 
oligodendrocytes by CD137L-activated human microglia. Employing a 
antagonistic anti-CD137L antibody could further answer or determine whether 
the death of human oligodendrocytes were CD137L-mediated or dependent. 
 
 Lastly, it would be meaningful to further evaluate the exclusivity of CD137 / 
CD137L signalling in the CNS (e.g. expressions of CD137 on neurons and 
CD137L on microglia). Given that CD137 / CD137L is overexpressed uniquely 
on certain types of CNS cells during CNS pathogeneses, localized treatment 
155 
 
targeting this receptor-ligand in the CNS may then produce safe, effective and 
beneficial outcomes while causing little or no toxic side effect(s) to other parts of 
the body simultaneously. 
 
4.7 Other remarks 
 
 Like recombinant CD137 protein, preactivated T cells are capable of driving 
murine microglia activation. It was also demonstrated that WT microglia can 
become further activated in the presence of preactivated T cells to express 
CD40, CD80, CD86 and MHCII for antigen presenting, and the upregulation of 
these markers was impaired when CD137L-/- microglia are employed. While 
demonstrating the enhanced CD137 expression in EAE WT cerebellar Purkinje 
neurons compared to the naive WT scenario, it was interesting to observe that 
CD137 is further intensified on the same cell type in EAE CD137L-/- cerebellum. 
Although we are still unclear about the source or driver for CD137 upregulation 
since inflammation is absent or less profound, this finding shed light on the 
importance of the ligand in conferring activated microglia their acquired function 
or potency during disease. Otherwise, the system would not have engaged in 
the metabolic activity to upregulate the protein, which would not only require 
more time but also additional energy under the already stressed or disease 
state. The manifestation of EAE in CD137L-/- mice (e.g. by upregulating CD137, 
which is necessary to activate microglia) is evidently futile and still impaired due 
to the absence of the ligand, which was demonstrated to be critical for microglia 




 The detection of apoptotic CD137-expressing Purkinje neurons in close 
association with activated microglia in the human MS brains indicated that both 
cell types could participate in EAE and MS pathogenesis via CD137-CD137L 
co-stimulatory pathway. Adding to the loss of myelin sheath due to 
oligodendrocyte apoptosis which was reported, the death or loss of Purkinje 
neurons during EAE or MS further compromised the biological system's ability 
to establish an effective negative or inhibitory feedback loop to keep the 
excitatory signals in proper check and balance during neurodegeneration, 
which otherwise would have been normal during physiology. 
 
 It might be quite astounding or even farfetched that the CNS from the naive 
CD137L-/- mice would invest time and energy in upregulating CD137 with the 
aim to restore CD137-CD137L signaling, which could potentially lead to 
proinflammation or even worsening of neurodegeneration. However, the effects 
of CD137L signaling that were reported to be more harmful than beneficial were 
in the context of EAE from our studies. In addition, CD137L might have other 
important developmental or physiological roles in a healthy and 
uncompromised CNS in which the regenerative and housekeeping properties 
of microglia could also potentially depend on CD137-CD137L system to be 
intact and functional. Moreover, given that microglia are highly versatile and 
plastic, the information on whether CD137L signaling could potentially be 
beneficial in normal physiology or even during neurodegeneration warrants 
deeper investigations. 
 
 CD137 and CD137L biology in the CNS is a new entity in neuroimmunology, 
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which requires deeper exploration using different neuroinflammatory models 
and knockout animals. While ROS production by CD137L-activated microglia 
led to the apoptosis of oligodendrocytes in EAE (Yeo, et al., 2012), end-stage 
mSOD1 M1 microglia were found to be toxic to motor neurons during ALS 
(Liao, et al., 2012). Adult microglia isolated from ALS mice at disease onset 
developed an M2 phenotype that protected the motor neurons whereas 
microglia isolated from late-stage disease ALS mice adopted an M1 phenotype 
and are neurotoxic supporting the dual phenotypes of microglia and their 
transformation during disease pathogenesis in ALS mice. The temporal effects 
of CD137L-activated microglia in EAE and MS, however, remains to be 
elucidated. 
 
 Given the striking similarities between MS and ALS such as Chromosome 9 
intronal sequence implications (Jagodic et. al., 2009; Renton et. al., 2011), 
elevated glutamate levels, TDP43 mutations (Lagier-Tourenne, Polymenidou 
and Cleveland, 2010), the possibility of the involvement of CD137 and CD137L 
system in the pathogenesis of closely related neurodegenerative disorders 
such as ALS remained hopeful for further elucidation. Given the identification of 
CD137 and CD137L involvement in neurodegenerative disorders, lead drug 
targets can be more effectively optimized and developed for further testings to 
treat probably not just one but two or more neurodegenerative diseases in 
future. 
 
 Battling and bettering science, the field of CD137 and CD137L signaling 
has flourished. As such, the past understanding of CD137 and CD137L being a 
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potent immune receptor-ligand system for regulating immune cells in the bone 
marrow and the peripheral blood is incomplete and hence is opened for better 
definition. Adding to the body of literature, the CD137 and CD137L system also 
has profound implications on microglia and oligodendrocytes during EAE and 
MS, which could potentially implicate the neurons as well. The stage of 
excitement and anticipation has now emerged and diversified for future studies 
to include the CNS as a new challenging research perspective and initiative, 
and for scientists to progressively unravel the potential of the receptor-ligand 
system even at other immune-privileged sites of the body.  
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CHAPTER 5  SUMMARY AND CONCLUSION 
 
 Succinctly, CD137L is required for murine microglia activation. CD137L 
signaling activates microglia cell lines and primary microglia cells in vitro 
leading to morphological changes, enhanced adhesion, increase in secretion 
of pro-inflammatory cytokines, elevated reactive oxygen species (ROS) 
production and increase in phagocytosis. CD137L is also important for 
microglia activation in vivo, as its absence in genetically modified i.e. CD137L-/- 
mice results in lower microglia activation during EAE, which is likely be due to 
fewer infiltrating T cells and less profound inflammation. A key event in the 
pathogenesis of EAE and MS is the destruction of oligodendrocytes and their 
axonal myelin sheaths by activated immune cells. CD137L-activated microglia 
indeed induce apoptosis in oligodendrocytes, the myelin producers in the CNS, 
and this cell death, which is CD137L-dependent, is mediated by ROS. 
 
 Demonstrated by CD137L inhibition and with CD137L-/- mice, CD137L may 
be critical for the activation and maturation of murine microglia. The 
coexistence of CD137-expressing activated T cells and activated microglia in 
EAE WT but not EAE CD137L-/- spinal cord suggests that microglia may 
become activated by infiltrating activated T cells. Indeed, CD137L is required 
for the activation and maturation of murine primary microglia by preactivated T 
cells. Moreover, CD137L is detected on activated human microglia during MS, 
suggesting that CD137L may also be implicated in the human disease. 
Enhanced human oligodendrocyte apoptosis is also detected in MS compared 
to healthy brains. Similar to EAE, we postulate that microglia activation and 
ROS production may lead to greater oligodendrocyte apoptosis. Furthermore, 
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the discovery of CD137-expressing apoptotic human Purkinje neurons in close 
association with activated human microglia suggests that microglia activation 
via CD137L and CD137 crosstalk may also play a crucial role leading to 
neuronal death during MS.  
 
 This study extends previous work on CD137L signals activating myeloid 
cells by showing for the first time that it also activates microglia. Further, this 
study demonstrates an involvement of the CD137 receptor / ligand system in 
neuroinflammatory conditions suggesting it may also contribute to 
neurodegenerative diseases. Albeit our data also show an important 
contribution of the CD137 receptor / ligand system to neuroinflammatory 
reactions in the murine CNS, it remains unknown whether the CD137 receptor 
/ ligand system also plays a similar role in the human brain. 
 
 With greater research efforts, the cellular source or nature of CD137 is 
addressed. Both activated T cells as well as neurons expressing CD137 were 
detected to be in close proximity with activated microglia in the EAE and / or 
MS CNS. The identification of the type of apoptotic neurons expressing CD137 
during EAE or MS awaits further characterization in vitro. Moreover, whether 
human CD137L-activated microglia will lead to human oligodendrocyte cell 
death remains to be deciphered and verified in vitro. In the long term, based on 
the obtained murine results as well as future findings from the neuronal and 
human-centric projects, we hope to obtain a better understanding of CNS 
inflammatory disease progression involving CD137 and CD137L interplay and 
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Appendix I Buffers and solutions 
 
ELISA and IHC wash buffer (PBST) 
0.05% Tween-20 in PBS 
 
RBC lysis buffer 
0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA in H2O, pH 7.4 
 
FACS buffer 
0.5% FBS, 0.02% NaN3 in PBS, pH 7.4 
 
MACS buffer 
0.5% FBS, 2 mM EDTA in PBS, pH 7.4 
 
PBS solution (working concentration, 1x) 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 in 1 L H2O, pH 7.4 
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Appendix II List of antibodies employed in the project 
 
Antibody Clone Vendor 
Rat anti-mouse CD137L (PE, biotin) TKS-1 eBioscience 
Rat IgG 2a, κ (PE, biotin) RTK2758 eBioscience 
Hamster anti-mouse CD137 (PE) 17B5 eBioscience 
Armenian hamster IgG (PE, FITC, APC, biotin) eBio299Arm eBioscience 
Hamster anti-mouse CD3e (PE, FITC, APC) 145-2C11 eBioscience 
Rat anti-mouse CD11b (PE, APC) M1/70 eBioscience 
Rat anti-mouse MHC-II (I-A/I-E) (efluor 450) M5/114.15.2 eBioscience 
Rat anti-mouse CD40 (PE) 1C10 eBioscience 
Rat anti-mouse CD80 (PE) 16-10A1 eBioscience 
Rat anti-mouse CD86 (B7-2) (PE) PO3.1 eBioscience 
Rat IgG 2a, κ (PE) eBR2a eBioscience 
Rat IgG 2b, κ (PE) eB149/10H5 eBioscience 
Rat anti-mouse CD86 (PE, biotin) PO3 BD Pharmingen 
Rat (SD) IgG2b, κ (PE, biotin) A95-1 BD Pharmingen 
Hamster anti-mouse CD80 (B7-1) 16-10A1 BD Pharmingen 
Hamster IgG2, κ (PE) B81-3 BD Pharmingen 
Rat anti-mouse CD3 (LEAF) 17A2 BioLegend 
Rat anti-mouse CD3 17A2 BioLegend 
Hamster anti-mouse CD28 (LEAF) 37.51 BioLegend 
Rat anti-mouse GM-CSF (LEAF) MP1-22E9 BioLegend 
Rat anti-mouse CD137L (LEAF) TKS-1 BioLegend 
Rat IgG2b, κ (LEAF) RTK4530 BioLegend 
Rat IgG2b, κ RTK4530 BioLegend 
Syrian hamster IgG (LEAF) SHG-1 BioLegend 
Rat IgG2a, κ (LEAF) RTK2758 BioLegend 
Rat anti-mouse GM-CSF MP1-22E9 BD Pharmingen 
Rat IgG2a, κ R35-95 BD Pharmingen 
   
   
Rabbit anti-mouse Iba-1 Polyclonal Wako 
Chemicals 
Normal Rabbit IgG  - Santa Cruz 
Normal Rabbit IgG-B, biotin  - Santa Cruz 
Donkey anti-rabbit IgG (minimal x-reactivity) 
(DyLight™ 649, Cy5) 
Poly 4064 Biolegend 
Goat anti-rabbit IgG (H+L), highly cross- 
adsorbed (AF647, Cy5) 
- Invitrogen 
Mouse anti-rat IgG (FITC) - ebioscience 
   
   
Mouse anti-human CD137L (FITC) 5F4 BioLegend 
Mouse anti-human CD137 (biotin) 4B4-1 BD Pharmingen 
Mouse anti-human CD137 (biotin) BBK-2 NeoMarkers 
Mouse IgG1 (unconjugated, PE) MOPC-21  Sigma 
Goat anti-mouse CD137 (biotin)  Polyclonal R&D Systems 
Goat IgG (biotin) Polyclonal R&D Systems 
Donkey anti-goat IgG (H&L), cross- Polyclonal Abcam 
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adsorbed (Cy3) 
Sheep anti-human Nogo-A Polyclonal R&D systems 
Donkey anti-sheep IgG (H+L) (AF555, Cy3) - Invitrogen 
Normal sheep IgG - Santa Cruz 
   
   
Streptavidin (HRP) - Sigma 
Streptavidin (Cy3) - ebioscience 
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Appendix III Publications 
 
 
International Scientific Publication(s) 
 
1. Yeo, A.Y., Martínez Gómez, J.M., Croxford, J.L., Gasser, S., Ling, E.A. and 
Schwarz, H. (2012) CD137 ligand activated microglia induces 
oligodendrocyte apoptosis via reactive oxygen species. Journal of 
Neuroinflammation, 9, 173. 
 
 Local & International Scientific Conference Posters & Oral Presentation 
 
1. Yeo, A.Y., Martínez Gómez, J.M., Croxford, L., Gasser, S., Ling, E.A. and 
Schwarz, H. CD137 and CD137 ligand system in microglia activation. 
FASEB Summer Conference on Translational Neuroimmunology: From 
Mechanisms to Therapeutics. Carefree, Arizona, USA, from 29 July - 03 
August 2012. Selected to conduct an oral presentation entitled "CD137 
ligand activated microglia induces oligodendrocyte apoptosis via reactive 
oxygen species." on 02 Aug 2012. 
 
2. Yeo, A.Y., Martínez Gómez, J.M., Croxford, L., Gasser, S., Ling, E.A. and 
Schwarz, H. CD137 and CD137 ligand system in microglia activation. 
Singapore Neuroscience Association (SNA) Symposium, NUS, Singapore, 
on 19 April 2012. Presented with the 3rd best poster presentation award. 
 
3. Yeo, A.Y. and Schwarz, H. An investigation of CD137 and CD137L activities 
in murine microglia. 3rd Annual DUNES Symposium, Duke NUS, Singapore, 
on 7 October 2011. 
 
4. Yeo, A.Y. and Schwarz, H. An investigation of CD137 and CD137L activities 
in murine microglia. Gordon Research Seminar and Conference on 
Phagocytes, Davidson College, Davidson, North Carolina, USA, from 18-24 
June 2011. 
 
